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Zusammenfassung 
 
Shigella flexneri ist ein gram-negatives, humanpathogenes Bakterium, welches Shigellose bzw. 
Bakterienruhr verursacht. Diese fäkal-oral übertragene Krankheit tritt insbesondere in 
Entwicklungsländern auf und ist charakterisiert durch einen schleimigen und blutigen Durchfall. 
Während des Infektionszyklus leben und vermehren sich die Bakterien intrazellulär im Zytoplasma von 
Epithelzellen des Dünndarms. Normalerweise werden intrazelluläre Krankheitserreger vom 
Autophagiesystem erkannt und abgebaut. Shigellen haben jedoch einen Tarnmechanismus entwickelt, 
welcher ihre Erkennung und den Abbau verhindert. 
Die Erkennung von Shigellen durch das Autophagiesystem basiert auf der Erkennung von VirG, ein 
Oberflächenprotein von S. flexneri, welches am alten Zellpol akkumuliert und es der Bakterienzelle 
ermöglicht sich durch das menschliche Zytoplasma zu bewegen. Es bildet einen Komplex mit dem 
menschlichen Protein N-WASP und dem Arp2/3 Komplex, welcher Aktin polymerisiert und das 
Bakterium vorwärts treibt. Das menschliche Protein ATG5 erkennt VirG und markiert die 
Bakterienzellen für den Abbau durch Autophagie. Als Gegenmaßnahme sekretiert Shigella das Protein 
IcsB, welches ebenfalls an VirG bindet und mit ATG5 um die Bindungsstelle konkurriert. Durch die 
höhere Affinität von IcsB, wird die Erkennung von VirG durch ATG5 verhindert, was den 
Tarnmechanismus von Shigellen ausmacht. 
Das Ziel dieser Arbeit war die bessere Charakterisierung der molekularen Grundlagen dieses 
Tarnmechanismus, durch biochemische Methoden und Methoden der Strukturbiologie. Dafür sollten 
die Bindestellen von ATG5 und IcsB auf der Oberfläche von VirG, durch das Kristallisieren und das 
Lösen der Strukturen der einzelnen Proteine VirG, IcsB und ATG5, als auch ihrer Komplexe VirG/IcsB 
und VirG/ATG5, charakterisiert werden. 
Acht initiale VirG Konstrukte lieferten ungenügende Mengen an löslichem, für die Kristallisation 
geeignetem Protein. Daher wurde das ESPRIT System genutzt, um nach löslichen Konstrukten der VirG 
α-Domäne zu suchen. Es wurden 18 interessante Konstrukte identifiziert, welche Bereiche von VirG 
abdeckten, für die noch keine strukturellen Informationen verfügbar waren. 13 von ihnen enthielten 
Teile der IcsB/ATG5 Bindedomäne. VirGE76 (340-758) war eins dieser Konstrukte, welches den 
Großteil der IcsB/ATG5 Bindedomäne abdeckte (außer den ersten 20 Aminosäuren). Es konnte löslich 
exprimiert werden und wurde in Interaktionsstudien verwendet, kristallisierte jedoch nicht. VirGE94 
(419-758) war ein weiteres Konstrukt, welches die letzten 15 Aminosäuren der IcsB/ATG5 
Bindedomäne beinhaltete. Es wurde kristallisiert und seine Struktur wurde durch Röntgenkristallografie 
gelöst. 
Die VirGE94 Struktur enthielt die bereits bekannte Struktur der VirG Autochaperondomäne, eine 
Fortsetzung der β-Helix um etwa 4 Windungen und eine bisher unbekannte Domäne, welche hier VirG 
Insertionsdomäne (VID) genannt wurde, die auf der β-Helix saß. Die Faltung der VID hatte Ähnlichkeit 
zur Faltung der Autochaperondomänen verschiedener Autotransporterproteine. Ihre Funktion könnte 
daher die einer zweiten Autochaperondomäne sein, welche den Keim für eine Fortsetzung der β-Helix 
bildet. SAXS Experimente bestätigten, dass VirGE94 in Lösung durch eine Interaktion der VIDs 
dimerisierte. Diese Dimere besitzen allerdings höchstwahrscheinlich keine in vivo Funktion, da im 
längeren VirGE76 keine Dimerisierung beobachtet werden konnte und die Dimerisierungsoberfläche 
durch eine verlängerte β-Helix blockiert würde. Die schon früher beschriebene polare 
Lokalisierungsdomäne von VirG wurde als ein Teil der β-Helix identifiziert. Sie enthält eine negativ 
geladene Tasche, welche wichtig für die Interaktion mit einem unbekannten Partner sein könnte, welcher 
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für die beobachtete Verteilung von VirG verantwortlich ist. Kristallisationsexperimente von weiteren 
35 VirG Konstrukten führten nicht zur Identifizierung von zusätzlichen kristallisierbaren Konstrukten, 
welche weiter N-terminale Bereiche der VirG α-Domäne abdeckten. 
Expression und Reinigung von 37 IcsB Konstrukten ergaben in den meisten Fällen große Mengen an 
löslichem, homogenem Protein, allerdings konnten keine Kristallisationsbedingungen identifiziert 
werden. Verschiedene Strategien zur Verbesserung der Kristallisation, wie die Reduktion der 
Oberflächenentropie, Methylierung von Oberflächenlysinen und in situ Proteolyse führten ebenfalls 
nicht zum Erfolg. CD-spektroskopische Messungen zeigten, dass ein größerer Teil von IcsB aus 
Random Coil Sekundärstrukturelementen besteht, welche die Kristallisation verhindert haben könnten. 
Die IpgA Bindestelle von IcsB wurde im Bereich der Aminosäuren 26-125 lokalisiert, im Gegensatz zur 
vorher publizierten Bindestelle zwischen 171-247. Die Gegenwart von IpgA stabilisierte jene IcsB-
Konstrukte, welche die IpgA Bindestelle beinhalteten, und welche in Abwesenheit von IpgA zur 
Aggregation neigten. Dieser stabilisierende Effekt wurde durch Thermofluor-Experimente bestätigt. Die 
Interaktionen von IcsB und den publizierten Interaktionspartnern Toca-1 und Cholesterin konnten hier 
nicht bestätigt werden. Die Ergebnisse einer Phyre2 Strukturvorhersage wurden verwendet, um eine 
Interaktion zwischen IcsB und N-WASP, mit einem aktivierenden Effekt auf N-WASP, vorherzusagen. 
Hinweise auf diese Interaktion wurden in einem Thermofluor-Assay mit N-WASP–IcsB 
Fusionsproteinen gefunden. 
Die Kristallstruktur von humanem ATG5 konnte gelöst werden. Sie zeigte zwei Ubiquitin-artig gefaltete 
Domänen und eine Region mit α-helikalen Bündeln. SAXS Experimente bestätigten, dass ATG5 in 
Lösung monomerisch vorliegt. Die Phosphorylierung von ATG5 T75 hat einen inhibitorischen Effekt 
auf die Autophagie, indem die Fusion von Autophagosomen und Lysosomen verhindert wird. Hier 
wurden die molekularen Mechanismen dieses Effekts untersucht, indem die Strukturen einer 
phosphomimetischen Mutante T75E und einer Kontrollmutante T75A gelöst wurden. Es konnten jedoch 
keine Unterschiede in den Strukturen der ATG5 Varianten, sowie in deren Stabilitäten oder 
Interaktionen mit ATG16L1 festgestellt werden, was darauf schließen lässt, dass die Phosphorylierung 
von T75 einen eher indirekten Effekt auf die Autophagie hat, z.B. über einen unbekannten 
Interaktionspartner. 
In Interaktionsstudien zwischen den drei am Shigella Tarnmechanismus beteiligten Proteinen, wurden 
Indizien für eine direkte Interaktion zwischen IcsB und VirGE76 durch MST gefunden. Im Gegensatz 
dazu konnte keine Interaktion zwischen ATG5 und einem VirG-Konstrukt beobachtet werden. Der 
Grund könnte in den Limitierungen der hier verwendeten Konstrukte gelegen haben, es ist jedoch auch 
möglich, dass das molekulare Modell des Shigella Tarnmechanismus modifiziert werden muss, falls 
zusätzliche Faktoren beteiligt sein sollten. 
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Summary 
 
Shigella flexneri is a gram-negative, human-pathogenic bacterium, which causes shigellosis/bacillary 
dysentery. This foodborne disease occurs primarily in developing countries and manifests itself in severe 
bloody diarrhea. During the infection cycle the bacterial cells live and proliferate intracellularly in the 
cytosol of epithelial cells of the small intestine. Normally, intracellular pathogens are recognized and 
degraded by the autophagic system, but S. flexneri developed an evasion mechanism to circumvent 
autophagic recognition and escape degradation. 
Autophagic recognition targets VirG, a surface protein of S. flexneri, which accumulates at one cell pole 
and enables the bacterial cell to move through the cytosol of human cells. It forms a complex with the 
human protein N-WASP and the Arp2/3 complex, which polymerizes actin and propels the bacterium 
forward. The human protein ATG5 recognizes VirG and targets the bacterial cell for autophagic 
degradation. However, as a countermeasure S. flexneri secretes the protein IcsB, which competes with 
ATG5 for binding to VirG. Due to the higher affinity of IcsB, recognition of VirG by ATG5 is blocked, 
thus masking S. flexneri from the autophagic system. 
The objective of this work was a better characterization of the evasive mechanism of S. flexneri on the 
molecular level, using biochemical and structural biology methods. To this end, the binding sites of 
ATG5 and IcsB on the surface of VirG should be characterized, by crystallizing and solving the 
structures of the three individual proteins VirG, IcsB and ATG5, as well as the VirG/IcsB and 
VirG/ATG5 complexes. 
Eight initial VirG-constructs didn’t yield sufficient amounts of soluble protein, suitable for 
crystallization. Therefore the ESPRIT system was deployed to screen for soluble constructs of the VirG 
α-domain. 18 interesting constructs, covering parts of VirG, where no structural information was 
available yet, were identified, 13 of which contained parts of the IcsB/ATG5 binding domain. VirGE76 
was one of those constructs, comprising residues 340-758, that covered most of the IcsB/ATG5 binding 
domain (except for the first 20 aa). It was expressed solubly and was used in interaction studies, but did 
not crystallize. VirGE94 was another construct, comprising residues 419-758, that covered the last 15 aa 
of the IcsB/ATG5 binding domain. It was crystallized and its structure was solved by X-ray 
crystallography. 
The VirGE94 structure contained the previously published structure of the VirG autochaperone domain, 
a continuation of the β-helix by about four turns and a previously unknown domain, here termed the 
VirG insertion domain (VID), that resided on top of the β-helix. It had a fold similar to the autochaperone 
domains of different autotransporter proteins, which indicated that it might act as a second 
autochaperone domain, nucleating the fold of a continuation of the β-helix. SAXS experiments 
confirmed that VirGE94 formed a dimer in solution, which was mediated by an interaction of the VIDs. 
However, this dimer most probably does not have an in vivo function, as dimer formation was abolished 
in the longer VirGE76 construct and the dimer interface would be blocked by a prolonged β-helical 
backbone. The polar localization domain has been identified to be a part of the β-helical backbone of 
VirG and contains a negatively charged cleft that might be involved in the interaction with an unknown 
binding partner, which is responsible for the unipolar distribution pattern of VirG. Screening of 35 
additional constructs did not result in the identification of crystallizable constructs, covering more N-
terminal parts of the VirG α-domain. 
Expression and purification of 37 IcsB-constructs mostly yielded high amounts of soluble and 
homogenous proteins, but no crystallization conditions were identified. Different rescue strategies like 
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surface entropy reduction, surface lysine methylation and in situ proteolysis were applied, but failed. 
CD-spectroscopy indicated that IcsB contains a major fraction of random coils that might have hindered 
crystallization. The IpgA binding site was mapped to IcsB residues 26-125, in contrast to the previously 
published binding site between residues 171-247. The presence of IpgA stabilized IcsB-constructs, 
containing the IpgA binding site, which were otherwise prone to aggregate. This stabilizing effect was 
confirmed by thermofluor-assays. The interactions of IcsB with the published binding partners Toca-1 
and cholesterol could not be confirmed here. Using Phyre2 results, an interaction of IcsB and the N-
WASP-GBD, with an activatory effect on N-WASP, was predicted. Indications for this interaction were 
observed in a thermofluor-assay, using N-WASP–IcsB fusion proteins. 
The crystal structure of individual human ATG5 was solved and showed two ubiquitin-like fold domains 
and an α-helical bundle region. SAXS experiments confirmed that ATG5 was monomeric in solution. 
ATG5 T75 phosphorylation had been shown to inhibit autophagy, by the prevention of autophagosome-
lysosome fusion. Here the molecular mechanisms have been investigated, by the crystallization of the 
phosphomimetic mutant T75E and a control mutant T75A. The structures of the ATG5 variants, their 
stabilities and their interactions with ATG16L1 were very similar, indicating a more indirect effect of 
T75 phosphorylation on autophagy, e.g. via a yet unidentified binding partner. 
Interaction studies between the three proteins, involved in the Shigella camouflage mechanism, showed 
indications for a direct interaction between IcsB and VirGE76 by MST. In contrast, no interaction 
between ATG5 and any VirG-construct was observed. The reason might have been the limitations of 
the utilized constructs, but it might also be necessary to modify the molecular model of the Shigella 
camouflage mechanism, as additional factors might be involved. 
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1 Introduction 
1.1 Autophagy 
Autophagy is a conserved eukaryotic cellular pathway, which was first recognized in yeast as a process 
that recycles cellular components to sustain the metabolism in times of starvation. More recently, 
additional tasks of autophagy have been identified, like the degradation of aged or damaged cellular 
organelles and large protein complexes [1]–[3], as well as functions in the innate and adaptive immune 
response during infections with intracellular pathogens [4], [5]. Three different types of autophagy can 
be distinguished. First macroautophagy, which is characterized by the de novo formation of a double 
membrane vesicle called an autophagosome. Second microautophagy, whereby a small invagination of 
the lysosomal membrane is formed that segregates and degrades a small part of the cytoplasm. Third 
chaperone-mediated autophagy, by which proteins are transported directly into the lysosome [6]. From 
here on, macroautophagy is referred to as autophagy for the remainder of this work. 
1.1.1 Autophagosome biogenesis 
Autophagy targets cytosolic components that are engulfed by a double membrane structure, called the 
isolation membrane. The main source of this membrane is the mitochondria-associated endoplasmic 
reticulum membrane (MAM), but also other membranes contribute to it [7]. Once the isolation 
membrane closes around its cargo, the vesicle is called an autophagosome. Subsequently the outer 
membrane of the autophagosome fuses with a lysosome, forming an autolysosome, and the lysosomal 
enzymes degrade the inner membrane and the autophagosomal cargo [6]. Degradation products like 
amino acids are transported across the autolysosomal membrane and are recycled [8] (Figure 1). 
 
Figure 1: Scheme of the autophagic pathway. Cytosolic components are engulfed by an isolation membrane. The closed vesicle 
is called an autophagosome, which then fuses with a lysosome. The contents of the formed autolysosome are degraded and the 
degradation products like amino acids are transported across the membrane to be recycled (modified from [9]). 
In yeast, more than 30 genes have been identified that are involved in the autophagy pathway [10]. TOR 
is the key regulator of starvation induced autophagy. It is a serine/threonine kinase, which is active under 
nutrient rich conditions and inactive under starvation conditions. It regulates the Atg1 complex, which 
plays an important role in the initiation of autophagy. Atg1 is a serine/threonine kinase whose substrates 
are still unknown. It forms a complex with Atg13, Atg17, Atg29 and Atg31. Atg13 is hyper-
phosphorylated by the active TOR kinase, which leads to the inhibition of Atg1 kinase activity and 
consequently to the downregulation of autophagy under nutrient rich conditions [11]. 
A second protein complex, comprising Vps34 (a phosphatidylinositol kinase), Vps15, Vps30/Atg6, 
Atg14 and Atg38, is responsible for the generation of phosphatidylinositiol-3-phosphate (PI(3)P) in the 
autophagosomal membrane [12], [13]. PI(3)P is a phospholipid that recruits effector proteins to the 
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autophagosomal membrane. One example is the Atg5-12/16 complex, which plays a role in the 
conjugation of Atg8 to phosphatidylethanolamine (PE). The formation of this complex and the 
conjugation of Atg8 to PE are described in the following section. 
Two ubiquitin-like conjugation systems, which are essential for autophagy [14], play a role in the 
expansion of the isolation membrane [15]. The first system conjugates the ubiquitin-like protein Atg12 
to Atg5 via an isopeptide bond, involving the C-terminal G186 of Atg12 and the K149 sidechain of Atg5 
[16]. Atg7 acts as the E1 activating enzyme [17] and Atg10 as the E2 conjugating enzyme [18], but no 
typical E3 ligase is involved. The Atg5-12 conjugate interacts with Atg16. Atg16 dimerizes and a 
complex involving two copies of Atg5-12/16 is formed [19], [20]. The second system conjugates the 
ubiquitin-like protein Atg8 to PE [21]. Atg7 also acts as the E1 activating enzyme in this second process, 
while the E2 conjugating enzyme is Atg3 [21]. The Atg5-12/16 complex, formed by the first conjugation 
system, functions as the E3 ligase in the second process [22] (Figure 2). Orthologues of each component 
of the two ligation systems are also present in human cells [23]. For instance ATG16L (two isoforms 
L1/L2) is the human orthologue of yeast Atg16 [24] and LC3A (two isoforms)/B/B2/C, as well as 
GABARAP/L1/L2 are the seven human orthologues of yeast Atg8 [25]. 
 
Figure 2: The two ubiquitin-like conjugation systems in autophagy. In the first system, Atg12 is conjugated to Atg5 by Atg7 
and Atg10. The second system conjugates Atg8 to PE through the actions of Atg7, Atg3 and the Atg5-12/16 complex (modified 
from [26]). 
The Atg5-12/16 complex interacts with PI(3)P [20] and localizes to the outer surface of the growing 
isolation membrane [27]. As it promotes the lipidation of Atg8, it has a function in targeting the Atg8-
PE conjugate to the correct membrane [28]. After the completion of the autophagosome it rapidly 
dissociates from the membrane [29]. Atg8-PE localizes to both sides of the growing isolation membrane. 
It mediates membrane hemifusion, which is important for the expansion of the growing isolation 
membrane [30], and it probably functions as a scaffolding protein that supports the growing membrane 
[26]. Like the Atg5-12/16 complex it dissociates from the outer surface of the completed autophagosome 
[31], but it remains attached to its inner membrane [32] (Figure 3). 
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  7 
 
Figure 3: The Atg5-12/16 complex is associated with the outer surface of the growing isolation membrane, while Atg8-PE 
localizes to both sides. Upon closure of the vesicle, the Atg5-12/16 complex and Atg8 dissociate from the outer surface of the 
autophagosome, but Atg8 stays associated with the inner membrane [26]. 
1.1.2 Autophagy in infection and disease 
Intracellular pathogens have to be detected by the cell, before they are degraded by autophagy. Pattern 
recognition receptors (PRRs) detect compounds that are characteristic for pathogens, called pathogen 
associated molecular patterns (PAMPs). PRRs comprise different proteins like the membrane-bound 
Toll-like receptors (TLRs) and the cytosolic NOD-like receptors (NLRs). For instance, 
lipopolysaccharides are detected by TLR4, while ssRNA is recognized by TLR7 [33], [34]. In both cases 
autophagy is activated in subsequent steps [4]. Nod1 and Nod2, which recognize the bacterial 
peptidoglycan constituents D-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, recruit 
Atg16L1 to the plasma membrane at the entry site of S. flexneri, thus targeting autophagy to invading 
bacterial cells [35]. Beside the stimulation of autophagy, PRRs also activate either the NF-κB innate 
immune response for the production of proinflammatory cytokines or caspase 1 for the induction of 
programmed cell death [36]. 
Following their recognition, membrane structures surrounding the bacteria, and possibly also the 
bacterial surface itself, are polyubiquitinated [37], which is a general degradation signal. Still, the 
responsible molecular systems, as well as the protein targets for ubiquitination remain elusive. Only 
recently, the E3 ubiquitin-ligases parkin and LRSAM1 have been identified, which play roles in the 
polyubiquitination of Mycobacterium tuberculosis and S. flexneri [38], [39].  Different adaptor proteins 
like p62, NBR1, NDP52 and OPTN direct the growth of the isolation membrane around the bacterium, 
by binding to both the polyubiquitin signals, associated with the bacteria, and the LC3 on the inner 
surface of the growing isolation membrane [40]. Upon closure of the vesicle, the autophagosome fuses 
with a lysosome and the bacterium is degraded by the lysosomal enzymes, as described above. A 
different pathway targets bacteria, which are about to escape the phagosome. Galectin 8 binds to both 
host glycans, which are exposed on damaged Shigella containing vacuoles, and to NDP52. This way 
antibacterial autophagy is targeted to the escaping bacterium [41]. 
1.1.3 Bacterial autophagy evasion strategies 
Despite the described antimicrobial pathways, some intracellular pathogens circumvent degradation by 
autophagy and others even exploit the autophagic mechanisms for their own benefit. For instance, 
Anaplasma phagocytophium, Coxiella burnetii, Legionella pneumophila, Mycobacterium spp., 
Staphylococcus aureus and Yersinia pestis first induce their uptake by an autophagosome, but then 
inhibit autophagosome-lysosome fusion. This way they create a vacuolar replicative niche [42]. Other 
bacteria developed mechanisms for the down regulation of autophagy. The ubiquitination of infection-
specific aggresomes usually leads to a general increase in autophagy. Salmonella spp., L. pneumophila 
and pathogenic Escherichia coli dampen the autophagic response, by blocking the ubiquitination of 
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aggresomes or by expressing specific deubiquitinases [42]–[44]. Another example is L. pneumophila, 
which secrete the RavZ protein that inhibits autophagy by the deconjugation of LC3 from PE. RavZ 
cleaves LC3 one residue N-terminal of the conjugation point, which also prevents reconjugation [45]. 
Finally, S. flexneri and Listeria monocytogenes developed camouflage mechanisms to avoid recognition 
by autophagy, by means of secreted proteins (IcsB, InlK) [46], [47] (Figure 4). The exact mechanism 
by which S. flexneri avoids autophagic recognition is described in greater detail in chapter 1.3.1. 
 
Figure 4: Intracellular pathogens avoid autophagic degradation by different means. L. monocytogenes and S. flexneri developed 
a camouflage mechanism to avoid autophagic recognition. L. pneumophila RavZ deconjugates LC3 from PE and inhibits the 
maturation of the autophagosome. A. phagocytophium, C. burnetii, L. pneumophila, Mycobacterium spp., S. aureus and Y. 
pestis induce their uptake by an autophagosome, but inhibit autophagosome-lysosome fusion at a later stage. Finally pathogenic 
E. coli, L. pneumophila and Salmonella spp. downregulate the autophagy system, by avoiding aggresome ubiquitination 
(reproduced from [9]). 
1.2 The actin cytoskeleton 
A number of pathogens have adopted to an intracellular live style by developing an actin based motility 
(ABM), thus exploiting the eukaryotic actin polymerization system that is described in this chapter. 
Beside the intermediate filaments, the microtubules and the septin filaments, the actin- or microfilaments 
are a component of the cytoskeleton with important functions in cellular motility and as tracks for 
myosin motor proteins. The actin filament network can generate forces, when the growing ends of actin 
filaments push against barriers like cellular membranes, which is necessary for cellular motility. Actin 
naturally occurs in two different states, as monomeric globular (G) actin and as polymeric filamentous 
(F) actin [48]. 
1.2.1 G-actin 
G-actin is a highly conserved 375 amino acid protein with a MW of about 42 kDa. Vertebrates express 
six different actin isoforms: four α-isoforms (expressed in skeletal, cardiac and smooth muscle tissue), 
one β-isoform and one γ-isoforms (mainly expressed in non-muscle tissue) [48]. The first G-actin 
structure has been solved in 1990 in complex with DNase I [49]. Actin is composed of four different 
subdomains. Subdomains 1 and 3 are similar in structure, while subdomains 2 and 4 can be viewed as 
large insertions into the former two subdomains. Between subdomains 1/2 and 3/4 the hinge region, the 
nucleotide cleft and the target binding cleft are located [50]. The nucleotide cleft binds a nucleotide 
(either ADP or ATP) and a divalent cation (Mg2+). The hydrophobic target binding cleft is the binding 
site for most actin binding proteins (ABPs) [51]. Subdomain 2 carries the DNase I-binding (D) loop that 
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plays an important role for the inter-subunit contacts in the filament, as it inserts into the target binding 
cleft of the neighboring subunit [50] (Figure 5). 
 
Figure 5: G-actin structure from PDB-entry 2A42. The numbers designate the four subdomains. A detailed description of the 
structural features is given in the text. 
Only minor conformational changes can be observed between the ADP- and ATP-bound form of 
G-actin, mainly involving the Ser14 β-hairpin loop and the sensor loop, carrying the methylated His73. 
Both loops contact the phosphates of the nucleotide. The conformational changes of the two loops 
propagate to subdomain 2 with the D-loop, which also shows only minor conformational changes. Still 
these differences in the structure seem to be the major cause for a decreased stability of F-actin in the 
ADP-bound state [52]. The actin monomers adopt a flatter conformation in F-actin than in G-actin, 
which is due to a rotation of subdomains 1/2 by about 20° with respect to subdomains 3/4 [53]. 
1.2.2 F-actin 
F-actin is composed of helically assembled actin monomers, which form the filament with a diameter 
of about 7 nm [48]. Current atomic models of the actin filament are derived from X-ray fiber diffraction 
of oriented actin gels or from cryo electron microscopy (EM). The resolution of initial X-ray fiber 
diffraction derived structures was only about 7 Å [54]. But actin fibers are diamagnetic and when they 
were placed in a strong magnetic field their order was increased and a resolution of 3.3 Å in radial and 
5.6 Å in equatorial direction was obtained [53]. The best cryo EM derived structure reaches a resolution 
of 6.6 Å [55]. These structures show that F-actin forms a left-handed helix of actin monomers with a 
repetitive motif, consisting of about 13 molecules that form six consecutive turns and cover an axial 
distance of 359 Å. The twist per molecule is -166.6°, which is close to -180°. Consequently the structure 
appears like two slowly turning right-handed chains (Figure 6). 
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Figure 6: Structure of F-actin from PDB-entry 3G37. Actin monomers form a left handed helix with a twist of -166.6° per 
molecule. As this value is close to -180°, the filament appears like two intertwining right handed helices. 
Actin has an ATPase function, but ATP hydrolysis is not very efficient in G-actin compared to F-actin, 
which readily hydrolyzes ATP to ADP with a half-life of 2 s [50], [56]. Subsequently, the γ-phosphate 
slowly dissociates with a half-life of 6 min [57]. F-actin is a polar filament and has two inequivalent 
ends, a barbed/+ end and a pointed/– end (Figure 6). The two ends have different critical actin 
concentrations, which indicate the concentration of G-actin, where the polymerization rate equals the 
depolymerization rate. The critical concentration of the barbed end is 0.1 μM, while the critical 
concentration of the pointed end is 0.6 μM. Consequently actin monomers usually join the barbed end 
of a filament in the ATP-bound state with diffusion limited rate, then hydrolysis takes place in the 
filament and finally ADP-bound actin dissociates from the pointed end [58]. In solution, ADP is replaced 
by ATP and actin can reassociate with the barbed end. This process is called actin filament tread milling 
[59] (compare Figure 7). 
1.2.3 Actin binding proteins (ABPs) 
In vivo, actin is present at high intracellular concentrations of 20-100 μM, which lies far above the 
critical concentrations. Therefore actin filament formation needs to be tightly regulated, which is 
accomplished by the action of different ABPs. The dynamics of the actin cytoskeleton are controlled by 
small Rho-GTPases. Rho itself controls the formation of stress fibers, Rac the formation of lamellipodia 
and Cdc42 the formation of filopodia. They regulate a number of ABPs, which are responsible for the 
nucleation, elongation, stability, depolymerization and different other aspects of the actin cytoskeleton. 
For instance, Tβ4 and profilin are actin sequestering proteins. They bind monomeric G-actin and prevent 
its uncatalyzed nucleation. Profilin promotes the exchange of ADP for ATP. It binds to the barbed end 
of actin monomers, thereby leaving the pointed end free for barbed end growth of the filament, while 
inhibiting pointed end growth. Besides binding to actin monomers, profilin also binds proline rich 
sequences, which are present in several ABPs, e.g. the Arp2/3 complex and formins (see below). It thus 
delivers actin monomers for the formation of filaments. Another ABP is the actin depolymerization 
factor cofilin, which severs and depolymerizes actin filaments in the ADP-bound state. Different 
capping proteins like CapZ or tropomodulin bind to the barbed or pointed ends of the filament and 
stabilize them. Other proteins like filamin and fascin act as actin filament cross linkers. Finally, a number 
of proteins and complexes are able to initiate actin filaments, which include the ubiquitously expressed 
Arp2/3 complex and formins. The expression of other initiating proteins like Spire, Cobl, VopL/VopF, 
TARP and Lmod is limited to special tissues [48]. 
1.2.3.1 The Arp2/3 complex 
The Arp2/3 complex initiates a filament branch, starting from an existing filament. The resulting 
branched filament network pushes forward the leading edge of motile cells (Figure 7). 
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Figure 7: 1. The active Arp2/3 complex initiates new actin filaments, starting from an existing filament. 2./3. The growing 
barbed ends of the filaments push against the plasma membrane, forming a lamellipodium. 4. The barbed end growth of some 
filaments is stopped by capping proteins. 5. When the actin monomers join the barbed ends of the filaments, they are ATP 
bound. ATP is quickly hydrolyzed to ADP + Pi and the phosphate dissociates from the filament. 6. ADF/cofilin severs and 
depolymerizes ADP-bound filaments. 7. The emerging ADP-bound actin monomers bind to profilin, which catalyzes the 
exchange of ADP for ATP. 8. Finally ATP-bound actin-profilin complexes rejoin the barbed end. This circulation of actin is 
called actin filament treadmilling (adapted from [60]–[62]). 
The Arp2/3 complex consists of seven subunits: Arp2, Arp3 (actin related subunits), p16, p20, p21, p34 
and p40. The two actin related subunits are stabilized in an inactive state by the five other subunits. The 
activation of the complex is accomplished by the cooperative action of nucleation promoting factors 
(NPFs), an actin filament and an actin monomer. The structure of the inactive complex has been solved 
in 2001 (Figure 8 a), but up to date there is no structure of the active complex. Arp2 and Arp3 structurally 
resemble actin but the nucleotide cleft is more open and lacks a bound nucleotide. The Arps lie head to 
tail, like subunits in an actin filament, but they are rotated by -180° around the filament axis relative to 
each other (not -166.6° like in a filament). In this conformation the nucleation of an actin filament is not 
possible. A proposed model for the conversion of the inactive into an active complex includes 1) the 
binding of two nucleotides to Arp2 and Arp3 to close their nucleotide clefts and 2) a rotation of about 
20°, which rearranges the Arps into a conformation that acts as nucleation template of a new filament 
(Figure 8 c). The Arps are then the first subunits in the new branch (Figure 8 b). The role of the NPFs 
might be the stabilization of the active complex by bridging p21, p40 and the pointed ends of the Arps. 
After the activation of the Arp2/3 complex, the NPFs dissociate in a sub-second timescale [62] [63]. 
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Figure 8: a) Structure of the Arp2/3 complex from PDB-entry 1K8K. b) Reconstruction of an actin filament branch, including 
the Arp2/3 complex, from electron micrographs [62], [64]. c) Proposed model for the activation of the Arp2/3 complex [62], 
[63]. 
1.2.3.2 Formins and other initiating proteins 
Formins nucleate and elongate unbranched filaments for actin bundles in filopodia and the contractile 
ring. In contrast to the Arp2/3 complex, a previously existing filament is not necessary. In humans, 15 
different formins exist, which are grouped into eight families [65]. Formins form homodimers. They 
contain several domains including formin homology 1 (FH1), FH2 and regulatory domains. FH1 
domains contain one or more short proline rich sequences, which bind profilin-actin complexes and 
accumulate them near the end of the growing filament. Two FH2 domains form a ring that is wide 
enough to accommodate two actin subunits (Figure 9 a). They can nucleate actin polymerization, by 
stabilizing actin dimers and stay associated with the barbed end of the growing filament over thousands 
of subunits and seconds, a property called processive capping. Other domains are more diverse. 
Diaphanous related formins contain an N-terminal diaphanous inhibitory domain (DID), also called 
GTPase binding domain (GBD), that binds to a C-terminal diaphanous autoregulatory domain (DAD), 
resulting in autoinhibition similar to N-WASP. Activated Rho can bind to the GBD, which releases the 
DAD and leads to the activation of the formin [66]. A current model of the elongation mechanism of 
formins claims that they adopt two different states, an open and a closed one. After the addition of each 
actin subunit, the formin transiently adopts the closed or capped state to maintain its position at the end 
of the filament. Profilin increases the elongation rate, depending on the number of profilin-binding sites 
in FH1. The elongation rate can even increase over the diffusion limited rate of free barbed ends. The 
profilin binding sites in FH1 create higher local actin concentrations, supporting this elevated rate 
(Figure 9 b) [62]. 
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Figure 9: a) Structure of a FH2-dimer (red, violet) in complex with two actins (grey) from PDB-entry 1Y64. b) Processive 
barbed end growth of an actin filament, catalyzed by a formin [67]. 
Finally Spire, Cobl, VopL/VopF, TARP and Lmod nucleate actin filaments by means of their tandem 
WH2-domains. One WH2 domain consists of 17-27 amino acids that form an N-terminal helix, which 
binds the target-binding cleft of an actin monomer, and a C-terminal linker. By the binding of three to 
four actin subunits the local actin concentration is increased and a nucleus is formed more readily. These 
proteins only catalyze the nucleation, not the elongation of an actin filament [68]. 
1.2.3.3 Nucleation promoting factors (NPFs) and Toca-1 
NPFs include proteins of the Wiskott-Aldrich syndrome protein (WASP) family like WASP, N-WASP 
and Scar/WAVE [69]. WASP and N-WASP have most of their domains in common: a pleckstrin 
homology (PH) domain that binds phosphatidylinositol-4,5-bisphosphate (PIP2), an IQ motif that binds 
calmodulin, a GBD that binds Cdc42, a proline-rich region (PRR) and a VCA domain including 
verprolin homology/WASP homology 2 (V/WH2), connecting/cofilin homology (C) and acidic (A) 
subdomains [70]. The VCA domain has been shown to activate the Arp2/3 complex [71]. V and C have 
an affinity for actin, while C and A interact with the Arp2/3 complex. The acidic A-domain probably 
binds to basic surface patches on p21 and p40 and stabilizes the Arp2/3 complex in an active 
conformation, while at the same time the first actin monomer of the new filament is anchored by the V-
domain in the correct position. This presents an effective strategy, as actin trimers are normally very 
unstable [63]. In an unbound state N-WASP is complexed with N-WASP interacting protein (WIP) and 
stabilized in an autoinhibited conformation [72], [73], where an intramolecular interaction between the 
GBD and the C-domain inhibits the activity of the VCA-domain. N-WASP can be activated by the 
cooperative action of Cdc42 and Toca-1. Upon interaction, the VCA domain is released and is free to 
interact with and thereby activate the Arp2/3 complex [74]. 
Toca-1 is a protein that together with CIP4 and Fbp17 belongs to the Pombe Cdc15 homology (PCH) 
family. It contains an F-BAR domain, an HR1 domain and a SH3 domain. F-BAR domain proteins 
usually form dimers and play important roles in the remodeling of membranes [75]. The HR1 domain 
adopts a coiled coil fold and has been shown to bind Cdc42 [74]. Finally the SH3 domain interacts with 
proline rich sequences in both N-WASP and formins [74], [76], [77]. Hence, Toca-1 is involved in the 
regulation of actin polymerization by both the Arp2/3 complex and formins [78]. 
1.2.4 Actin based motility (ABM) 
Several intracellular pathogens exploit the actin polymerization system to move through the cytosol, a 
process called actin based motility. A number of different mechanisms have evolved for this purpose. 
L. monocytogenes is the causative agent of listeriosis, which manifests as gastroenteritis or as infection 
of the central nervous system. Listeria are capable of ABM by means of their outer membrane protein 
ActA, which directly activates the Arp2/3 complex by mimicking the action of activated N-WASP. This 
leads to the formation of actin tails and the generation of a propulsive force, pushing the bacterial cells 
through the cytoplasm [79]–[81]. Different pathogenic Rickettsia species, the causative agent of spotted 
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fever, express the outer membrane protein Sca2, which is a bacterial mimic of formins. In contrast to 
the branched tails of Listeria, they are generating propulsion by the formation of linear actin tails [82], 
[83]. Also the vaccinia virus is capable of ABM via its surface protein A36R that interacts with an N-
WASP accessory protein like Nck or WIP. Consequently, N-WASP and the Arp2/3 complex are 
activated [84], [85]. 
Finally, also Shigella species are capable of ABM [86], which in this case is mediated by the outer 
membrane protein VirG/IcsA [87], [88]. VirG localizes to the old cell pole where it interacts with and 
activates N-WASP, which in turn activates the Arp2/3 complex [89]. A branched actin tail, similar to 
the one of Listeria, is formed that pushes the bacterial cell through the cytoplasm (Figure 10). When a 
Shigella cell reaches the plasma membrane, a protrusion is formed, reaching into the neighboring cell. 
The protrusion is taken up and Shigella can escape into the cytoplasm of a new cell. Efficient 
intracellular motility requires N-WASP and Arp2/3, but efficient intercellular spread requires formins. 
Actin tails in the cytoplasm consist of branched filaments, indicating a formation by the Arp2/3 complex, 
while actin tails in protrusions consist of parallel filaments, indicating a formation by formins. Indeed, 
the inhibition of the formin Dia1 prevents the formation of protrusions and inhibits intercellular spread, 
but not intracellular motility. Dia1 colocalizes with Shigella cells in protrusions, but not in the 
cytoplasm. IpgB2, a protein secreted by Shigella, has been shown to be able to bind and activate Dia, 
but deletion mutants are not deficient in intercellular spread, indicating the existence of other means for 
the activation of formins [90]. Consequently, for a successful infection Shigella has to manipulate both 
the Arp2/3 and the formin actin polymerization systems. The next chapter introduces Shigella in more 
detail and describes the infection mechanism. 
 
Figure 10: The Shigella outer membrane protein VirG (green) activates N-WASP in a manner similar to Cdc42, by binding to 
its GBD (yellow circle). The N-WASP VCA domain (orange line) in turn activates the Arp2/3 complex (blue), by stabilizing 
a filament nucleus, comprising Arp2, Arp3 (blue circles) and an actin monomer (red circle). Starting from these nuclei, actin 
filaments (grey) are forming a branched actin tail. 
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1.3 Shigella 
The genus Shigella comprises four different species: S. dysenteriae, S. flexneri, S. boydii and S. sonnei. 
All of them can cause shigellosis, also called bacillary dysentery, which is a severe bloody diarrhea. In 
Germany, 552 cases were reported to the Robert Koch Institut in 2014 [91], while in the United States, 
7746 cases were reported to the Centers for Disease Control and Prevention in 2012 [92]. In both 
countries, the main cause of infection was S. sonnei. Taken these numbers, shigellosis is not a major 
health problem in industrialized countries, but it does pose a major problem in developing countries. 
Shigellosis is endemic in most developing countries [93] with 160 million cases and 1.1 million deaths 
per year worldwide, mainly caused by S. flexneri, as estimated in 1999 [94]. The major mode of 
transmission is the fecal-oral route [95]. Hence, the main problems are poor sanitation and hygienic 
standards, the lack of clean drinking water, malnutrition and the costs of antibiotic treatment. 
Shigella are gram-negative, facultative anaerobe, non-motile and non-encapsulated bacteria. In the 
absence of flagellar or capsular antigens, the antigenic characterization is based on the O-antigens. 
Accordingly, S. dysenteriae (group A) are subdivided into 15 sero-types, S. flexneri (group B) into 15 
sero- and sub-types, and S. boydii (group C) into 20 sero-types [96]. S. sonnei (group D) comprises just 
1 sero-type, subdivided into 5 bio-types [97]. Considering that the major cause of Shigella infections is 
S. flexneri and the dominant sero-type is 2a, most research on Shigella infections has been performed 
on this sero-type and additionally on sero-type 5a. Shigella and E. coli are highly similar, both 
biochemically and on the genetic level. Accordingly they can be considered as members of the same 
species in the genus Escherichia. The current classification is kept for historical reasons [98]. 
The host immune response is sero-type specific and results in immunity against infections with the same 
sero-type. Thus vaccination is possible in principle [95]. Currently, different approaches to develop 
vaccines are being followed. These include the development of vaccines directed against the O-antigen, 
conjugate vaccines and conserved-protein-directed vaccines. Still, up to date no vaccine is available 
being effective against all different sero-types [96]. Currently, Shigella infections are treated with 
antibiotics, whose continuous use is compromised by an increasing number of resistant strains [99]. The 
lack of a vaccine and the increasing number of resistant strains shows the importance of the identification 
of new ways to control Shigella infections. 
All pathogenic strains share a 220 kb virulence plasmid, that carries most of the virulence factors [100] 
including all necessary components of a type three secretion system (TTSS), translocators (IpaB, IpaC), 
transcription activators (VirF, VirE, MxiE), effector proteins (IcsB, IpaA, IpaB, IpaC, IpgB1, IpgB2, 
IpgD, VirA) and chaperones (IpgA, IpgC, IpgE, Spa15) [101]. The expression of the virulence genes is 
controlled by the environmental temperature. Expression is upregulated upon a temperature shift from 
30°C to 37°C, which corresponds to an uptake of the bacterial cell into the human body [102]. 
Responsible for the temperature regulation is the histone-like protein 1 (H-NS protein) [103]. The 
bacterial TTSS is a complex machine, which is able to transport a set of about 25-30 effector proteins 
from the bacterial cytoplasm directly into the host cytoplasm [104]. It is composed of a cytoplasmic 
part, a transmembrane domain, spanning the inner membrane, the periplasm with the peptidoglycan 
layer and the outer membrane, and an extracellular needle [105]. It is activated upon contact to the host 
cell membrane. 
A number as small as ten Shigella cells can cause an infection in humans [106]. The bacterial cells pass 
the acidic milieu of the stomach by an unknown mechanism to reach the small intestine. The presence 
of the bile salt deoxycholate (DOC) is a stimulus for Shigella to prepare for infection. IpaB is recruited 
to the tip of the TTSS needle by a conformational change of IpaD, induced by the binding of DOC [107]. 
Also, in the presence of DOC, the Shigella surface protein VirG acts as an adhesin, that mediates the 
contact of bacterial and human cells via an unknown receptor [108]. Shigella cells have three known 
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ways to pass the epithelial barrier: 1) by translocation through M-cells [109], 2) by passing between the 
epithelial cells after manipulation of the tight junctions and 3) by passing through gaps created by 
polymorphonuclear leucocytes in response to interleukins [95]. In the solitary lymphatic nodules, 
underlying the M-cells, they infect macrophages [110], which undergo induced apoptosis [111]. The 
released Shigella cells then infect enterocytes via the basolateral membrane. They induce membrane 
ruffling to be taken up by phagocytosis. The internalized cells immediately disrupt the phagocytic 
membrane and are released into the cytoplasm, where they are motile by ABM and proliferate. When 
bacterial cells reach the plasma membrane, protrusions are formed reaching into the neighboring 
epithelial cells. These cells take up the bacteria in vacuoles, which again are immediately disrupted. This 
way, Shigella disseminates from cell to cell without being exposed to the environment, thus 
circumventing the humoral immune response (Figure 11). 
 
Figure 11: Shigella cells translocate through M-cells and infect macrophages, where they proliferate and later induce apoptosis. 
The released bacterial cells induce their phagocytic uptake by epithelial cells via the basolateral membrane. Once inside they 
immediately disrupt the phagosome and are motile by ABM. When a plasma membrane is touched, a protrusion reaching into 
the neighboring cell is formed, which is taken up by this cell. Shigella escapes into the cytoplasm, thus infecting a new cell and 
spreading the infection [112]. 
Shigella not only evades the humoral immune response, additionally it uses a number of ways to 
modulate the innate immune response. Shigella lipopolysaccharides (LPS) and peptidoglycans are the 
source of a strong inflammatory response of the innate immune system. The inflammation causes the 
epithelial barrier to break down, resulting in an increased invasion of bacterial cells from the lumen of 
the small intestine [113]. A number of effector proteins secreted by the TTSS are also involved in the 
modification of the innate immune response. OspG is a kinase that binds to a set of ubiquitin conjugating 
enzymes, especially those involved in the degradation of I-κB, an inhibitor of NF-κB [114]. OspF, a 
phosphothreonine lyase, inactivates the MAP kinases p38 and Erk1/2. This results in the inhibition of a 
set of NF-κB controlled genes, leading to the repression of the innate immune response [115]. IpaH9.8 
has an E3 ubiquitin ligase function and binds the splicing factor U2AF35, resulting in a modulation of 
the inflammatory response [116], [117]. All these factors act together in the modulation of the innate 
immune response to allow for the most efficient propagation of the Shigella infection in the tissue. 
A number of other effectors play important roles in the uptake of the bacterial cell by phagocytosis, 
including IpaA, IpaB, IpaC, IpgB1, IpgB2, IpgD and VirA [118]. IpaA is an effector with multiple 
functions. It interacts with the head domain of vinculin [119], reduces the affinity of β1-integrin for the 
extracellular matrix and increases the activity of RhoA [120]. These activities cause a rearrangement of 
the cellular actin, which results in the formation of membrane ruffles and an efficient uptake of the 
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bacterial cell. IpaB and IpaC form the translocator, a 25 Å pore in the host cell membrane, through 
which further effector proteins are transported [104], but they also exert additional functions. IpaB 
interacts with CD44 [121] and α5β1 integrin [122], which facilitates the bacterial uptake. It also activates 
caspase 1, leading to apoptosis in macrophages [123], and disrupts the vacuolar membrane, allowing 
Shigella cells to escape to the cytoplasm [124]. IpaC induces actin polymerization and formation of 
filopodia [125]. IpgB1 and IpgB2 mimic the effects of activated Ras-like GTPases. They modulate actin 
dynamics and lead to the formation of stress fibers and membrane ruffles [126]. IpgD dephosphorylates 
PIP2, resulting in the detachment of the cytoskeleton from the plasma membrane, thus facilitating the 
extension of membrane ruffles [127]. Finally VirA interacts with microtubules and destabilizes them, 
leading to the activation of Rac and membrane ruffling [128]. It has also been shown to facilitate the 
intracellular motility [129], although this might not be a direct effect of VirA [130]. Together, these 
effector proteins modulate the actin polymerization system, with the aim to remodel the actin 
cytoskeleton and the cell surface, to promote the uptake of a bacterial cell by phagocytosis into a 
normally non-phagocytic cell. 
1.3.1 The pathogenic camouflage mechanism of S. flexneri 
Intracellular pathogens are normally degraded by autophagy as described in chapter 1.1. However, 
Shigella developed a camouflage mechanism enabling it to avoid autophagic recognition and 
degradation. In 2005, the molecular basis of this camouflage mechanism has been discovered [46]. In a 
previous publication, it was shown that the effector protein IcsB is important for the pathogenicity of 
Shigella [131]. Upon infection of BHK or MDCK cells with Shigella IcsB deletion mutants, the bacteria 
initially proliferated normally. However, after four hours multiplication plateaued and the bacteria 
colocalized with GFP-LC3, an autophagosome specific marker, indicating that the cells were targeted 
for autophagic degradation. Additional experiments confirmed that the phenotype of the IcsB deletion 
mutant was associated with autophagy and that the cells were enclosed by autophagosomes. At the 
beginning of the infection no influence of the lack of IcsB on the ABM was observed. After two hours 
the bacteria became less motile, which may be caused by the trapping in autophagosomes. 
Complementation of IcsB expression restored the wild type phenotype [46]. 
In BHK cells, infected with Shigella IcsB deletion mutants, occasional localization of ATG5 and LC3 
to one of the bacterial cell poles was observed, a distribution that is typical for the Shigella surface 
protein VirG. In a second experiment, the association of Shigella VirG deletion mutants with autophagy 
markers was barely detectable. In both cases the reconstitution of protein expression restored the wild 
type phenotype. Deletion mutants deficient in the expression of both IcsB and VirG showed the recovery 
of Shigella intracellular growth. Together, these results indicate that VirG is the target of autophagic 
recognition of Shigella. This hypothesis was tested by the infection of BHK cells with E. coli expressing 
VirG. The association of LC3 with these cells was observed, confirming the previous results [46]. 
In pulldown and immunoprecipitation experiments VirG was able to precipitate ATG5 from COS-7 and 
293T cell lysates, but only if IcsB was not present. Increasing amounts of purified IcsB in the mixture 
resulted in decreased binding of ATG5 to VirG in a dose dependent manner, indicating a competitive 
binding of IcsB and ATG5 to VirG. The binding region of both proteins was located in between residues 
320-433 of VirG [46]. 
Finally a model was presented, stating that the interaction of ATG5 and VirG targets the bacterial cell 
for autophagic degradation and might act as a seed for the isolation membrane, which engulfs the 
bacterium. The secretion of the effector protein IcsB constitutes the Shigella camouflage mechanism, as 
IcsB competitively binds to VirG with a higher affinity than ATG5, thus masking the bacterial cell and 
avoiding recognition by the host autophagy system (Figure 12). 
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Figure 12: The Shigella outer membrane protein VirG (green) is bound by human ATG5 (blue), thus targeting the bacterial 
cell for autophagic degradation. As a countermeasure Shigella secretes the IcsB protein (red), which occupies the ATG5 
binding site on VirG with a higher affinity than ATG5. The bacterial cell is not recognized by the innate immune response 
anymore and is free to move and proliferate inside the human cytoplasm. 
In the next chapters the proteins VirG, IcsB and ATG5, which are involved in the autophagy evasion 
mechanism of Shigella are introduced in greater detail. 
1.3.2 VirG 
VirG is a S. flexneri outer membrane protein of 116 kDa and the target for autophagic recognition of 
Shigella cells by ATG5. It is composed of 1102 amino acids and contains three major domains. Residues 
1-52 comprise an unusual signal peptide, responsible for the secretion to the periplasm by the sec-
pathway. The passenger- or α-domain, comprising residues 53-758, is the soluble domain, which is 
presented on the cell surface. It has a MW of 78.0 kDa and a pI of 4.7. The β-core, comprising amino 
acids 759-1102, adopts a β-barrel fold and anchors VirG to the bacterial outer membrane [132]. An 
overview of the VirG domains is given in Figure 13 a. The virG gene is located on the Shigella virulence 
plasmid [100]. 
 
Figure 13: a) Annotated functional regions in VirG. b) Structure of the autochaperone domain from PDB-entry 3ML3. In the 
N-terminal part (light blue) it shows two turns of a right-handed parallel β-helix, while the C-terminal part (dark blue) 
consists of a β-sandwich [133]. 
VirG is a member of the type Va secretion system [134], also called an autotransporter protein or more 
precisely a self-associating autotransporter (SAAT), as it homo-oligomerizes [135], [136]. Already in 
the cytoplasm, it localizes to the old pole of the bacterial cell, where it is secreted by the sec-pathway to 
the periplasm [137], [138]. Once there, the signal peptide is removed by a special signal peptidase [139] 
and the β-core inserts into the outer membrane. Subsequently the passenger domain is passed through 
the β-core and is presented on the cellular surface [132]. The distribution of VirG observed in the 
cytoplasm is retained on the bacterial surface, where it forms a gradient with the highest concentration 
at the old cellular pole. The gradient formation is further enhanced by the activity of the specific protease 
IcsP, which cleaves VirG between positions 758 and 759, resulting in the release of the α-domain [140]. 
The presence of LPS is essential for the correct localization of VirG, as defects in the LPS result in 
abnormal distribution of VirG on the cellular surface [141], [142]. 
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The α-domain, which is presented on the bacterial surface, contains a number of subdomains and 
stretches with annotated functions. Residues 634-735 form the autochaperone domain, which assists in 
the folding of the α-domain by forming a structured nucleus, once it is passed through the β-core [143]. 
A stable fragment of this domain has been identified by limited proteolysis and its structure was solved 
by X-ray crystallography [133] (Figure 13 b). A β-sandwich structure constitutes the C-terminal part of 
the autochaperone domain and the N-terminal part is formed by two turns of a right-handed β-helix. The 
stretch between residues 532-570 is called the polar targeting region. It is sufficient to localize VirG to 
the old pole of the bacterial cell, although the responsible molecular system and binding partners have 
not been identified yet [136]. A region comprising residues 320-433 binds both human ATG5 and 
Shigella IcsB and plays a role in the targeting of Shigella cells by autophagy and the bacterial 
camouflage mechanism as described in chapter 1.3.1. 
The region comprising residues 117-332 is formed by a series of glycine-rich repeats (GRRs) [144]. 
Residues 103-433, which comprise the GRRs and additional N- and C-terminal stretches, are sufficient 
for the interaction with N-WASP in vitro [145]. For N-WASP interaction in vivo and actin tail formation 
residues 53-729, so essentially the whole α-domain, are necessary [146]. Recently the N-WASP binding 
region was narrowed down to three stretches: 1) N-WASP interaction region I (IRI) comprising residues 
185-312, 2) IRII comprising residues 330-382 and 3) IRIII comprising residues 508-730. Amino acids 
V382, Y716 and D717 are of special importance for this interaction. It has also been shown that one 
molecule of N-WASP interacts with different molecules of VirG [135]. VirG binds the N-WASP-GBD 
in a manner similar to Cdc42 and thereby activates N-WASP [85], [89]. Activated N-WASP in turn 
activates the Arp2/3 complex that generates a propulsive force by forming the branched actin tail, typical 
for the intracellular motility of Shigella cells (chapter 1.2). 
Residues 104-506 are essential for the interaction with vinculin, a protein that links actin filaments and 
focal adhesions [147]. Vinculin interacts with VASP and the presence of VASP could enhance actin 
polymerization [148]. It was also proposed that the actin filaments, which are bound to vinculin, 
facilitate the formation of new branches by the Arp2/3 complex [149]. However the interaction with 
vinculin is not essential for ABM [150]. Only recently, residues 507-758 were shown to interact with 
apyrase, a periplasmic Shigella enzyme with ATPase activity. Apyrase has been shown to be important 
for the unipolar localization of VirG and intercellular spread [151]. An overview of the different 
functional regions of the VirG α-domain is given in Figure 13 a. 
Two different functions have been assigned to the VirG protein. The first is the function in intracellular 
ABM by the activation of N-WASP, already described in chapter 1.2. VirG is the only Shigella protein 
that is essential for ABM, as VirG expressing E. coli cells also show ABM in vitro [152]. Earlier in the 
infection cycle, when Shigella cells reside in the intestinal lumen, VirG acts as an adhesin binding to a 
still unknown receptor on the surface of human cells [108], which is its second function. VirG shows 
different proteolytic digestion patterns, depending on what function it exerts, indicating that the two 
states adopt different conformations [108]. Additionally VirG has an ATPase activity, whose biological 
role has yet to be identified [144]. 
1.3.3 IcsB and IpgA 
The IcsB protein is the factor, which is responsible for the Shigella camouflage mechanism as described 
in chapter 1.3.1. IcsB is a 56.4 kDa protein that is coded upstream the ipaBCDA-operon, which is located 
in the pathogenicity island of the virulence plasmid. It comprises 494 amino acids with a calculated pI 
of 9.3. It is an effector protein, secreted via the Shigella TTSS, and is complexed by a specific chaperone 
as long as it resides inside the bacterial cytoplasm. In the case of IcsB, this chaperone is IpgA [131]. 
The structure of IcsB or homologues, like Burkholderia spp. BopA, is currently unknown. 
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Functional annotations exist for several regions of the IcsB protein. The first 15 amino acids represent 
a signal peptide, which is important for secretion by the TTSS. The chaperone binding domain (CBD), 
comprising residues 171-247, binds the specific chaperone IpgA [131]. Additionally a Rho-GTPase 
inactivation domain (RID) has been identified by a bioinformatics approach, which resides between 
residues 128-169 and 263-319. This domain is predicted to have a protease or acetyltransferase function 
and to inactivate small Rho-GTPases like Rho, Rac or Cdc42 [153]. Between residues 288-351, a 
cholesterol binding domain has been located [154]. In the UNIPROT database [155], a potential coiled 
coil domain, comprising residues 431-458, is annotated that has been identified by prediction software, 
e.g. COILS [156]. The predicted coiled coils might be involved in a so far unreported dimerization of 
the protein. An overview of the functional regions of IcsB is given in Figure 14. 
 
Figure 14: Annotated functional regions in IcsB. 
IpgA is the specific chaperone of IcsB and a small protein of 15.1 kDa. It is composed of 129 amino 
acids and has a calculated pI of 4.8. It is coded directly downstream of icsB on the virulence plasmid 
[131]. Unlike typical chaperones that help in the folding of proteins, the function of IpgA is to keep the 
CBD of IcsB in an unfolded state. It also serves for the recognition of IcsB as a substrate for the TTSS. 
The inner diameter of the TTSS needle is about 20 Å [157]. Hence, secreted proteins have to pass the 
needle in an at least partially unfolded state. The already unfolded CBD inserts easily into the needle, 
while the tertiary structure of the remaining protein is removed in an ATP-dependent fashion, during 
the transport of the protein through the needle complex [158]. IpgA is removed in this process and stays 
in the bacterial cytoplasm, while IcsB refolds after its secretion into the host cytoplasm. 
IcsB is required for Shigella pathogenicity [131]. It has a function in binding VirG, which comprises the 
Shigella camouflage mechanism, as described in chapter 1.3.1. The VirG binding regions in IcsB have 
not been identified yet. Secreted IcsB localizes to the bacterial surface [131] and, as recently described, 
helps in the recruitement of Toca-1 to the surface of Shigella cells [159]. Toca-1 is required for the 
activation of N-WASP, as described in chapter 1.2. Even though Toca-1 is essential for Shigella ABM 
[160], the localization to the bacterial surface is not, as deletion of IcsB does not lead to decreased 
intracellular mobility [131] and IcsB is not necessary for actin tail formation [159]. 
1.3.4 ATG5 
ATG5 is the human protein that recognizes VirG and targets Shigella cells for autophagic degradation, 
as described in chapter 1.3.1. ATG5 is a 32.4 kDa protein, which is composed of 275 amino acids and 
has a calculated pI of 5.5. A second isoform has been reported that results from alternative splicing and 
begins with residue M80 [155]. ATG5 consists of two ubiquitin-like fold domains, UFD-1 and UFD-2, 
and an α-helical bundle region (HBR) [161]. An overview of the annotated domains of ATG5 is shown 
in Figure 15 a. At the beginning of this PhD work, structural information on ATG5 was limited to the 
X-ray structure of the Saccharomyces cerevisiae protein in complex with N-terminal fragments of Atg16 
(PDB-entries 2DYM, 2DYO) (Figure 15 b). Residue K130 in the HBR is coupled to the C-terminal 
glycine of ATG12 via an isopeptide-bond in an ubiquitin-like conjugation reaction, involving both 
ATG7 and ATG10, as described in chapter 1.1. Residue T75 is a phosphorylation site of the MAP-
Kinase p38. Phosphorylation in this location results in reduced autophagy [162]. Between residues T193 
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and T194, a calpain cleavage site has been located. Cleaved ATG5 is transported to mitochondria, which 
results in the release of cytochrome c and the activation of caspases, leading to apoptosis [163]. 
However, more recent studies couldn’t confirm the previously reported calpain mediated cleavage of 
ATG5 [20], [164]. 
 
Figure 15: a) Annotated domains in ATG5. b) S. cerevisiae Atg5 structure from PDB-entry 2DYM. Atg5 consists of an N-
terminal α-helix (orange), two ubiquitin-like fold domains (UFDs, blue and red), an α-helical bundle region (HBR, green) and 
two linker regions (grey). 
ATG5 exerts a number of different functions in human cells. 1) ATG5 is a central regulator in autophagy. 
ATG16L1 and TECPR1 bind competitively to ATG5 by means of their ATG5 interaction motifs 
(AFIMs) [165]. Three stretches in ATG5, comprising residues D4-R15, P34-K51 and H241-T249, are 
implicated in these interactions (derived from PDB-entries 4GDK, 4TQ1). Binding with ATG16L1 is 
associated with autophagosomal elongation, as described in chapter 1.1. In contrast binding to TECPR1 
is a prerequisite for the fusion of autophagosomes and lysosomes [166]. 2) ATG5 also regulates 
apoptotic cell death. The interaction of ATG5 with the death domain of FADD plays an important role 
in apoptosis, as depletion of ATG5 results in suppression of IFN-γ induced cell death, while 
overexpression of ATG5 results in the induction of cell death [36]. FADD is a protein that interacts with 
the death receptor Fas and transfers the death signal by binding and activation of procaspase 8 [167]. 3) 
ATG5 has been shown to interact with VirG, resulting in targeting of internalized bacterial cells by 
autophagy, as described in chapter 1.3.1. 
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2 Aims of this work 
 
The objective of this work was a more detailed understanding of the molecular basis of the Shigella 
camouflage mechanism, using biochemical and structural biology methods. For this reason, the three 
involved proteins, VirG, IcsB and ATG5, first had to be produced as homogenous and soluble protein 
in high purity and quantity, to be suitable for crystallization experiments. Then the structures of the three 
individual proteins, as well as the complex structures of VirG/IcsB and VirG/ATG5, should be solved 
by X-ray crystallography to characterize the interaction surfaces. Using these results, a reporter system 
should be designed, to use a high throughput screening method for the search of a low MW compound 
that acts as an inhibitor of the camouflage mechanism, by disrupting the VirG/IcsB interaction, while 
leaving the VirG/ATG5 interaction undisturbed. This compound would have reestablished the host cell’s 
pathogen defense systems and induce autophagy and degradation of Shigella, hence it could be used as 
a lead structure for the development of a new therapeutic treatment, specific against Shigella infections. 
Biophysical and biochemical methods should be used for the further characterization of the proteins, 
complexes and interactions involved in the camouflage mechanism, e.g. SAXS for the characterization 
of the proteins in solution and different interaction methods for the determination of dissociation and 
inhibitory constants. 
As a side project, the molecular mechanism for the inhibitory effect of the phosphorylation of ATG5 
residue T75 on autophagy, should be investigated. To this end, the structures of a phosphomimetic 
ATG5 mutant T75E and a control mutant T75A, should be elucidated and compared to the structure of 
the wild type protein. These results should be complemented with a biophysical characterization of the 
ATG5 variants and interaction studies with ATG16L1. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Buffers, solutions and media 
Table 1: Buffers used in this work. 
Name Formulation 
PBS buffer (10x) 1.37 M NaCl 
27 mM KCl 
14.4 g/l Na2HPO4 
2.4 g/l KH2PO4 (≙ 120 mM Phosphate pH 7.4) 
adjust pH to 7.4, using 10 M NaOH 
sterile-filter, using 0.2 μm filter, store at room temp. 
PBS-T buffer 0.1% (v/v) Tween20 
in 1x PBS 
store at room temperature 
EDTA 0.5 M EDTA 
adjust pH to 8.0 to dissolve 
sterile-filter, using 0.2 μm filter, store at room temp. 
DNA loading buffer (10x) 20% (w/v) Ficoll 400 
0.25% (w/v) Bromphenol blue 
0.25% (w/v) Xylene cyanol 
in 0.5 M EDTA pH 8.0 
store at -20°C 
TAE buffer (50x) 2 M TRIS base 
1 M Acidic acid 
50 mM EDTA 
autoclave, store at room temperature 
SDS loading buffer (2x) 100 mM TRIS pH 6.8 
4% (w/v) SDS 
20% (v/v) Glycerol 
200 mM DTT 
0.2% (w/v) Bromphenol blue 
store at -20°C 
Laemmli buffer (10x) 0.25 M TRIS pH 8.5 
1.92 M Glycine 
1% (w/v) SDS 
store at room temperature 
Coomassie Brilliant Blue staining solution 0.1% (w/v) Coomassie brilliant blue R250 
40% (v/v) Ethanol 
10% (v/v) Acidic acid 
store at room temperature 
Destaining solution 40% (v/v) Ethanol 
10% (v/v) Acidic acid 
store at room temperature 
CD buffer 1.378 g/l Na2HPO4∙2H2O 
0.352 g/l NaH2PO4∙2H2O 
(≙ 10 mM Phosphate pH 7.4), prepare freshly 
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Lysine methylation buffer 50 mM HEPES pH 7.5 
250 mM NaCl 
prepare freshly 
Lysine methylation SEC buffer 20 mM TRIS pH 7.5 
200 mM NaCl 
prepare freshly 
BLI regeneration buffer 25 mM Glycine 
adjust pH to 2.5 
Transfer buffer 25 mM TRIS pH 8.0 
192 mM Glycine 
10% (v/v) Methanol 
store at room temperature 
TBS buffer (10x) 100 mM TRIS pH 7.5 
1.5 M NaCl 
sterile-filter, using 0.2 μm filter, store at room temp. 
TBS-T buffer 0.1% (v/v) Tween20 
in 1x TBS 
store at room temperature 
Blocking solution 5% (w/v) skim milk powder 
in TBS-T 
store in fridge 
Staining solution 10 ml alkaline phosphatase buffer 
66 μl NBT 
33 μl BCIP 
Test-expression lysis buffer 50 mM TRIS pH 8.0 
200 mM NaCl 
5 mM BME 
1 mM PMSF 
prepare freshly 
Test-expression washing buffer 50 mM TRIS pH 8.0 
200 mM NaCl 
5 mM BME 
10 mM Imidazole 
prepare freshly 
VirG lysis buffer 50 mM HEPES pH 7.0 
300 mM NaCl 
5 mM BME 
prepare freshly 
IcsB lysis buffer 50 mM HEPES pH 7.4 
200 mM NaCl 
5 mM BME 
prepare freshly 
ATG5 lysis buffer 50 mM HEPES pH 7.0 
500 mM NaCl 
5% Glycerol 
5 mM BME 
prepare freshly 
washing buffer lysis buffer with 30 mM Imidazole, prepare freshly 
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elution buffer lysis buffer with 250 mM Imidazole, prepare freshly 
regeneration buffer lysis buffer with 500 mM Imidazole, prepare freshly 
SourceQ low salt buffer 50 mM TRIS pH 8.0, 5 mM DTT 
sterile-filter, using 0.2 μm filter, degas, 
prepare freshly 
SourceQ high salt buffer 50 mM TRIS pH 8.0, 1 M NaCl, 5 mM DTT 
sterile-filter, using 0.2 μm filter, degas, 
prepare freshly 
SourceS low salt buffer 50 mM MES pH 6.0, 5 mM DTT 
sterile-filter, using 0.2 μm filter, degas, 
prepare freshly 
SourceS high salt buffer 50 mM MES pH 6.0, 1 M NaCl, 5 mM DTT 
sterile-filter, using 0.2 μm filter, degas, 
prepare freshly 
SEC buffer lysis buffer with 5 mM DTT instead of BME 
sterile-filter, using 0.2 μm filter, degas, prepare freshly 
 
Table 2: Media used in this work. 
Name Formulation 
LB medium 10 g/l Tryptone 
5 g/l Yeast extract 
7 g/l NaCl 
for solid medium add 16 g/l agar 
autoclave, store at room temperature 
TB salts (10x) 0.17 M KH2PO4 
0.72 M K2HPO4 
autoclave, store at room temperature 
TB medium 12 g/l Tryptone 
24 g/l Yeast extract 
0.4% (v/v) Glycerol 
fill up to 900 ml 
autoclave, store at room temperature 
add 100 ml TB salts before use 
Mg solution (100x) 1 M MgCl2 
1 M MgSO4 
autoclave, store at room temperature 
Glucose solution (100x) 2 M Glucose 
sterile-filter, using 0.2 μm filter, store at room temperature 
SOC medium 20 g/l Tryptone 
5 g/l Yeast extract 
10 mM NaCl 
2.5 mM KCl 
autoclave 
before use add 10 ml/l Mg solution, 10 ml/l glucose solution, 
adjust pH to 7.0 using 10 M NaOH 
sterile-filter, using 0.2 μm filter, store at -20°C 
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Table 3: Antibiotics used in this work. 
Name Formulation 
Ampicillin (1000x) 100 g/l Ampicillin 
sterile-filter, using 0.2 μm filter, store at -20°C 
Kanamycin (1000x) 30 g/l Kanamycin 
sterile-filter, using 0.2 μm filter, store at -20°C 
Chloramphenicol (1000x) 34 g/l Chloramphenicol 
in 70% (v/v) ethanol 
store at -20°C 
 
Table 4: Buffers and media used for the ESPRIT system in the laboratories of Darren Hart at the EMBL in Grenoble. 
Name Formulation 
MgSO4 solution 9 g/l MgSO4∙7H2O 
autoclave, store at room temperature 
Hogness modified freezing medium 
(HMFM, 10x) 
63 g/l K2HPO4 
18 g/l KH2PO4 
9 g/l Na3Citrate 
44% (v/v) Glycerol 
autoclave 
add 50 ml MgSO4 solution 
sterile-filter, using 0.2 μm filter, store at room temp. 
Biotin solution 20 mM Biotin 
dissolve in half of the final volume 
add 1 M NaOH until the solution clears up 
fill up to final volume 
sterile filter, using 0.2 μm filter, store in fridge 
Denaturation solution 0.5 M NaOH 
1.5 M NaCl 
store at room temperature 
Neutralization solution 1 M TRIS 
1.5 M NaCl 
adjust pH to 7.5 using HCl 
store at room temperature 
Saline sodium citrate (SSC) buffer (20x) 0.3 M Na3Citrate 
3 M NaCl 
adjust pH to 7.0 using HCl 
store at room temperature 
Gomori buffer (10x) 40.96 g/l Na2HPO4 
25.37 g/l NaH2PO4 (≙ 0.5 M Phosphate pH 7.0) 
sterile-filter, using 0.2 μm filter, store at room temp. 
Spheroplast formation buffer 20 mM TRIS pH 8.0 
300 mM NaCl 
20% (w/v) Sucrose 
0.1% (w/v) Lysozyme 
store in fridge 
 
 
 
 
  Materials and Methods 
  27 
Lysis buffer 10 mM TRIS pH 7.0 
0.5% (v/v) Brij 
0.005% (v/v) Benzonase 
store in fridge 
Washing buffer 300 mM NaCl 
5 mM Imidazole 
in 1x Gomori buffer 
store in fridge 
Elution buffer 300 mM NaCl 
300 mM Imidazole 
in 1x Gomori buffer 
store in fridge 
Blocking solution 5% (w/v) whole milk powder 
in PBS-T 
store in fridge 
 
3.1.2 Bacterial strains 
Table 5: Bacterial strains used in this work. 
Name Description Supplier 
DH5α F- λ- endA1 glnV44 thi-1 recA1 relA1 
gyrA96 Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 hsdR17 (rK- mK+) phoA supE44 
Thermo Fisher Scientific Inc. 
Rosetta 2 (DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pRARE2 (CamR) 
Merck KGaA 
 
3.1.3 Plasmids 
Table 6: Plasmids used in this work. 
Identifier Description Source 
pSA010 pGEX_GST_Thr_TEV_mcs own lab 
pSA035 pET15b_His_TEV_mcs own lab 
pSA052 pCOLA_Duet_His_MBP_TEV_mcs1_mcs2_S own lab 
pVP006 pCOLA_Duet_Strep_TEV_mcs1_mcs2_S own lab 
pVP008 pCOLA_Duet_Strep_TEV_mcs1_mcs2_S own lab 
pLS063 pESPRIT002_His_TEV_mcs_BAP received from Darren Hart, EMBL 
pLS064 pACYC_Flag_TEV_mcs received from Darren Hart, EMBL 
pAA054 pCOLA_Duet_ZZ_His_TEV_mcs1_mcs2_S own lab 
 
3.1.4 Oligonucleotides 
The oligonucleotides used in this work are listed in the appendix chapter A1. 
3.1.5 Ordered Genes and peptides 
A synthetic human Toca-1 gene, which was codon optimized for E. coli expression, was ordered from 
Eurofins Genomics GmbH. An ATG16L1 peptide, comprising residues 11-43, was ordered from an in 
house peptide synthesis service. 
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3.1.6 Kits 
Table 7: Kits used in this work. 
Name Supplier 
QIAquick PCR Purification Kit Qiagen N.V. 
QIAquick Gel Extraction Kit Qiagen N.V. 
QIAprep Spin Miniprep Kit Qiagen N.V. 
 
3.1.7 Chemicals and Biochemical 
Chemicals were bought in quality p.A. or similar from the following companies: Carl Roth, Honeywell 
Riedel-de Haën, J.T. Baker, Merck KGaA, SERVA, Sigma-Aldrich and VWR International. 
Table 8: Enzymes used in this work. 
Name Supplier 
2x Red PCR Master Mix P.J.K. GmbH 
KOD Hot Start DNA Polymerase Merck KGaA 
T4 DNA Ligase Thermo Fisher Scientific Inc. 
T4 Polynucleotide Kinase Thermo Fisher Scientific Inc. 
Antarctic phosphatase New England Biolabs 
DNase I F. Hoffmann-La Roche AG 
Restriction Endonucleases: NotI-HF, KpnI-HF New England Biolabs 
Lysozyme Sigma-Aldrich 
TEV protease own lab 
 
Table 9: Standards used in this work. 
Name Supplier 
GeneRuler DNA Ladder Mix Thermo Fisher Scientific Inc. 
Unstained Protein Molecular Weight Marker Thermo Fisher Scientific Inc. 
ColorPlus Prestained Protein Marker New England Biolabs 
 
Table 10: Column materials used in this work. 
Name Supplier 
Superdex 200 pg GE Healthcare 
Superdex 200 GL GE Healthcare 
Superdex 75 GL GE Healthcare 
SOURCE 15Q GE Healthcare 
SOURCE 15S GE Healthcare 
Ni Sepharose 6 Fast Flow GE Healthcare 
Strep-Tactin Superflow high capacity IBA GmbH 
Strep-Tactin Macroprep IBA GmbH 
Glutathion Sepharose 4 Fast Flow GE Healthcare 
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3.1.8 Crystallization screens 
Table 11: Crystallization screens used in this work. 
Name Supplier 
Additive Screen Hampton Research 
AmSO4 Qiagen N.V. 
Anions  Qiagen N.V. 
Cations  Qiagen N.V. 
Index  Hampton Research 
JB Classic HTS II Jena Bioscience GmbH 
JCSG+ Qiagen N.V. 
JCSG Core I  Qiagen N.V. 
JCSG Core II  Qiagen N.V. 
JCSG Core III  Qiagen N.V. 
JCSG Core IV Qiagen N.V. 
MBClass Qiagen N.V. 
MIDAS  Molecular Dimensions Ltd. 
Morpheus Molecular Dimensions Ltd. 
PEGs Qiagen N.V. 
PEGs II  Qiagen N.V. 
PGA-LM Molecular Dimensions Ltd. 
pHClear Qiagen N.V. 
Protein Complex Qiagen N.V. 
Silver Bullets Hampton Research 
 
3.1.9 Laboratory equipment 
Table 12: Laboratory equipment used in this work. 
Name Function Supplier 
BP2100S, I2000D Balance Sartorius AG 
XB6200D Balance Precisa Gravimetrics AG 
XS204 Balance Mettler-Toledo International Inc. 
Variomag Mono Direct Magnetic stirrer H+P Labortechnik GmbH 
MR 2000/2002/3001/ 
Hei-Standard 
Magnetic stirrer Heidolph Instruments 
Thermomixer 
comfort/5436/5437 
Thermo mixer Eppendorf AG 
Nutating Mixer Nutating mixer VWR International 
Vortex-Genie 2 Vortex mixer Scientific Industries Inc. 
Sorvall RC 6 (Plus) 
Heraeus Multifuge X3R 
Heraeus Fresco 21 
Centrifuge Thermo Fisher Scientific Inc. 
5417R/5810R Centrifuge Eppendorf AG 
Micro Star 17(R) Centrifuge VWR International 
R-963 Microwave Sharp K.K. 
Milli-Q Advantage A10 Water purification system Merck KGaA 
Herasafe Cleanbench Thermo Fisher Scientific Inc. 
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T-Personal, T-Professional, 
T3000 
Thermocycler Biometra GmbH 
CFX96 Real-Time PCR 
Detection System 
Realtime PCR Bio-Rad Laboratories 
PowerPac 300/Basic Power Supply Bio-Rad Laboratories 
Mini-PROTEAN 
3 Cell/Tetra Cell 
SDS-gel running system Bio-Rad Laboratories 
Trans-Blot Turbo Western blot transfer system Bio-Rad Laboratories 
(Wide) Mini-Sub Cell GT Cell Agarose gel running system Bio-Rad Laboratories 
Gel Logic 212 Pro Gel documentation system Carestream Health Inc. 
UV Transilluminator UV transilluminator Intas Science Imaging 
Instruments GmbH 
Heraeus microbiological 
incubator 
Incubator Thermo Fisher Scientific Inc. 
Multitron Standard Incubation shaker Infors AG 
Bandelin Sonopuls HD 200 Ultrasonic homogenizer BANDELIN electronic GmbH 
& Co. KG 
TS Series Benchtop Homogenizer Constant Systems Ltd. 
EmulsiFlex-C3 Homogenizer Avestin Inc. 
ÄKTApurifier Liquid chromatography system GE Healthcare 
CO8000 Cell Density Meter Cell density meter Biochrom Ltd. 
ND-1000 UV-Vis spectrophotometer Thermo Fisher Scientific Inc. 
Ultrospec 3000 UV-Vis spectrophotometer Pharmacia 
J-815 Circular Dichroism 
Spectrometer 
CD-spectrometer JASCO Inc. 
MicroCal VP-ITC ITC GE Healthcare 
Octet RED96 BLI Pall Corp. 
Monolith NT.115 MST Nanotemper Technologies 
GmbH 
Formulator Liquid handling system Formulatrix Inc. 
Rock Imager 182/1000 Imaging system Formulatrix Inc. 
Honeybee 961 Protein crystallization robot Digilab Inc. 
OryxNano Protein crystallization robot Douglas Instruments Ltd. 
SteREO Discovery.V8 
Stemi SV 8 
Stereomicroscope Carl Zeiss AG 
SZ40 Stereomicroscope Olympus 
Micromax-007 HF X-ray generator Rigaku Corp. 
Saturn 944+ 
R-AXIS IV++ 
X-ray detector Rigaku Corp. 
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Table 13: Laboratory equipment used for the ESPRIT system in the laboratories of Darren Hart at the EMBL in Grenoble. 
Name Function Supplier 
QFill2 Microplate dispenser Genetix 
HiGro Plate incubation shaker GeneMachines 
 Picking and gridding robot Kbiosystems robotic solutions 
Genesis Workstation 200 Liquid handling system Tecan Group AG 
Typhoon Trio Variable Mode 
Imager 
Fluorescence scanner GE Healthcare 
 
3.2 Methods 
3.2.1 Cloning 
3.2.1.1 Polymerase chain reaction (PCR), 2 step PCR, Colony PCR 
For the amplification of a DNA fragment for cloning, 0.5 μl template DNA, 5 μl KOD buffer (10x), 5 μl 
dNTPs (2 mM each), 3 μl MgSO4 (25 mM), 2 μl forward primer (10 pmol/μl), 2 μl reverse primer 
(10 pmol/μl), 1 μl KOD DNA polymerase and 31.5 μl H2O were mixed and the following PCR program 
was run: 
1. 95°C, 2 min 
2. 95°C, 30 sec 
3. 55°C, 15 sec 
4. 70°C, 20 sec/1000 bp → 2. (40x) 
5. 70°C, 10 min 
6. 10°C, hold 
DNA loading buffer (10x) was added and the reaction mixture was loaded on a 0.8% agarose gel. The 
correct band was excised and the DNA was purified, using the QIAquick Gel Extraction Kit. 
To perform a 2-step PCR, the two PCR reactions for the first step were run according to the protocol 
above. 0.5 μl of the two reactions were used as template to set up a new PCR reaction for the second 
step, which was again run according to the protocol above. The DNA was loaded on an agarose gel and 
purified, as described above. 
For a colony PCR, 10 μl 2x Red PCR Master Mix, 2 μl forward primer, 2 μl reverse primer and 6 μl 
H2O were mixed. An Eppendorf tube with 0.5 ml of LB-medium was prepared. A colony from a LB-
agar plate was picked and transferred to both the PCR tube and the Eppendorf tube. The Eppendorf tube 
was incubated at 37°C. The following PCR program was run on the PCR tube: 
1. 95°C, 5 min 
2. 95°C, 30 sec 
3. 55°C, 30 sec 
4. 70°C, 1 min/1000 bp → 2. (26x) 
5. 70°C, 10 min 
6. 10°C, hold 
The PCR reaction mixture was loaded directly on a 0.8% agarose gel and checked for a PCR product of 
the correct size. If the clone was positive, 5 ml of LB in a test-tube were inoculated with 200 μl of culture 
from the Eppendorf tube and incubated at 37°C, 130 rpm overnight. 
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3.2.1.2 Restriction enzyme digestion 
≤ 10 μg plasmid or PCR fragment, 5 μl NEBuffer 4 (10x), 1 μl NotI-HF and 1 μl KpnI-HF were mixed, 
filled up to 50 μl with H2O and incubated at 37°C for 1 h. To dephosphorylate a plasmid, 5 μl antarctic 
phosphatase buffer and 2 μl antarctic phosphatase were added and incubated at 37°C for 30 min, then at 
65°C for 5 min. DNA loading buffer (10x) was added and the reaction mixture was loaded on a 0.8% 
agarose gel. The correct band was excised and the DNA was purified, using the QIAquick Gel Extraction 
Kit. 
3.2.1.3 Ligation 
0.5 μl plasmid (digested, dephosphorylated), 4 μl insert (digested PCR fragment), 2 μl T4 DNA ligase 
buffer, 1 μl T4 DNA ligase and 12.5 μl H2O were mixed and incubated at room temperature for 30 min. 
3.2.1.4 Transformation 
10 μl of ligation reaction mixture or 1 μl of purified plasmid was added to one aliquot of competent cells 
and incubated on ice for 30 min. The cells were heat shocked at 42°C for 90 sec, incubated on ice for 
2 min and 1 ml of SOC medium was added. The cells were incubated at 37°C, 700 rpm for 1 h, then a 
part or all of them were plated on LB-agar and incubated at 37°C overnight. For cotransformations 2 μl 
of each purified plasmid were added and all of the cells were plated. 
3.2.1.5 Plasmid sequencing 
500 ng plasmid (concentration ≤ 500 ng/μl, volume ≤ 5 μl) and 1 μl primer (10 pmol/μl) per sequencing 
reaction were sent to an in house sequencing service to obtain the sequence of a plasmid. 
3.2.1.6 Storage of bacterial strains 
0.5 ml of overnight culture grown to stationary phase and 0.5 ml 86% glycerol were mixed briefly, using 
a vortex mixer and stored at -80°C (also possible at -20°C for short periods of time). 
3.2.2 Protein production and purification 
3.2.2.1 Small scale test-expressions 
Small scale test-expressions were performed to determine the best expression conditions for the 
production of a certain protein of interest. Usually different temperatures, IPTG concentrations and 
expression times were tested, but also other conditions like the type of culture medium and the 
expression strain could have been varied. A large culture of an E. coli strain, expressing the protein of 
interest, in TB was inoculated from an overnight preculture to OD 0.03 and grown at 37°C, 130 rpm to 
OD 0.6-0.8. At this point the culture was split into a number of smaller cultures, each containing 30 ml 
of volume, and induced, using two different IPTG concentrations (50 and 200 μM). The cultures were 
further incubated at two different temperatures (20°C and 37°C), 130 rpm overnight. A first 10 ml 
sample was taken 3 h after induction, a second 10 ml sample after overnight expression. 
The samples were centrifuged at 4°C, 5000 rpm for 5 min and the cell pellets were resuspended in 1 ml 
of lysis buffer each. The cells were lysed by sonication at 4°C, three times 10 seconds at 50% amplitude. 
20 μl samples were taken and centrifuged at 4°C, 13000 rpm for 10 min. The pellet was boiled in 20 μl 
SDS loading buffer as a sample of the insoluble proteins. The rest of the lysed cells was centrifuged at 
4°C, 13000 rpm for 30 min and the supernatant was given to 20 μl of the affinity beads, matching the 
affinity tag of the protein of interest. They were incubated at 4°C for 30 min for protein binding. The 
beads were spun down at 4°C, 2000 rpm for 1 min and washed twice in 1 ml of washing buffer. Finally 
the beads were boiled in 20 μl SDS loading buffer as a sample of the purified soluble protein. 
All protein samples were analyzed on an SDS-gel. The expression condition, yielding most purified 
soluble protein, was identified and used in later large scale expressions. 
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3.2.2.2 Large scale protein expression and purification 
Large scale expressions and purifications were performed to produce pure protein for crystallization 
setups and biochemical studies. Depending on the expected protein quantity, 0.5 l up to 16 l of TB were 
inoculated from an overnight preculture to OD 0.03 and grown at 37°C, 130 rpm to OD 0.6-0.8. If the 
best expression condition was at 20°C, the temperature was switched at OD 0.4. The cultures were 
induced, using the IPTG concentration determined in test-expressions (usually 50 μM) and grown for 
the determined period of time (usually overnight). The cultures were spun down at 4°C, 5000 rpm for 
10 min, the pellets were weighed and resuspended 5∙x ml of lysis-buffer per x g of pellet. 1 mM PMSF, 
5 mM MgCl2, 50 μg per liter of culture DNase and 5 mg per liter of culture lysozyme were added and 
the cells were lysed twice, using a homogenizer. The lysate was centrifuged at 4°C, 16000 rpm for 
45 min. 
For a His-tagged protein purification 20 mM imidazole were added to the cleared lysate. His-affinity 
beads were prepared by washing with 20 column volumes (CV) H2O and 20 CV lysis buffer and added 
to the cleared lysate. The amount of beads was calculated, so that they were slightly overloaded, 
according to the expected protein quantity. The lysate was stirred at 4°C for 1 h for protein binding. The 
beads were loaded into a column and washed, using 50 CV of washing buffer. The protein was eluted 
from the beads with 10 CV of elution buffer before the beads were regenerated by washing with 10 CV 
regeneration buffer, 20 CV H2O, 10 CV 5 M guanidinium chloride, 20 CV H2O and 10 CV 20% EtOH 
(for storage). 
For a Strep-tagged protein purification the Strep-affinity beads were prepared by washing with 20 CV 
of lysis buffer and added to the cleared lysate. The lysate was stirred at 4°C for 1 h for protein binding. 
The beads were loaded into a column and washed, using 50 CV of lysis buffer. The protein was eluted 
with four times 1 CV of lysis buffer, supplemented with 2.5 mM D-desthiobiotin. The beads were 
regenerated by washing with 10 CV of lysis buffer, supplemented with 1 mM HABA, and 20 CV of 
lysis buffer (also for storage). If the HABA couldn’t be completely removed, a high pH washing step 
was added. 
For a GST-tagged protein purification the lysis buffer was replaced by PBS buffer, as with PBS usually 
higher protein yields were obtained. The GST-affinity beads were prepared similar to His-affinity beads 
and added to the cleared lysate. The lysate was stirred at 4°C for 1 h for protein binding. The beads were 
loaded into a column and washed, using 50 CV PBS supplemented with 5 mM BME. The protein was 
eluted with four times 1 CV of PBS supplemented with 5 mM BME and 20 mM GSH (pH adjusted). 
Then the beads were regenerated similar to His-affinity beads. 
If the affinity tag was to be cleaved off, 1-2% (w/w) TEV protease were added to the elution fraction 
and incubated at 4°C overnight. Samples of all affinity purification steps were analyzed on an SDS-gel 
and the protein concentrations in the elution fractions were determined spectrophotometrically. 
The buffers for all following chromatography steps were 0.2 μm filtered and degassed. For ion exchange 
chromatography (IEC), the column was prepared by washing with 2 CV of H2O and repeated low salt, 
high salt washing steps of 0.5 CV. Finally the column was equilibrated in low salt buffer. The protein 
was diluted to about 50 mM NaCl with low salt buffer, 0.2 μm filtered and loaded onto the column. The 
column was washed with 2 CV of buffer at 50 mM NaCl before a gradient to 750 mM NaCl over 20 CV 
was applied. The elution from the gradient was fractionated and analyzed on an SDS-gel to identify the 
protein containing fractions, which were pooled. The column was cleaned by washing with 5 CV high 
salt and 5 CV low salt buffer, before the washing program from the beginning was repeated, and it was 
stored in 20% EtOH. 
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For size exclusion chromatography (SEC) the column was prepared by washing with 1 CV of H2O and 
equilibrated with 1 CV of SEC buffer. The protein was concentrated to 1-2% of the CV, using an 
appropriate Vivaspin concentrator. It was centrifuged at 4°C, 13000 rpm for 10 min to remove particles 
and loaded onto the column. 1 CV of SEC buffer was run over the column and the elution was 
fractionated and analyzed on an SDS-gel to identify the protein containing fractions, which were pooled. 
The column was washed with 1 CV H2O and 1 CV 20% EtOH for storage. The protein was concentrated 
to 10-20 mg/ml before it was aliquoted, frozen in liquid nitrogen and stored at -80°C for further use. 
3.2.3 Lysine methylation 
Lysine methylation is a fast and easy method to modify the surface of a protein if it is not possible to 
identify initial crystallization conditions. The protein sample was dialyzed against 4 l lysine methylation 
buffer at 4°C overnight. It was diluted to a concentration of 1 mg/ml, 20 μl 1 M dimethylaminoborane 
complex (ABC) and 40 μl 1 M formaldehyde per ml of protein solution were added and it was incubated 
at 4°C for 2 h. Another 20 μl 1 M ABC and 40 μl 1 M formaldehyde per ml of protein solution were 
added and it was incubated at 4°C for another 2 h. Finally 10 μl 1 M ABC per ml of protein solution 
was added and the mixture was incubated at 4°C overnight. The protein was centrifuged at 4°C, 
13000 rpm for 10 min to remove precipitate and separated on a SEC column in lysine methylation SEC 
buffer. This protocol was adapted from [168]. 
3.2.4 Protein characterization 
3.2.4.1 Western blot 
Western blotting was used to detect a certain protein or affinity tag in a complex mixture with high 
sensitivity. An SDS-gel was equilibrated in transfer buffer for 10 min and a PVDF-membrane was first 
activated in 100% MeOH for 5 min, then also soaked in transfer buffer for 10 min. The blotting device 
was assembled, first on the anode a Whatman paper soaked in transfer buffer, then the membrane, the 
gel and on top, in contact with the cathode, another transfer buffer soaked Whatman paper. The gel was 
blotted onto the membrane, using 25 V, 1 A for 30 min. The membrane was incubated in blocking 
solution at room temperature for 1 h. It was washed in TBS-T three times for 5 min, before it was 
incubated with the primary antibody (mouse anti-GST, 1:1000) in TBS-T at room temperature for 1 h. 
The membrane was washed again in TBS-T three times for 5 min and in TBS for 15 min before it was 
incubated with the secondary antibody (goat anti-mouse IgG alkaline phosphatase conjugate, 1:5000) at 
room temperature for 1 h. It was washed again in TBS-T three times for 5 min and in TBS for 15 min. 
Finally the blot was stained by adding staining solution. The staining was stopped by adding H2O, then 
the membrane was washed in H2O and dried. 
3.2.4.2 Thermofluor-assay 
The thermofluor-assay is a method to determine the melting temperature of a protein. It uses the SYPRO 
Orange dye, which binds to hydrophobic regions of proteins. In solution the fluorescence of the dye is 
quenched, but upon binding its fluorescence signal can be detected at 570 nm. The protein and the dye 
are mixed in a certain buffer condition and heated up slowly, starting at 10°C and finishing at 95°C, 
while the fluorescence is monitored by a real time PCR machine. Usually at low temperatures the 
fluorescence is low, as the protein is folded and mostly hydrophilic amino acids cover the surface. The 
protein unfolds at the melting temperature and the fluorescence signal increases, because the 
hydrophobic core of the protein is exposed and the dye binds to it. Upon further heating the fluorescence 
signal decreases again, as the protein aggregates and the hydrophobic residues are not accessible 
anymore. The melting point of the protein is defined as the inflection point of the fluorescence curve 
(Figure 16). By screening different buffer conditions, the optimal buffer for a certain protein can be 
identified. This buffer stabilizes the protein the most, resulting in the highest melting temperature. 
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Figure 16: A typical melting curve of a protein in a thermofluor-assay. The SYPRO Orange dye is used that binds to 
hydrophobic residues. In solution its fluorescence is quenched, but upon binding its fluorescence signal can be detected at 
570 nm. At low temperatures the dye does not bind to the protein and the fluorescence is low. At the melting temperature Tm 
the protein unfolds, the dye binds to the exposed residues from the hydrophobic core and the fluorescence signal rises. At even 
higher temperatures the protein aggregates, the hydrophobic residues are not accessible anymore and the fluorescence signal 
slowly decreases. Tm is defined as the first inflection point of the fluorescence curve. 
First a test was run to determine the optimal concentrations of the protein and the dye. Dilutions of the 
protein to 0.5, 1 and 2 mg/ml, and of the dye to 100x, 50x and 10x from a 5000x stock (from supplier, 
unknown absolute concentration) were prepared. Every combination of protein- to dye-concentration 
was tested. 40 μl protein buffer, 5 μl protein and 5 μl SYPRO Orange were mixed for all the conditions 
and the experiment was run on a realtime PCR machine, as described above. From the appearance of 
the fluorescence curves, the best condition was selected. The curve should have had a shape as described 
above and a sufficient amplitude. Usually 2 mg/ml of protein and 50x or 100x SYPRO Orange were 
identified to yield the best results. 
Table 14: Thermofluor-assay buffer and additive screen used in this work. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 50mM 
Acetate 
pH 4.0 
50mM 
Acetate 
pH 4.4 
50mM 
Citrate 
pH 5.0 
50mM 
Citrate 
pH 5.4 
50mM 
MES 
pH 6.0 
50mM 
MES 
pH 6.4 
50mM 
HEPES 
pH 7.0 
50mM 
HEPES 
pH 7.4 
50mM 
TRIS 
pH 8.0 
50mM 
TRIS 
pH 8.4 
50mM 
CHES 
pH 9.0 
50mM 
CHES 
pH 9.4 
B 50mM 
Acetate 
pH 4.0 
100mM 
NaCl 
50mM 
Acetate 
pH 4.4 
100mM 
NaCl 
50mM 
Citrate 
pH 5.0 
100mM 
NaCl 
50mM 
Citrate 
pH 5.4 
100mM 
NaCl 
50mM 
MES 
pH 6.0 
100mM 
NaCl 
50mM 
MES 
pH 6.4 
100mM 
NaCl 
50mM 
HEPES 
pH 7.0 
100mM 
NaCl 
50mM 
HEPES 
pH 7.4 
100mM 
NaCl 
50mM 
TRIS 
pH 8.0 
100mM 
NaCl 
50mM 
TRIS 
pH 8.4 
100mM 
NaCl 
50mM 
CHES 
pH 9.0 
100mM 
NaCl 
50mM 
CHES 
pH 9.4 
100mM 
NaCl 
C 50mM 
Acetate 
pH 4.0 
200mM 
NaCl 
50mM 
Acetate 
pH 4.4 
200mM 
NaCl 
50mM 
Citrate 
pH 5.0 
200mM 
NaCl 
50mM 
Citrate 
pH 5.4 
200mM 
NaCl 
50mM 
MES 
pH 6.0 
200mM 
NaCl 
50mM 
MES 
pH 6.4 
200mM 
NaCl 
50mM 
HEPES 
pH 7.0 
200mM 
NaCl 
50mM 
HEPES 
pH 7.4 
200mM 
NaCl 
50mM 
TRIS 
pH 8.0 
200mM 
NaCl 
50mM 
TRIS 
pH 8.4 
200mM 
NaCl 
50mM 
CHES 
pH 9.0 
200mM 
NaCl 
50mM 
CHES 
pH 9.4 
200mM 
NaCl 
D 50mM 
Acetate 
pH 4.0 
500mM 
NaCl 
50mM 
Acetate 
pH 4.4 
500mM 
NaCl 
50mM 
Citrate 
pH 5.0 
500mM 
NaCl 
50mM 
Citrate 
pH 5.4 
500mM 
NaCl 
50mM 
MES 
pH 6.0 
500mM 
NaCl 
50mM 
MES 
pH 6.4 
500mM 
NaCl 
50mM 
HEPES 
pH 7.0 
500mM 
NaCl 
50mM 
HEPES 
pH 7.4 
500mM 
NaCl 
50mM 
TRIS 
pH 8.0 
500mM 
NaCl 
50mM 
TRIS 
pH 8.4 
500mM 
NaCl 
50mM 
CHES 
pH 9.0 
500mM 
NaCl 
50mM 
CHES 
pH 9.4 
500mM 
NaCl 
E empty 
F 2mM 
ATP 
2mM 
ADP 
2mM 
AMP 
2mM 
GTP 
2mM 
GDP 
2mM 
NAD 
2mM 
FAD 
1% 
glycerol 
5% 
glycerol 
10% 
glycerol 
20% 
glycerol 
3% 
DMSO 
G 1mM 
DTT 
5mM 
DTT 
10mM 
CaCl2 
10mM 
MgCl2 
10mM 
MnCl2 
10mM 
ZnCl2 
10mM 
NiCl2 
10mM 
FeCl3 
100mM 
KCl 
100mM 
LiCl 
200mM 
KSCN 
10mM 
spermidine 
H 10mM 
Arginine 
10mM 
Alanine 
10mM 
Methionine 
100mM 
Glycine 
3% 
Glucose 
3% 
Galactose 
10mM 
Urea 
5% 
PEG400 
0.5% n- 
Hexyl 
gluco- 
pyranosid 
0.05% n- 
Decyl 
gluco- 
pyranosid 
0.01% 
Triton 
X100 
H2O as 
reference 
 
The second step was the actual buffer screen. The screen shown in Table 14 (row A-D) had been 
prepared in our laboratory and has been used for all conducted assays. Sufficient amounts of the protein 
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and the dye in the optimal concentrations were prepared and 40 μl buffer, 5 μl protein and 5 μl SYPRO 
Orange were mixed for all the conditions. The experiment was performed as described above and the 
optimal buffer condition, corresponding to the highest protein melting temperature, was selected. 
An optional third step was an additive screen. The lower part of the screen in Table 14 (row F-H) 
contained different additives that might have stabilized a protein in solution. A sufficient amount of the 
eight times concentrated buffer, identified in the step before, the protein and the dye in the optimal 
concentrations were prepared and 5 μl buffer, 5 μl protein, 5 μl SYPRO Orange and 35 μl additive were 
mixed for all the conditions. The experiment was performed as described above and stabilizing or 
destabilizing additives were identified by their influence on the protein melting temperature. 
3.2.4.3 Protein interaction studies 
3.2.4.3.1 Pulldowns 
High affinity interactions can be identified by the copurification or protein pulldown of the two binding 
partners. Ideally the two proteins carry different affinity tags, but also one tagged and one untagged 
protein can be used. To identify an interaction, the first protein is bound to the according affinity beads. 
The beads are washed and the second protein, which is not interacting with the affinity-beads, but 
possibly with the first protein bound to the beads, is added. The beads are washed again and are analyzed 
on an SDS-gel. If the second protein is present, it has been pulled down by the first protein, confirming 
an interaction of the two. For this experiment the two proteins can either be provided as lysates or as 
purified proteins. An unspecific interaction of the second protein with the beads can be excluded, by 
running a negative control without the first protein in parallel. The interaction can be verified by binding 
the second protein to the according affinity beads and adding the first protein afterwards. Usually 20 μl 
of affinity beads were incubated with either 1 ml of lysate, containing the first protein, or with 20 μg of 
the purified first protein in 1 ml of buffer, at 4°C for 30 min for protein binding. The beads were washed 
twice with 1 ml of washing buffer, before the second protein was added in 1 ml of lysate or buffer. The 
beads were incubated again at 4°C for 30 min, before they were washed twice with 1 ml of washing 
buffer, boiled in 20 μl SDS loading buffer and analyzed on an SDS-gel. 
3.2.4.3.2 Size exclusion chromatography (SEC) 
SEC can also be used to identify high affinity interactions. The two potential binding partners are mixed 
and separated on a SEC column. The elution is fractionated and analyzed on an SDS-gel. As a control, 
the two individual proteins are run on the same column. The two proteins are interacting, if in the 
mixture, compared to the two single proteins, a new absorption peak emerges at a lower elution volume. 
This new peak corresponds to the complex, which has a higher MW than the two individual proteins. 
The interaction can be verified by the presence of the two protein bands in the corresponding elution 
fractions on the SDS-gel. Usually 1 mg of each of the two proteins were mixed in total volume of 0.5 ml 
and incubated on ice for 30 min, before they were separated on a SEC column. 
3.2.4.3.3 Isothermal titration calorimetry (ITC) 
ITC is a universal method to identify protein-protein, but also protein-small compound and other 
interactions. It is possible to determine the binding affinity KD, the stoichiometry n and the 
thermodynamic parameters ΔH and ΔS. An isothermal titration calorimeter contains two chambers, a 
reference cell filled with water or buffer and a sample cell filled with a solution of the first protein. 
Initially both cells are heated with a small and constant power. Thermoelements measure the temperature 
in both cells and a feedback element modifies the heating power of the sample cell, so that it is heated 
the same way as the reference cell. In the experiment the second protein or binding partner is repeatedly 
injected into the sample cell by a syringe and binds to the first protein in an endo- or exothermic reaction. 
The feedback element increases or decreases the heating power accordingly, to adjust the temperature 
in the sample cell to the one in the reference cell. In case of an exothermic reaction, less heating power 
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is needed to keep the temperature in both cells at the same level, whereas in the case of an endothermic 
reaction, the heating power needs to be increased. The time course of the electric heating power is 
recorded, resulting in a number of peaks, corresponding to the power adjustments during the individual 
injections. The area under the peaks corresponds to the thermodynamic heat that is released or absorbed 
in the reaction and from the course of the whole experiment the above mentioned parameters can be 
determined. 
To prepare the experiment the two protein samples were dialyzed against 4 l of protein buffer at 4°C 
overnight to assure that the buffers were identical. If the binding affinity KD was not known, the 
concentration of the protein in the cell was adjusted to 20 μM and the concentration of the protein in the 
syringe was adjusted to 200 μM. If the binding affinity KD was already known from previous 
experiments, appropriate concentrations for the proteins were calculated, using Equation 1 and Equation 
2. 
 
 ≈ 20 − 100 Equation 1 
 
 ≈ 10 Equation 2 
The protein solutions were temperated to 23°C and degassed. Meanwhile the sample cell and the syringe 
were washed with water and buffer. The two proteins were filled into the sample cell and the syringe 
and the experiment was started. Normally the measurement was performed at 25°C and the protein from 
the syringe was added in 29 10 μl injections. Binding was recognized by the typical curve, showing high 
peaks in the beginning and decreasing peaks later in the experiment. Random peaks with amplitudes 
lower than 0.1 μcal/s indicated that no binding was present. In this case the experiment was repeated at 
least once, using a different temperature. Data analysis was performed, using the software package 
accompanying the ITC machine. 
3.2.4.3.4 Biolayer interferometry (BLI) 
Biolayer interferometry is a technique to quantify the interaction of two biomolecules, using an optical 
interference technique. An incident beam of white light is reflected on a reference surface and on a layer 
of biomolecules. Thereby a wavelength dependent interference pattern is produced. The presence of a 
binding partner on the surface causes an increase of the thickness of the biolayer and thereby a shift of 
the interference pattern by a certain wavelength Δλ that is monitored in realtime. Usually one binding 
partner is immobilized on the surface, while the second binding partner is flushed over it and the 
interaction of the two is monitored as the time dependent wavelength shift. 
BLI can be used to determine the binding affinity KD and the kinetic parameters kon and koff, which are 
the association and dissociation rate constants. kon and koff are directly determined from the time 
dependent wavelength shift and KD is calculated as the quotient of koff and kon. Another possibility to 
determine KD is to use different concentrations of the binding partner and to calculate it from the 
equilibrium concentrations (or wavelength shifts) of the formed complex, using a Michaelis-Menten like 
model. 
The BLI machine used in this work utilized optical fibers with functionalized tips. Usually tips coupled 
to an anti-His antibody were used to immobilize a His-tagged protein and a GST-tagged binding partner 
was tested for interaction. The machine allowed the parallel measurement of up to eight reactions. After 
coupling the His-tagged protein (at a concentration of 20 μg/ml) to the eight tips, the association and 
dissociation of the binding partner at seven different concentrations and one buffer blank were 
monitored. The tips were cleaned in BLI regeneration buffer before another seven concentrations were 
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assessed. The buffer composition as well as the concentration range of the binding partner had to be 
optimized for each experiment, here concentrations between 0.1 and 10 μg/ml were used. For this setup, 
the unspecific interaction of GST with the tips or the His-tagged protein had to be excluded in a control 
experiment. The binding affinity KD was calculated from the equilibrium concentrations of the protein 
complex, using the accompanying software package. 
 
Figure 17: BLI setup to detect the binding of one protein to an immobilized ligand. The reflection of an incident beam of white 
light on two surfaces, produces a wavelength dependent interference pattern. One surface is an internal reference, the second 
surface is the layer of biomolecules. Interaction of the binding partner and the immobilized ligand increases the thickness of 
the layer and causes a shift of the interference pattern by a certain wavelength Δλ that is monitored in realtime. 
3.2.4.3.5 Microscale thermophoresis (MST) 
Thermophoresis is the property of small compounds to move in a temperature gradient, similar to 
electrophoresis, which is the property of charged particles to move in an electric field. The movement 
is dependent on the size, the charge and the hydration shell of the particles, which is represented by the 
Soret coefficient. For proteins, the movement is also influenced by conformational changes and the 
binding of other proteins or small compounds. Even binding a single ion influences the hydration shell 
and the Soret coefficient and thus the mobility of the protein. Microscale thermophoresis can be used to 
determine the binding affinity KD of two proteins. For this purpose, one of the binding partners is labeled 
fluorescently. The concentration of the labeled binding partner has to be optimized, to exclude the 
saturation of the fluorescence detector, and is kept constant in the course of the experiment. It is mixed 
with a dilution series of the unlabeled binding partner and filled into capillaries. The buffer and the type 
of capillary have to be optimized in the first steps of an experiment, to exclude aggregate formation and 
the interaction of the proteins with the capillary surface. An infrared laser generates a temperature 
gradient of some Kelvin on a distance of a few micrometers, resulting in a thermophoretic force, 
experienced by the molecules. The thermophoretic force results in the movement of the proteins along 
the temperature gradient. The movement of labeled protein is monitored, by observing its fluorescence, 
using the same light path as the infrared laser. At higher concentrations of the binding partner, a complex 
is formed, which moves differently in the temperature gradient, due to its changed Soret coefficient, 
resulting in different equilibrium fluorescence values. Complex formation can be recognized by 
sigmoidal binding curves, if the normalized equilibrium fluorescence is plotted against the logarithmic 
concentration of the unlabeled binding partner. The binding affinity KD is calculated by the 
accompanying software, using a Michaelis-Menten like model. 
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The MST machine used in this work measured 16 capillaries, corresponding to 16 concentrations of 
unlabeled protein, at once. One of the binding partners was fluorescently labeled, according to the 
supplied manual. Unlabeled protein concentration between about 10 nM to 100 μM were used. 
3.2.4.4 Circular dichroism (CD) spectroscopy 
Circular dichroism is the property of chiral compounds to differentially absorb left- and right handed 
circularly polarized light. In proteins not only the amino acids, but also the secondary structure elements 
have chiral properties and generate distinct CD-spectral signatures. For this reason CD-spectroscopy 
can be used to determine a proteins secondary structure composition. 
A protein sample was dialyzed twice against 4 l of CD buffer, the first time for 3 h, the second time 
overnight. Afterwards its concentration was adjusted to 1 mM amide bonds. A cuvette with 1 mm light 
path was rinsed extensively with water and buffer. First a buffer blank and afterwards the protein sample 
was filled into the cuvette and the CD-signal was measured between 260 and 190 nm at 20°C. The CD-
signal of the buffer blank was subtracted from the CD-signal of the sample, to obtain the CD-signal of 
the pure protein. Using this data, the accompanying software estimated the secondary structure 
composition of the protein. 
3.2.4.5 Mass spectrometry (MS) 
The following mass spectrometry analyses were performed by an in house service. For the identification 
of protein bands from a Coomassie stained SDS-gel, the bands were excised, washed three times with 
H2O and dried in a vacuum concentrator for 10 min. The protein in the band was subjected to tryptic 
digestion and the sizes of the resulting peptides were determined by mass spectrometry. The protein was 
identified by searching a database, containing theoretical digestion patterns. 
Edman degradation was used to identify the N-termini of protein fragments, resulting from limited 
proteolysis. An SDS-gel containing the fragment was blotted onto a PVDF-membrane. The membrane 
was stained with Coomassie and the fragment band was excised. It was washed three times with H2O 
and dried in a vacuum concentrator for 10 min. The N-terminal residue of the fragment was repeatedly 
removed by the reaction with a phenylisothiocyanate, which was then identified chromatographically. 
The MWs of peptides in a complex mixture of protein fragments, e.g. resulting from limited proteolysis, 
were identified by mass spectrometry and used to calculate their C-termini, using the known N-termini 
from Edman degradation. To perform this experiment a 30 μl sample was dialyzed against 4 l H2O at 
4°C for 2 h and given directly for the identification by mass spectrometry. 
3.2.4.6 Small angle X-ray scattering (SAXS) 
Small angle X-ray scattering is a method to obtain structural informations from a protein in solution. In 
contrast to X-ray crystallography no crystalline material is necessary. An incident X-ray beam falls onto 
a capillary, flushed with a protein solution. The X-rays are scattered and fall on a detector, where their 
distribution is monitored. Proteins in solution are randomly oriented, thus X-ray scattering results in 
radially decreasing intensity distributions (Figure 18). From the form of this intensity distribution, 
certain properties of the protein, like the average particle size and shape, can be deduced. The lower 
resolution limit of SAXS is about 10 Å, hence informations about the quaternary structure of a complex 
or the tertiary structure of a protein can be obtained. As not only the electrons in the protein, but also 
the electrons in the buffer contribute to the X-ray scattering, a buffer blank has to be measured and 
subtracted to obtain the scattering curve of the pure protein. 
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Figure 18: Setup of a typical SAXS experiment. An X-ray beam with wavelength λ is scattered by a protein solution in a 
capillary. The scattered X-rays fall on a detector. Because the proteins are randomly oriented, a radially decreasing scattering 
intensity distribution is observed. Normally the logarithmic intensity is plotted against the momentum transfer s. From the form 
of this scattering curve, certain properties of the protein can be deduced. 
Using SAXS data, it is possible to create low resolution models of the protein. The problem is that a 
three dimensional model is calculated from a one dimensional scattering curve. The assignment is 
mathematically not unique, meaning that differently formed particles can produce the same scattering 
curve. For this reason a number of different models of the protein are created, aligned and averaged to 
obtain the most reliable features. SAXS can also be used to assess conformational changes of a protein 
or the arrangement of proteins in a complex by modifying the quaternary arrangement of different 
domains or proteins to fit the experimental data. It is also possible to determine the oligomerization state 
of a protein and to distinguish between several possible oligomers. 
The ATSAS data analysis software is a program package, developed by the Biological Small Angle 
Scattering group at the EMBL in Hamburg Germany [169]. It contains a number of programs to work 
with and analyze small angle scattering data. Primus is a program to visualize and work with raw 
scattering curves, including operations like subtraction, averaging and merging of curves [170]. Crysol 
calculates the theoretical scattering curve of a protein with known structure and fits it to an experimental 
scattering curve [171]. A chi-value indicates the quality of the fit, the lower the chi-value, the better the 
fit. It can be used, if a high resolution model of the protein in solution is available and has to be verified. 
Gnom calculates the distance distribution function from the scattering curve [172], which is further used 
by dammif, a program that calculates the shape of a protein, using a bead model, which is optimized by 
simulated annealing [173]. The four programs damsel, damsup, damaver and damfilt are used to align 
and average the output models of several dammif runs [174]. Finally sasref is a program that modifies 
the quaternary arrangement of several subdomains or proteins, to fit an experimental SAXS scattering 
curve [175]. Also a number of other programs are included in the package that serve different functions. 
Using the online tool SAXS MoW, the MW of a protein can be determined from its SAXS scattering 
data [176]. 
To perform a SAXS experiment, a protein sample was dialyzed against 2 l of the protein buffer at 4°C 
overnight. It was centrifuged at 4°C, 13000 rpm for 30 min to remove particles and a dilution series was 
prepared, comprising 100 μl samples at concentrations of 5, 2.5, 1.25, 0.63 and 0.31 mg/ml. All 
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concentrations were measured spectrophotometrically. A large amount of buffer was filtered through a 
100 kDa MW cutoff (MWCO) Vivaspin concentrator to remove particles and sent together with the 
protein sample to be measured. SAXS measurements were performed at BM29 of the ESRF in Grenoble, 
France and beamline P12 of PetraIII in Hamburg, Germany. SAXS data analysis was performed, using 
the ATSAS package. 
3.2.5 Protein crystallization 
X-ray crystallography is a method to obtain atomic resolution models of proteins. Other methods 
comprise NMR and cryo EM. However, with NMR it is difficult to work with proteins larger than 
40 kDa and up to date there are only a limited number of atomic or near-atomic resolution structures 
from cryo EM. This makes X-ray crystallography the standard method in the structure determination of 
proteins. The bottleneck in X-ray crystallography is the production of protein crystals, which for some 
proteins is difficult and time consuming or even impossible. 
To crystallize a protein, a solution of highly concentrated (generally 5-20 mg/ml) and pure (>95%) 
protein is necessary. A precipitant is added to decrease the solubility of the protein. This leads to 
supersaturation of the protein and in the best case to the formation of crystals. The phase diagram in 
Figure 19 shows the different phases, the protein solution adopts, depending on the concentrations of 
protein and precipitant. At low concentrations the phase is stable, the protein is soluble and no crystal 
formation is taking place. At intermediate concentrations a metastable phase is formed, which is 
bipartite. In the heterogeneous nucleation phase, crystal growth occurs only from preexisting nuclei, but 
no new nuclei are forming, while in the homogenous nucleation phase, spontaneous nucleation and 
crystal growth is taking place. At too high concentrations the phase is unstable and a precipitate forms, 
which is composed of solid state, non-crystalline protein. Thus for the formation of protein crystals, the 
concentrations of protein and precipitant have to be in the right range. 
 
Figure 19: Crystallization phase diagram. At low protein and precipitant concentrations the phase is stable and no crystal 
formation is taking place. In the metastable heterogeneous nucleation phase, preexisting crystal nuclei can grow, but no new 
nuclei are forming. In the metastable spontaneous homogenous nucleation phase also new crystal nuclei are forming. Finally 
in the unstable precipitation phase the protein spontaneously precipitates, thus forming solid state, non-crystalline material. 
Typical precipitants are salts, alcohols and polymers. Aside from the precipitant, also the pH and the 
presence of other chemicals, so called additives, can influence the crystallization of a protein. However, 
it is not possible to predict, in which combination and concentration ranges, crystal formation takes 
place. For this reason crystallization screens have been developed, to identify the crystallization 
conditions of a certain protein. In principal there are three different kinds of screens. Sparse matrix 
screens probe a wide range of different chemicals and crystallization conditions. In grid screens two 
variables like pH and precipitant concentration are systematically modified. Finally in random screens 
certain classes of chemical substances are mixed in random combinations and concentrations. A large 
number of screens is commercially available from different manufacturers, mostly sparse matrix and 
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grid screens. Random screens are usually used, when a first crystallization condition has been identified, 
to optimize this condition. 
There are many different ways to set up a crystallization experiment, two of which are described here. 
In the sitting drop method a large reservoir is filled with a buffer of a certain composition (crystallization 
or reservoir solution). Apart from the reservoir, a small drop of highly concentrated protein is mixed 
with the buffer in a 1:1 ratio. The space, containing both the drop and the reservoir, is sealed (Figure 
20). As the buffer, containing the protein, is 50% diluted, a net transfer of water from the drop to the 
reservoir occurs by vapor diffusion, until the chemical equilibrium is reestablished. In this process the 
drop volume shrinks and the concentrations of protein and precipitant rise. In the optimal case the 
solution is in the stable phase in the beginning and moves into the metastable phase in the course of the 
experiment, where first crystal nuclei form that grow into crystals. The hanging drop method is 
essentially similar, except that the protein drop is hanging under a cover slip (Figure 20). 
 
Figure 20: Crystallization experiment setups. In the sitting drop setup, a reservoir is filled with buffer of a certain composition. 
A protein drop is mixed with buffer in a 1:1 ratio and placed apart from the reservoir. The space is sealed to prevent drying out. 
Water is transferred by vapor diffusion from the drop to the reservoir, until an equilibrium is reached. The drop volume shrinks 
and the protein and precipitant concentrations rise. The hanging drop setup is similar, the difference is that the drop hangs under 
the coverslip that seals the space. 
Initial crystallization screens were prepared, using a robotic system (96-well sitting drop setups). 
Usually protein concentrations of 5 and 10 mg/ml and a buffer control were used in initial screens. The 
reservoir contained 60-70 μl and the drop had a size of 0.4 μl (0.2 μl protein + 0.2 μl buffer). The plate 
was sealed, using Crystal Clear sealing tape, then it was incubated and monitored at 20°C or 4°C in plate 
incubators and regularly checked for initial crystallization conditions. These conditions were optimized 
in later steps, using self-prepared grid and random screens (24-well hanging drop setups). Here the 
reservoir contained 500-1000 μl and the drop had a size of 2 μl (1 μl protein + 1 μl buffer). The wells 
were sealed, using grease and cover slips. The aim was to obtain large three dimensional crystals, 
suitable for X-ray diffraction experiments. 
To perform X-ray diffraction experiments, protein crystals have to be frozen in liquid nitrogen to avoid 
radiation damage. A cryo protectant solution is needed to prevent the formation of ice crystals during 
the freezing process. Normally the crystallization condition is supplemented with a cryo protectant, e.g. 
glycerol, and tested for the presence of water crystals in an X-ray diffraction experiment. The solution 
without ice crystals, containing the lowest cryo protectant concentration, is then used to freeze the 
protein crystals. The crystal is washed in the cryo protectant solution, mounted onto a nylon loop and 
shock frozen in liquid nitrogen. In this work, usually up to 25% of glycerol were used as cryo protectant. 
The frozen crystals were tested in house for diffraction and sent for data collection to a synchrotron, if 
suitable. Data was collected at PETRA III in Hamburg, Germany, at BESSY II in Berlin, Germany, at 
the SLS in Villigen, Switzerland and at the ESRF in Grenoble, France. 
The setup of a typical X-ray diffraction experiment is shown in Figure 21. The crystal in its nylon loop 
is mounted on a goniometer head, which can be turned in several space dimensions. The crystal is cooled 
in place, by a nitrogen gas cryo stream. An incoming X-ray beam hits the crystal and is partially 
diffracted. The diffracted X-rays hit the detector, which is placed behind the crystal, while the 
undiffracted photons are blocked by the beamstop to prevent detector damage. The crystal is rotated and 
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a series of images is taken by the detector, recording the diffraction patterns. First the space group of 
the crystal is determined, by collecting four diffraction images at 90° angular distance. In this work, 
these images were indexed by iMosflm and a strategy was calculated for optimal data collection. 
 
Figure 21: X-ray diffraction experiment setup. The crystal is mounted on a goniometer and cooled in place by a cryo stream. 
The incoming X-ray beam is partially diffracted and the detector records the diffraction images, while the crystal is rotated. 
The undiffracted X-rays hit the beamstop to prevent detector damage. 
3.2.6 Structure Determination 
A crystal is a macroscopic object that is composed of a translationally repeated general motif, the unit 
cell. The translational symmetry of a crystal is described by the crystal lattice, which can be thought of 
as a pattern of points in space. 14 Bravais lattices, grouped in 7 lattice systems, characterize the different 
possible translational symmetries. The three dimensional unit cell is defined by the length of the three 
lattice vectors a, b and c and by the three angles, enclosed by these vectors α, β and γ. 11 different point 
groups describe the possible internal unit cell symmetries of a protein crystal. The asymmetric unit is 
the smallest motif, by which the content of the unit cell can be reconstructed, using the point group 
symmetry operations (Figure 22 a). The combination of the 11 point groups with the 14 Bravais lattices 
results in 65 space groups, describing the possible symmetries of a protein crystal. Lattice planes are 
mathematical constructs that slice the crystal lattice in a distinct and periodic way. Sets of lattice planes 
are described by Miller indices (h k l) (Figure 22 b). 
 
Figure 22: A two dimensional crystal. a) A crystal is composed of translationally repeated unit cells (black frames), 
characterized by the length of the unit cell vectors a and b. The translational symmetry is described by the crystal lattice (yellow 
dots). Here the unit cell has an internal C2 point group symmetry, thus the content of a unit cell is generated from the content 
of the asymmetric unit (grey line, half of the unit cell) by a 180° rotation. The asymmetric unit contains two copies of a protein, 
the unit cell four copies. b) Lattice planes slice the crystal lattice in a periodic way. Here two sets of lattice planes (blue/red 
lines) with Miller indices (1 3) and (1 -1) are shown. 
The diffraction pattern of a crystal is characterized by distinct spots or reflections of different intensities, 
corresponding to constructively interfering diffracted X-rays (Figure 21). Bragg’s law describes the 
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geometric requirements, which are necessary for constructive interference to occur (Equation 3). The 
diffraction of a crystal is interpreted as the reflection of X-rays on sets of lattice planes. Positive 
interference occurs if the path difference of the reflected waves (2 sin ) is an integer multiple of 
the wavelength () (Figure 23). 
  = 2 sin  Equation 3 
 
 
Figure 23: Diffraction of X-rays in a crystal is interpreted as the reflection of X-rays on sets of lattice planes.   and !  are the 
incoming and diffracted wave vectors, "  is the scattering vector (" = ! −  ),  is the scattering angle of the reflected wave 
and  is the interplanar distance of a set of lattice planes (hkl) (modified from [177]). 
Like lattice planes, the reciprocal lattice is a mathematical concept. It greatly simplifies the description 
of diffraction events and of the conditions, necessary for diffraction to occur. Reciprocal space is 
characterized by inverse relations to real space. Sets of lattice planes in real space are represented by 
reciprocal lattice vectors ∗  in reciprocal space. Using the concept of reciprocal space, the diffraction 
condition from Bragg’s law can be visualized by the Ewald construction. The scattering diagram from 
Figure 23 is placed inside an Ewald sphere of radius 1/λ (Figure 24). From the diagram the relation 
$" $ = 2 sin ⁄  can be derived. The origin of the reciprocal lattice is placed on the right end of the 
Ewald sphere, where the extended incoming X-ray beam would leave the sphere. For a reciprocal lattice 
point, lying on the surface of the Ewald sphere, the condition &∗ & = $" $ = 2 sin  ⁄  is true, which 
corresponds to the constructive interference condition of Bragg’s law. Consequently reflections, 
corresponding to all the lattice planes, whose reciprocal lattice vectors lie on the surface of the Ewald 
sphere, can be observed. 
The question remains, how to reconstruct the electron density in a crystal from the recorded diffraction 
patterns. To find an answer, first the diffraction of a single atom is assessed, followed by the more 
complicated diffraction of molecules and crystals. The atomic scattering factor '( is a complex function 
that describes the diffraction of a single atom (Equation 4). 
 
'( = ) *+, -
.+/012-
 
345(  ,  Equation 4 
*+, - describes the electron density of the atom and "  is the scattering vector. The formula has the form 
of a Fourier integral, hence the electron density of the atom is physically Fourier transformed, resulting 
in a bell shaped intensity distribution. The diffraction patterns of molecules and whole crystals result 
from the addition of the contributions of the structure forming atoms. Diffraction of a single molecule 
produces a continuous and irregular, but centrosymmetric intensity distribution. The diffraction pattern 
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of a molecular crystal shows discrete spots with varying intensities. It can be described as the scattering 
function of the molecule, which is amplified by the number of molecules in the crystal and sampled in 
discrete spots. The positions of these spots can be derived from Bragg’s law, as described above. 
 
Figure 24: The scattering diagram from Figure 23 is placed inside a sphere of radius 1/λ, the Ewald sphere. The relation $" $ =
2 sin  ⁄  can be derived from the diagram. The origin (000) of the reciprocal lattice is placed on the right end of the Ewald 
sphere. If a reciprocal lattice point, described by a vector ∗ , lies on the surface of the Ewald sphere (bright green lattice 
points), the condition &∗ & = $" $ = 2 sin  ⁄  is true, which corresponds to the constructive interference condition from 
Bragg’s law. Consequently the corresponding reflections can be observed on the detector (modified from [177]). 
The formula for the diffraction of a molecular crystal can be rearranged to calculate the complex 
structure factor 6, which contains both the intensity and the phase information of a single reflection, 
described by the Miller indices of the corresponding set of lattice planes ℎ = +ℎ89- (Equation 5). 
 
6 = : '(,< ∙ 345 >? 
/012
<@!
 Equation 5 
'(,<  describes the atomic scattering factor and AB  the coordinates of atom j. The complex structure factor 
6 contains contributions of all atoms in the unit cell. Now the electron density in the crystal *+A - can 
be reconstructed from the complex structure factors, using inverse Fourier summation (Equation 6). 
 
*+A - = 2C : : : 6 cosF2Gℎ A − HI
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 Equation 6 
6 are here the structure factor amplitudes and H the structure factor phases. ℎ = +ℎ89- are the Miller 
indices of the corresponding sets of lattice planes. A problem arises, because the structure factor is 
complex, but only the intensity I of a reflection, which is proportional to |6|4, but not the phase can be 
measured by the detector. Hence the phase information has to be provided from other sources, a situation 
known as the phase problem. One solution is to calculate the phases, using the known structure of a 
similar protein, and to use them to calculate the electron density of the new structure, a method called 
molecular replacement. If no suitable structure is available, experimental methods can be used to obtain 
the needed phase information. Multi wavelength anomalous dispersion (MAD) uses the anomalous 
dispersion of heavy metal ions, which have to be incorporated in the crystal, to obtain the phase 
information. Normally three datasets, using different X-ray wavelength are collected: first at the 
absorption peak of the anomalous scatterer, second at the inflection point of the absorption curve and 
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third at a remote wavelength. Heavy metal ions can be incorporated in a crystal by soaking into a 
preformed crystal, by cocrystallization or by producing and crystallizing selenomethionine labeled 
protein. Single wavelength anomalous dispersion (SAD) needs only one dataset, collected at the 
absorption peak wavelength of the anomalous scatterer, and uses density modification methods to 
improve the initial phases. Multiple isomorphous replacement (MIR) needs at least two anomalous 
datasets with different heavy metals, incorporated in the crystal, additional to the dataset of the native 
crystal. For single isomorphous replacement (SIR) only one anomalous dataset is necessary and density 
modification methods are used to improve the phases. 
In this work, all necessary calculations for the structure determination were performed by computer 
programs. XDS was used to identify and index the spots in the images, then to integrate and scale their 
intensities [178]. In the XDS output files the most probable space group was indicated, which was 
checked, using Pointless. Pointless also tested for the presence of screw axes and checked for twinning 
[179]. The data was reprocessed, using XDS, which was provided with the correct space group. XDS 
included a scaling function, but XSCALE was used to rescale the data, utilizing provided resolution 
shells [178]. XDSCONV was used to convert the XSCALE ahkl output file to a Phenix mtz input file 
[178]. It also marked 5% of the data with an R-free flag, meaning this part of the data was not used in 
later refinement, but in the validation of the structure. The Phenix program Phaser-MR was used for 
molecular replacement [180], [181]. Phenix AutoBuild was used for automated model building [182], 
while WinCoot [183] and phenix.refine [184] were used for iterative manual model building and 
refinement steps. 
Several R-values are used for the evaluation of the quality of the data and the model. Rmeas describes the 
quality of the data, or to what extent symmetry related observations of the same reflection differ from 
each other (Equation 7). 
 
N2/ =
∑ P  − 1∑ $Q,< − 〈Q〉$<@!
∑ ∑ Q,<<  
Equation 7 
Rwork measures how good the refined model describes the experimental data, using a working dataset. 
Rfree is calculated the same way as Rwork, but a separate data set of randomly selected reflections is used, 
which are never used in refinement (Equation 8). Rfree is always larger than Rwork, but the difference 
should not rise above 5%, as this indicates overfitting of the model. 
 NT1/V = ∑ $6
1W − 6/$
∑ 61W  Equation 8 
3.2.7 The ESPRIT system 
The ESPRIT system has been developed in the laboratories of Darren Hart and is located at the EMBL 
in Grenoble, France. It is a system to screen for soluble truncated constructs of difficult to express 
proteins. This is accomplished by the generation of a truncation library of the gene of interest (GOI) on 
the DNA level and by the subsequent screening of a large number of clones for soluble protein 
expression. The GOI can be truncated from the N-terminus, the C-terminus or from both sides. The 
soluble protein expression is quantified by a colony blotting technique, detecting N- and C-terminal 
signals with fluorescent probes. The 96 most promising clones are further analyzed by small scale test-
expressions and the protein quantity is assessed by Western blotting and Coomassie stained SDS-gels. 
The process is highly automated by a robotic system for picking and handling of clones and a liquid 
handling system for test-expressions [185]. 
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The GOI has to be cloned into the pESPRIT002 vector, using the AscI and NsiI restriction sites. This 
vector contains an N-terminal His-tag and a C-terminal biotin acceptor peptide (BAP). For the detection 
of soluble protein, the His-tag can later be detected by fluorescently labeled antibodies. The BAP is 
coupled to biotin by E. coli, which can be detected by a fluorescently labeled streptavidin (Figure 25). 
If a second protein is to be coexpressed, it is cloned into the pACYC vector, using BamHI and NotI 
restriction sites. This vector contains an N-terminal Flag-tag. The cloning steps are performed at the 
home laboratory. 
 
Figure 25: The GOI is cloned into the pESPRIT002 vector that contains an N-terminal His-tag and a C-terminal BAP. Soluble 
expression of the resulting protein can be assessed by the detection of the His-tag, using fluorescently labeled antibodies, and 
the detection of the BAP, by a fluorescently labeled streptavidin. 
The next step is the generation of the truncation library, which is performed by the technical staff of the 
ESPRIT system. For the generation of an N-terminal truncation library of the GOI, the vector is cut 
open, using AatII and AscI restriction enzymes. AscI generates a 5’-overhang, which is sensitive to 
exonuclease III degradation, while AatII generates a 3’-overhang, which is not. By using this strategy, 
it can be assured that exonuclease III only digests the GOI, but not the backbone of the vector. After 
opening the vector, exonuclease III is added and the solution is incubated at 22°C for 1 h. 1/60th of the 
volume is taken every minute and put into a quenching tube, containing 3 M NaCl. After 1 h the 
exonuclease is denatured, by heating the quenching tube to 70°C for 20 min. The following treatment 
with mung bean nuclease at 30°C for 30 min and a Pfu polishing step at 72°C for 20 min generates blunt 
ends. The DNA is separated on an agarose gel and the library is excised from the gel in the preferred 
size range. The library can also be separated into sub-libraries, representing different sized fragments, 
to prevent the domination of small clones in the screen. The DNA library is extracted from the gel, 
ligated and transformed into chemocompetent OmniMAX cells by heat shock. 0.5 ml of LB are added 
and the cells are incubated at 37°C, 180 rpm for 1 h. A part is plated on LB-agar plates and incubated at 
37°C overnight. The rest of the cells is stored at 4°C until further use. The quality of the library is 
assessed either by screening 48 clones by colony PCR or by performing minipreps and restriction 
enzyme digestion of 20 clones. If the size range and distribution is acceptable, the remainder of the cells 
are plated on a Q-tray, containing LB-agar, and incubated at 37°C overnight. A Q-tray is a large agar 
plate of about 25 x 25 cm, containing 300 ml of LB-agar (compare Figure 26). The colonies are 
scratched from the plate, using PBS and a Drigalski spatula, made from a Pasteur pipette. The DNA is 
purified, using a QIAPrep Spin Miniprep Kit. 
At this stage of the experiment, a three week stay is organized to work with Philippe Mas, the technical 
assistant responsible for running and maintaining the ESPRIT-system. In the next step 60 ng of the 
library were transformed into one aliquot of 40 μl electrocompetent BL21 AI cells and 1 ml of LB was 
added. The cells were incubated at 37°C, 180 rpm for 1 h, before they were plated on a Q-tray, which 
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was incubated at 37°C overnight, then at room temperature for another night. This way the colonies 
became whiter and less translucent, thus improving the contrast for their automatic recognition. Six to 
eight thousand colonies per Q-tray should have been obtained, otherwise the amount of BL21 cells had 
to be modified before plating. 384-well plates were filled with 80 μl of TB, supplemented with HMFM, 
per well. Colonies were picked from the Q-trays into the 384-well plates, using a robotic system (Figure 
26). The number of picked colonies was chosen, so that every construct was represented three times at 
a one bp resolution. A maximum of about 28000 clones could be handled by the system. The 384-well 
plates were incubated at 37°C, 300 rpm overnight and then stored at -80°C. 
 
Figure 26: The Kbiosystems robotic solutions picking and gridding robot. A head contained 384 pins, which could be 
individually moved. The head was brushed in 100% EtOH, then air dried to sterilize it. A camera, attached to the head, scanned 
the Q-tray and a software recognized the colonies. 384 colonies were picked by the head and transferred to a 384-well plate, 
before the head was sterilized again and continued to pick further colonies. Up to four Q-trays and 120 384-well plates could 
be provided. The system was also able to blot 384-well plates on a nitrocellulose membrane and to inoculate one 384-well plate 
from a different one. 
The frozen plates were replicated by the robotic system into fresh 384-well plates, filled with 80 μl TB, 
supplemented with TB salts, per well. The plates were incubated at 37°C, 300 rpm overnight. In parallel, 
a positive control, expressing MBP, was incubated in TB at 37°C, 180 rpm overnight. In every 8th 384-
well plate, the clone in A1 was replaced by the positive control. A square shaped nitrocellulose 
membrane was put on a Q-Tray, containing LB-agar. The clones from up to 48 384-well plates were 
arrayed in duplicates onto the membrane by the robotic system, using a certain pattern shown in Figure 
27, which had the advantage that the clones could be correctly assigned, even if the square shaped 
membrane was unintentionally rotated. The membrane on the Q-tray was incubated at 25°C overnight. 
Then it was transferred to a new Q-tray, containing LB-agar, supplemented with 50 μM biotin and 0.2% 
arabinose, to induce protein production and incubated at 30°C for 4 h. 
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Figure 27: The clones of up to 48 384-well plates were blotted onto a square shaped nitrocellulose membrane. This membrane 
was divided into six fields, each containing the clones from eight 384-well plates. Each field contained 384 smaller 4x4 arrays 
of colonies, each array containing the clones of a certain well from all eight 384-well plates in duplicates. The clones in the 
4x4 arrays had a certain layout, which had the advantage that they could be correctly assigned, even if the square shaped 
membrane was unintentionally rotated. The colonies in the 4x4 array had a distance of 0.8 mm. The scan of a real membrane 
is shown in Figure 36. 
The membrane was transferred onto a Whatman paper, soaked in denaturation solution, for 10 min to 
lyse the cells. Then it was transferred onto a new Whatman paper, soaked in neutralization solution, for 
5 min twice to return to a neutral pH. Finally the membrane was submersed in SSC (2x) for 10 min. 
Now the proteins, which were contained in the cells, were bound to the nitrocellulose membrane and 
the residual cell debris was removed by scraping with a Drigalski spatula, made from a Pasteur pipette. 
The membrane was blocked by adding PBS-T, supplemented with rabbit-serum, at 4°C for 1 h. Then it 
was washed with PBS-T for 5 min and the first antibody (mouse anti-His) was added in 50 ml PBS-T 
and incubated at 4°C for 1 h. The membrane was washed in PBS-T three times for 2 min, before the 
second antibody (fluorescently labeled anti-mouse) and a fluorescently labeled streptavidin 
(Streptavidin Alexa Fluor 488 conjugate, Invitrogen) were added in 50 ml PBS-T and incubated at 4°C 
for 1 h. The membrane was washed again in PBS-T three times for 2 min and then scanned, using a 
fluorescence scanner. The fluorescently labeled anti-mouse antibody had an emission wavelength of 
532 nm, while the fluorescently labeled streptavidin had an emission wavelength of 488 nm. From here 
on, the fluorescence intensity values of the fluorescently labeled antibody is referred to as His-signal 
and the fluorescence intensity values of the labeled streptavidin as BAP-signal. 
The fluorescence values were analyzed, using the VisualGrid software, which converted them into a 
table format that was further analyzed in Microsoft Excel. A histogram was generated that divided the 
His-signals into 15 groups. The one group, containing the highest number of clones, was defined as 
background and was excluded from further analysis, together with the groups containing lower 
intensities. From the rest of the clones only the fourth quartile with the highest His-signals was included 
in further analysis. These clones were sorted according to their BAP-signals. The positive controls were 
excluded and finally the 95 clones with the highest BAP-signals were selected for further analysis. One 
positive control was included as the 96th clone. 
Statistically two third of the N-terminally truncated constructs are out of frame, resulting in the absence 
of the BAP and low BAP-signals. If insoluble protein is produced, the BAP is less accessible and thus 
not coupled to biotin efficiently, also resulting in low BAP-signals. Consequently only clones with both 
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high His- and BAP-signals should be highly soluble, in frame constructs, which are interesting for 
further analysis. 
A 96-well deep well block was filled with 0.5 ml LB each and inoculated with the culture from the 384-
well plates of the 96 best clones. The deep well block was closed, using Qiagen AirPore Tape Sheets 
and incubated at 37°C, 300 rpm overnight. 10% glycerol were added to each well, the deep well block 
was shaken again at 37°C, 300 rpm for 15 min and then frozen at -80°C. 
These 96 most promising clones were further analyzed by test-expressions in the next step. A 96-well 
deep well block was filled with 0.5 ml TB each, inoculated from the frozen deep well block and 
incubated at 37°C, 300 rpm overnight as a preculture. 24-well deep well plates were filled with 4 ml TB 
each, inoculated with 50 μl of the preculture and grown to OD 0.8-1.0, before they were induced with 
0.2% arabinose. Then they were incubated at 25°C, 300 rpm overnight. The cells were spun down at 
4°C, 3700 rpm for 10 min. Each pellet was resuspended in 4 ml spheroplast formation buffer and 
incubated at 25°C, 300 rpm for 15 min, before the cells were spun down again at 4°C, 3700 rpm for 
10 min. The buffer was removed carefully and the cells were lysed by freezing at -80°C for 30 min. 
Then the pellets were thawed at room temperature for some minutes, resuspended in 800 μl lysis buffer 
each and incubated at 25°C, 300 rpm for 5 min. The four 24-well plates were reformatted into a 96-well 
deep well block by a TECAN liquid handling system and the deep well block was centrifuged at 4°C, 
3700 rpm for 30 min. 
A 96-well TECAN receiver plate was loaded with 75 μl Ni-NTA beads each. The beads were washed 
with 700 μl H2O and 700 μl washing buffer each. The supernatant was transferred from the deep well 
block to the receiver plate with the His-affinity beads and incubated at 4°C for 30 min for protein 
binding. The TECAN liquid handling system washed the beads three times with 300 μl washing buffer 
and then added 60 μl elution buffer each. The beads were incubated in elution buffer for some minutes, 
before the buffer was removed and collected in a 96-well PCR plate, by centrifugation at 4°C, 100 rcf 
for 5 min. 
20 μl samples were loaded and run on SDS-gels, which were all blotted on the same membrane. The 
membrane was washed once with PBS-T, before it was blocked with 100 ml of blocking solution at 4°C 
overnight. The membrane was washed once with PBS-T for 5 min, before it was incubated with 50 ml 
of blocking solution, supplemented with the first antibody (rabbit anti-flag), at 4°C for 1 h. The 
membrane was washed with PBS-T three times for 5 min. The second fluorescently labeled antibody 
(Alexa Fluor 633 goat anti-rabbit IgG (H+L), Invitrogen) and fluorescently labeled streptavidin 
(Streptavidin Alexa Fluor 488 conjugate, Invitrogen) were added in 50 ml PBS-T and incubated at 4°C 
for 1 h. The membrane was washed again in PBS-T three times for 5 min and dried between two 
Whatman papers. Then the membrane was scanned in the fluorescence scanner, which detected the C-
terminal BAP of the GOI and the N-terminal Flag-tag of a coexpressed and copurified binding partner. 
All or a number of constructs were selected and samples were analyzed on SDS-gels, which were 
Coomassie stained, to assess the quantity of protein expression. Finally the 96 clones were sent back to 
the home laboratory. 
In the subsequent steps, the 96 clones were first spread on LB-agar plates and single colonies were 
picked and sequenced to determine the construct boundaries. The protein quality and quantity of 
interesting constructs was assessed by test-expressions and purifications. The TEV-cleavage of the His-
tag was tested as well as the oligomerization state of the protein on SEC. The last step before large scale 
protein production was the removal of the BAP and addition of a stop codon, by BspEI digestion and 
religation of the vector. 
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4 Results 
4.1 VirG 
4.1.1 Testing of the initial VirG-constructs 
The objective of this part of the work was the crystallization and the structural characterization of VirG, 
which required milligram amounts of soluble protein. For this reason, in a first step, constructs and 
expression conditions were determined that yielded sufficient amounts of protein, to perform the 
necessary crystallization experiments. 
Initially eight different Strep-tagged VirG-constructs (VirGK1-K8) were designed, based on predicted 
and experimentally determined domain boundaries, as well as secondary structure prediction. The 
smallest of these constructs (VirGK5) comprised only the putative IcsB/ATG5 binding domain, the 
largest one (VirGK4) nearly the whole α-domain (Figure 28). Test-expressions were done in Rosetta 2 
(DE3) cells, but only faint soluble expression for VirGK2, K3, K6, K7 and K8 was observed (Figure 29 
a). 
 
Figure 28: Overview of the eight initial VirG-constructs, VirGK1-K8. 
One strategy to increase the soluble expression of a difficult to express protein is to fuse it to a solubility 
tag like GST, Sumo or MBP. For this reason the same constructs (VirGK1-K8) were cloned as GST-
fusion proteins and test-expressions were performed (Figure 29 b). The GST-tagged constructs 
expressed slightly better than the Strep-tagged constructs, as soluble expression was observed for all of 
them, but still most protein bands were quite faint. GST-VirGK2, K3, K4 and K6 showed stronger 
expression than the rest of the constructs, but the amounts were still not sufficient. 
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Figure 29: a) Coomassie stained SDS-gels for Strep-VirG-constructs test-expressions; b) Coomassie stained SDS-gels for GST-
VirG-constructs test-expressions. Only soluble protein expression for the best expression condition is shown: TB, 20°C, 
200 µM IPTG, overnight. Red arrows mark the corresponding VirG protein bands if present. The asterisk marks the streptavidin 
band, originating from the affinity beads. For the Strep-VirG-constructs only weak expression was observed for K2, K3 and 
K6-K8. For the GST-VirG-constructs expression for all constructs was observed, with stronger expression for K2-K4 and K6. 
A different way to increase soluble protein yields, is coexpression with binding partners. In a complex, 
the solvent exposed protein surface is dramatically changed and the expression of the complex might be 
much better than the expression of the individual proteins. Hence, as a next step, the same Strep- and 
GST-tagged VirG-constructs were coexpressed with His- and Strep-tagged IcsB and ATG5 respectively 
(Figure 30 a, b). Pulldowns for both proteins in the complex were done, to check for the presence of 
both binding partners. IcsB and ATG5 were expressed strongly in all cases. For this reason, only the 
Strep- and GST-pulldowns, for the verification of the presence of the VirG-constructs, are shown here. 
Soluble protein expression levels of the VirG-constructs, using coexpression, were similar to VirG 
expression without coexpressed IcsB or ATG5. For both the Strep- and GST-fusion proteins, expression 
of nearly the same constructs was observed (compare Figure 29, Figure 30). Consequently the 
coexpression of the two binding partners IcsB and ATG5 didn’t have a positive effect on the soluble 
expression of VirG. If VirG and IcsB/ATG5 interacted as expected, the copurification of an additional 
IcsB/ATG5 band, of similar strength like the VirG band, would have been expected. As the VirG 
expression was generally weak, it was not possible to verify these interactions in this experiment. 
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Figure 30: a) Coomassie stained SDS-gels for Strep-pulldowns of Strep-VirG, His-IcsB/ATG5 test-coexpressions. b) 
Coomassie stained SDS-gels for GST-pulldowns of GST-VirG, Strep-IcsB/ATG5 test-coexpressions. For each VirG-construct 
the left lane corresponds to coexpression with ATG5 (green frame), the right lane with IcsB (blue frame). Only soluble protein 
expression for the best expression condition is shown: TB, 20°C, 200 µM IPTG, overnight. Red arrows mark the corresponding 
VirG protein band if present, blue arrows IcsB and green arrows ATG5. The asterisk marks the streptavidin band, originating 
from the affinity beads. Strep-VirGK3, K4, K6 and K7 showed weak expression. All GST-VirG-constructs expressed solubly, 
with stronger expression for K2, K3, K6 and K7. 
As VirG is an outer membrane protein and is normally secreted via the sec-pathway, in the next step 
periplasmic expression of four VirG-constructs (VirGK1-K4) was tested (Figure 31). For this purpose 
an N-terminal ompA secretion signal peptide [186] was cloned in front of the Strep-tag of the four 
constructs. Expression was observed for all four constructs, which was an improvement compared to 
the intracellular Strep-VirG expression, but the overall expression levels were similar to cytoplasmic 
GST-VirG expression levels. Hence, also periplasmic expression did not significantly increase the yields 
of soluble VirG protein. 
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Figure 31: Coomassie stained SDS-gels for Strep-VirG-constructs periplasmic test-expressions. Only soluble protein 
expression for the best condition is shown: TB, 20°C, 200 µM IPTG, overnight. Red arrows mark the corresponding VirG 
protein band. The asterisk marks the streptavidin band, originating from the affinity beads. Expression was observed for all 
four constructs, with stronger expression for VirGK2 and K3. 
For all the preceding approaches, only soluble protein expression levels are shown (Figure 29-Figure 
31). The reason is that in all cases the expression levels in the insoluble fraction were low or not present. 
Hence not only the solubility, but the general expression of VirGK1-K8 was problematic. The reason 
might have been that translation was not taking place or that the translated protein was quickly degraded. 
As further improvement of the VirG expression levels was not possible, 1 l large scale expressions and 
purifications were done for the best expressing GST-VirG fusion constructs (VirGK2, K3, K4 and K6), 
to increase the yield by increasing the volume. The elution fractions from the GST-affinity column were 
analyzed on an SDS-gel. A second, identical gel was blotted on a PVDF-membrane and the presence of 
the GST-fusion proteins was detected by Western blotting, using primary anti-GST antibodies (Figure 
32). In all cases protein expression was observed, the strongest for VirGK6, but also a ladder of C-
terminally truncated GST-tagged constructs was generated. Probably premature termination of 
translation was the reason for this phenomenon. 
 
Figure 32: For each GST-VirG-construct in the left lane a Coomassie stained SDS-gel of the first elution fraction of the GST-
affinity column and in the right lane the corresponding Western blot with anti-GST antibodies is shown. Red arrows mark the 
corresponding VirG protein band. Except for VirGK3, where the overall expression levels were weak, a ladder of C-terminally 
truncated constructs was seen, starting with individual GST at the lower MW end and ending with the full length GST-VirG 
fusion protein at the upper end. 
The GST-tags of VirGK3 and K6 were removed by digestion with TEV-protease. The protein sizes 
before and after the digestion were compared on an SDS-gel. Only VirGK3 was digested but not 
VirGK6, as only for the former a shift in the height of the protein band was observed. The identity of 
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the proteins was confirmed by Western blotting before. Hence poor accessibility of the TEV protease 
cleavage site might be the reason for the inefficient cleavage in the case of VirGK6. After digestion, 
both proteins were separated on an S200 16/60 column. Both proteins eluted in the void volume of the 
column, indicating that they formed soluble aggregates. This was problematic, as aggregated protein is 
usually not suitable for crystallization. 
As VirGK3 was digested by TEV, indicating that the protein might not have been completely 
aggregated, another 12 l large scale expression and purification of this protein was performed. The first 
two elution fractions from the GST-affinity column were pooled and digested with TEV-protease 
(Figure 33 a, b). The success of the digestion was verified by SDS-PAGE and the digested protein was 
separated on an S200 16/60 column (Figure 33 d). VirGK3 was identified in the void again, the only 
soluble protein was the removed GST-tag and the TEV-protease, corresponding to the lower and the 
upper band in the green fractions respectively (Figure 33 c). 
 
Figure 33: GST-VirGK3 large scale expression and purification. As a first step, the protein was purified, using a GST-affinity 
column. In a second step the protein mixture was separated, using an S200 16/60 column. a) Coomassie stained SDS-gel of 
different steps in the GST-affinity purification: P) pellet (insoluble protein), FT) flow through of the column, W) wash, E1-E5) 
elution fractions (20 mM GSH); b) Coomassie stained SDS-gel to control TEV-protease cleavage: -) control without protease, 
+) cleaved protein; c) Coomassie stained SDS-gel of different elution fractions from the S200 16/60 column. Elution fractions 
are color coded and correspond to the fractions marked in d); d) Elution profile of the run on the S200 16/60 column. Elution 
volumes are indicated. Red arrows mark VirGK3. 
To further investigate if VirGK3 was really aggregating or just formed a very large, but uniform 
complex, running in the void of an S200 column, a part of the eluted protein was rerun on a Superose6 
10/30 column that is able to separate proteins and complexes of up to 2 MDa (Figure 34). VirGK3 also 
eluted in the void volume of the Superose6 column, hence it formed soluble aggregates of sizes larger 
than 2 MDa. 
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Figure 34: VirGK3 run on a Superose6 10/30 column. a) Coomassie stained SDS-gel of different elution fractions from the 
Superose6 column. Elution fractions are color coded and correspond to the fractions marked in b); b) Elution profile of the run 
on the Superose6 column. Elution volumes are indicated. Red arrows mark VirGK3. 
As VirGK3 formed soluble aggregates, a thermofluor-assay was performed, using the purified protein, 
to test for better buffer conditions. However, no distinct melting curves were observed (Figure 35), 
indicating that the protein wasn’t properly folded in the first place. The SYPRO Orange fluorophore 
was able to bind to exposed hydrophobic patches right from the beginning, resulting in high initial 
fluorescence, which decreased as the protein aggregated with rising temperature. Hence no better buffer 
conditions and no stabilizing additives were identified for VirGK3. 
 
Figure 35: Thermofluor-assay for VirGK3. a) Melting curves and b) melting peaks of a buffer screen. c) Melting curves and d) 
melting peaks of an additive screen. No distinct melting curves were observed, indicating that the protein wasn’t properly 
folded in the first place. 
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VirGK3 formed soluble aggregates, which was shown by SEC and in a thermofluor-assay. To test for 
the solution state properties of the other VirG-constructs, in the next step GST-VirGK1-K4 were 
expressed and purified in large scale. The protein containing elution fractions from the GST-affinity 
column were pooled and split in half. One half was digested with TEV to remove the GST-tag, the other 
half was not, to test if the solubility tag could prevent protein aggregation. All constructs were separated 
on a Superose6 column and all constructs, with or without GST, eluted in the void volume, indicating 
that all of them formed soluble aggregates. 
Up to this point several VirG-constructs were expressed and purified, but all of them formed soluble 
aggregates. It was likely that the IcsB/ATG5 binding motif was not accessible in this form and that the 
protein was not able to bind its interaction partners. Additionally it was improbable that the protein 
crystallized in this state and that its structure could be solved. Hence at this point it was necessary to try 
a different approach for the identification of better constructs or conditions for expression and 
purification, to obtain suitable protein for crystallization and interaction studies. 
4.1.2 The ESPRIT system 
As described in chapter 3.2.7 the ESPRIT system is a system to screen for soluble constructs of difficult 
to express proteins, which was applied to VirG at this point. Two different C-termini were selected, 
residues 592 and 758. 592 and 758 were the approximate boundaries of the autochaperone domain, as 
identified by limited proteolysis [133]. All constructs ending with residue 592 excluded the 
autochaperone domain, while the constructs ending with residue 758 included it. This approach was 
chosen to make sure that not only different constructs of the autochaperone domain were identified, 
which had already been shown to be expressed solubly. 
In preparation of the experiment, for each of the two C-termini two libraries of N-terminally truncated 
constructs were created, one containing smaller and one containing larger fragments, resulting in a total 
of four libraries named 592(S)mall/(L)arge and 758 S/L. This preparatory step was performed by 
Philippe Mas in the laboratory of Dr. Darren Hart at the EMBL in Grenoble, France. 
 
Figure 36: Fluorescence scan of the nitrocellulose membrane, hybridized with a fluorescently labeled anti-His antibody and a 
fluorescently labeled streptavidin to detect the presence of a) the N-terminal His-tag and b) the C-terminal BAP. The pattern, 
by which the colonies were blotted onto the membrane, is described in chapter 3.2.7. 
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The following steps were performed during a three week visit in the laboratory at the EMBL Grenoble, 
where Philippe Mas and I performed the experiments together. From the four libraries a total of 18400 
clones were picked (592S: 3800, 592L: 4600, 758S: 3500, 758L: 6500 clones) and screened for soluble 
protein expression. They were gridded on a nitrocellulose membrane and the protein was detected by a 
Western blot like method, using fluorescently labeled Anti-His antibody and streptavidin, to label the 
N-terminal His-tag and the C-terminal BAP with fluorescent probes. The membrane was scanned, using 
a fluorescence scanner afterwards (Figure 36). 
Based on the fluorescence profile, the 96 best clones were selected, 24 clones per library. One clone was 
replaced by a positive control, expressing MBP, for the following expression tests. The expression was 
tested in 4 ml of TB. Samples of the purified protein were run on an SDS-gel and analyzed by Western 
blotting, using an anti-His primary antibody (Figure 37). The Western blot showed that many clones in 
the two 758 libraries expressed a protein with a MW of around 20 kDa. Most probably this fragment 
corresponded to the autochaperone domain, which has a MW of 18 kDa. This was a first hint that soluble 
domains could be identified. Clones showing higher MW bands were of special interest. Positive results 
were obtained for VirGE57, E76, E81, E82 and E94. Also in the two 592 libraries many clones showed 
a band with a size of around 20 kDa. As the autochaperone domain was not present in these constructs, 
the sequencing had to show which the boundaries of these constructs were. Also in these libraries some 
proteins with higher MW bands were identified, especially VirGE5, E14-E16, E20 and E21. 
 
Figure 37: Western blots of the best 24 clones of each library, 95 clones and one positive control (MBP) in total, using an anti-
His primary antibody. Many clones in the two 758 libraries showed a band at a size of around 20 kDa, which corresponds to 
the size of the autochaperone domain (18 kDa). Some also had a higher MW e.g. VirGE57, E76, E81, E82 and E94. Also for 
the two 592 libraries many clones showed a band at around 20 kDa, but some also had a higher MW e.g. VirGE5, E14-E16, 
E20 and E21. Apparent double bands are SDS-PAGE migration artifacts. 
Out of the 96 clones, 27 were selected that showed strong bands in the Western blot or interesting MWs. 
Samples of the purified proteins were analyzed on a Coomassie stained SDS-gel to assess the protein 
quantity (Figure 38). Most of the clones, expressing a protein of a size of around 20 kDa, showed strong 
expression, while higher MW constructs were expressed more weakly. As the scale up of weakly 
expressing constructs, identified by this method, is sometimes challenging, it was uncertain if the 
expression and purification of these constructs would have been possible. 
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Figure 38: Coomassie stained SDS-gels of 27 selected clones and the positive control (MBP). Most clones, showing a band at 
around 20 kDa, showed good expression, while the clones with higher MW bands showed weaker expression. 
The next step was the sequencing of the 95 clones from the N-terminal side, as the C-termini were fixed. 
Only the clones, showing interesting N-terminal boundaries, were sequenced completely. In Table 15 
the results of the sequencing reactions are shown. A number of clones contained contaminating DNA 
sequences (cont.), i.e. DNA sequences differing from virG. Other clones contained constructs of the 
autochaperone domain, which was a sign that the method worked, as the autochaperone domain 
previously had been shown to be a good expressing VirG-construct. Finally 18 interesting constructs 
have been identified that covered parts of the VirG protein, where no structural information was 
available yet. 4 of the 18 constructs contained a frame shift mutation in the beginning, making the protein 
expression questionable, even if it was shown in small scale test-expressions. 13 of the 18 constructs 
covered the IcsB/ATG5 binding domain at least partially (Figure 39). 
 
Figure 39: Overview of the 18 interesting VirG-constructs from the ESPRIT screening. 
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Table 15: Sequencing results of the 96 best clones from the ESPRIT system. The coding sequence column indicates which 
coding sequence has been identified in the vector (compare text). Start and end indicate the boundaries of the respective 
construct, MW the molecular weight of the resulting protein. A violet background indicates a construct similar to the already 
known autochaperone domain, a green background indicates an interesting construct that covered unknown regions of VirG 
and a yellow background indicates an interesting construct, containing a frame-shift mutation in the beginning. 
 
As a next step, test-expressions in a one liter scale were done for most of the 18 interesting ESPRIT-
constructs, as with regard to the small scale test-expressions only weak protein expression levels were 
expected. Test-expressions were performed and the elution fractions from the His-affinity column were 
analyzed on an SDS-gel (Figure 40). More than half of the constructs showed, in most cases faint, protein 
expression. The better expressing constructs were VirGE57 and VirGE94 and even there the bands were 
weak. As a first test of the properties of these constructs, VirGE57 was separated on a Superose6 column, 
where it eluted in the soluble fraction, indicating that it didn’t form aggregates. 
 
Figure 40: Coomassie stained SDS-gels of large scale test-expressions of His-VirG-constructs. Only soluble protein expression 
is shown. Red arrows mark the corresponding VirG protein band if present. The best expression was observed for VirGE57 
and VirGE94. 
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Consequently large scale expressions and purifications on a scale of 8 to 16 liters were done for VirGE57 
and two additional constructs. VirGE94 and VirGE76 were chosen, because they comprised some of the 
longest constructs, which resulted from the ESPRIT screening. VirGE94 showed a band in the test-
expression, while VirGE76 didn’t, but it contained most of the IcsB/ATG5 binding domain. Large scale 
expressions of all three constructs resulted in solubly expressed protein (Figure 41), even for the 
VirGE76. The highest yields were obtained for VirGE94 (about 1.1 mg of purified protein per liter of 
TB), while VirGE76 yielded the least protein (about 0.2 mg of purified protein per liter of TB). 
 
Figure 41: Large-scale expressions and purifications of a) VirGE57, b) VirGE94 and c) VirGE76. As a first step the protein 
was purified, using a His-affinity column. In a second step the protein mixture was separated, using an S200 26/60 column. 
Elution profiles and Coomassie stained SDS-gels of the runs on the S200 26/60 column are shown. Elution fractions are color 
coded in the elution profiles and the gels. Elution volumes are indicated. Red arrows mark the corresponding VirG-proteins. 
Also the expression of other VirG-constructs has been tested in large scale expressions. Interestingly it 
was not possible to obtain soluble protein for constructs with the C-terminal residue 592, lacking the 
autochaperone domain. As an example Figure 42 shows an SDS-gel with samples from the His-affinity 
purification of VirGE14. All protein expression was insoluble in the pellet, no soluble protein was eluted 
from the His-affinity column. 
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Figure 42: VirGE14 large-scale expression and purification. Coomassie stained SDS-gel of different steps in the His-affinity 
purification: 0, o.n.) samples taken directly from the culture before induction and after overnight expression, L) protein that 
was loaded to the column, FT) flow through of the column, P) pellet (insoluble protein), W) wash, E1) elution fraction (250 mM 
imidazole), E2) elution fraction (500 mM imidazole). -TEV) cleavage control without protease. +TEV) cleaved protein. The 
red arrow marks VirGE14. No soluble protein expression was observed. 
It was tried to improve the soluble protein yields of the insolubly expressed VirG-constructs, as many 
of them showed protein expression in the small and large scale test-expressions. VirGE14 was used to 
test different culture and lysis conditions. It was expressed and lysed, using different lysis buffers, 
containing additives that had been shown to have a stabilizing effect (10% Mannitol, 10% L-Arginine, 
10% NDSB 201, 10% K2HPO4, 10% CTAB, 10% CuCl2) [187]. Also addition of different 
concentrations of detergent was tested (0.03-3% DDM), as well as cell lysis using 10% Bugbuster, which 
also contained detergents. Only upon addition of very high concentrations of DDM (3%), a faint band 
of soluble VirGE14 was observed. Expression at very low temperatures (4°C) had been shown to 
improve the expression of some proteins [188], but after three to four days of expression at 4°C only an 
increase in the insolubly expressed protein was observed. Expression of VirGE76 at 4°C resulted in the 
disappearance of soluble protein expression. In summary, these methods failed to improve the soluble 
protein yields of the insolubly expressed VirG-constructs. 
The solubly expressed protein VirGE57 and VirGE94 were used for a thermofluor-assay to test for better 
buffer conditions for expression and purification (Figure 43). VirGE57 showed typical melting curves 
but the VirGE94 melting curves were unusual, showing very high and constant fluorescence values in 
the beginning and a sudden drop in fluorescence shortly before the melting temperature. The reason for 
this behavior was not known. Both proteins had melting temperatures of around 55°C. The ideal buffer 
conditions for both constructs were similar (50 mM HEPES pH 7.0, 300 mM NaCl) and close to the 
buffer that had already been used. Consequently the buffer wasn’t changed. 
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Figure 43: Thermofluor-assay for VirGE57 and VirGE94. a) Melting curves and b) melting peaks of a buffer screen for 
VirGE57. c) Melting curves and d) melting peaks of a buffer screen for VirGE94. Both proteins had melting temperatures of 
about 55°C, but the melting curves for VirGE94 were unusual. 
4.1.3 VirGE94 crystallization and structure 
Crystallization setups were done for all solubly expressed VirG-constructs (VirGE57, E94, and E76). 
VirGE57 and VirGE94 showed initial hits in different crystallization screens. The most promising was 
obtained for VirGE94 in condition 66 of the Midas screen (0.2 M KCl, 0.1 M TRIS pH 8.0, 30% 
Jeffamin M-2070) at 20°C, where small three dimensional crystals appeared after two days and 
continued growing for at least three weeks (Figure 44 a). The crystallization condition was reproduced, 
using a custom 24-well grid screen around this condition. Initially a shower of small crystals was 
obtained (Figure 44 b). When the crystals grew larger, additional smaller crystals began to grow on their 
surface, leading to multiple crystals growing into each other, resembling an intertwining spiral with a 
solid core (Figure 44 c). Several of those crystals were dissolved in SDS loading buffer and analyzed on 
an SDS-gel to identify the protein (Figure 44 e). The size corresponded to VirGE94 (37 kDa) and the 
protein in the band was identified as VirG by tryptic digestion and mass spectrometry. Finally a large 
crystal with dimensions of around 130x100x50 µm was found that was composed only of the solid core 
without crystals growing on top of it (similar to Figure 44 d). This crystal was used for data collection. 
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Figure 44: VirGE94 crystals. a) Condition 66 from Midas screen (0.2 M KCl, 0.1 M TRIS pH 8.0, 30% Jeffamin M-2070, 
5 mg/ml, 20°C). b) Reproduced in 24-well hanging drop setups (0.2 M KCl, 0.1 M TRIS pH 7.0, 26.7% Jeffamin M-2070, 
5 mg/ml, 20°C). c) Under optimized conditions (0.2 M KCl, 0.1 M TRIS pH 7.8, 26.7% Jeffamin M-2070, 5 mg/ml, 20°C) the 
crystals grew to a larger size, but smaller crystals grew on top of the larger ones. d) Finally some large crystals with few or no 
crystals on top and dimensions of up to 130x100x50 µm were found (0.2 M KCl, 0.1 M TRIS pH 7.2, 26% Jeffamin M-2070, 
2.5 mg/ml, 20°C). e) The size of the protein in the crystal corresponded to the size of VirGE94 and the protein was identified 
as VirG by tryptic digestion and mass spectrometry. 
The crystal diffracted to a resolution of around 3.0 Å in house. A dataset was collected at beamline 14.1 
of the BESSY II synchrotron, using the installed Pilatus 6M detector, an X-ray wavelength of 0.918 Å 
and a temperature of 100 K. The crystal diffracted to a resolution of around 1.9 Å there. The data was 
integrated using XDS and scaled using XSCALE. The structure was solved by molecular replacement 
using Phaser-MR and the published structure of the VirG autochaperone domain (PDB-entry 3ML3) as 
a search model. Phenix AutoBuild was used for initial automated model building. WinCoot and 
Phenix.refine were used for later manual model building and refinement steps. 
VirGE94 crystallized in the P21 space group with 2 molecules in the asymmetric unit. The structure of 
VirGE94 is shown in Figure 45. The two molecules in the asymmetric unit were very similar to each 
other with a RMSD of 0.25 Å for all atoms and 0.23 Å for the backbone residues. Minor differences 
were seen primarily in the conformation of the first N-terminal residues. 
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Figure 45: Crystal structure of VirGE94. Blue: autochaperone domain 591-740 (already known), green: continuation of the β-
helix 484-590, orange: new domain of unknown function (VirG insertion domain/VID) 422-483. 
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Table 16: Data collection and refinement statistics for VirGE94. 
Data collection  
   X-ray source BM 14.1, BESSY II 
   Wavelength [Å] 0.918 
   Resolution [Å] 1.90 (1.97 – 1.90) 
   Space group P21 
   Unit-cell parameters [Å] 35.9, 84.7, 114.3 
90.0, 98.5, 90.0 
   Rmerge 0.091 (0.817) 
   Rmeas 0.099 (0.884) 
   CC1/2 0.999 (0.824) 
   ‹I/σ(I)› 13.11 (2.50) 
   Completeness [%] 98.5 (97.6) 
   No. of reflections 360053 (35865) 
   Multiplicity 6.8 (6.9) 
Refinement  
   Resolution [Å] 42.3 – 1.90 
   No. of reflections 52462 (5172) 
   Rwork 0.167 (0.252) 
   Rfree 0.211 (0.285) 
   Asymmetric unit 2 molecules 
   No. of atoms  
      Protein 4829 
      Ligands 5 
      Water 420 
   Average B factor [Å2]  
      Protein 40.4 
      Ligands 58.9 
      Water 41.9 
   R.m.s. deviations  
      Bond length [Å] 0.006 
      Bond angles [°] 0.97 
   Ramachandran favored [%] 97 
   Ramachandran outliers [%] 0.3 
 
The structure of VirGE94 was composed of the C-terminal autochaperone domain, comprising residues 
591-740 (blue in Figure 45), an intermediate part, comprising residues 484-590, that extended the β-
helix by about four turns (green in Figure 45) and an N-terminal region, comprising residues 422-483, 
that formed a previously unknown domain (orange in Figure 45), which is named VirG insertion domain 
(VID) hereafter. 
One interesting property of VirGE94 in comparison to VirGE57 and VirGE76 was, that it formed dimers 
in solution. As can be seen in Figure 41, it eluted earlier from a SEC column than the larger VirGE76. 
In the crystal structure two different contacts that could have been responsible for the dimerization were 
identified. First the VID was involved in a crystal contact by the formation of an intermolecular β-sheet 
with a symmetry related copy of itself, which was rotated by 180°. The second contact was mediated by 
a Ni2+-ion, which was stripped off the His-affinity column during purification. 
An experiment was designed to test if the contact, mediated by the Ni2+-ion was responsible for the 
dimerization of VirGE94. VirGE94 was expressed and purified on a His-affinity column. The eluted 
protein was split in half. One half was dialyzed overnight against normal buffer, the other half against 
buffer containing 1 mM EDTA. The next day both samples were separated on an S200 10/30 column 
(Figure 46). If the Ni2+-ion was responsible for the dimerization, the VirGE94 dimer should have been 
disrupted in the preparation with EDTA, as EDTA depletes the Ni2+-ions by complexing them. The 
different size of the resulting monomers should have been detectable by SEC. However, no significant 
differences in the elution profile or volume were detected. Samples of the protein containing fractions 
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were analyzed on an SDS-gel and also looked similar. Hence the VirGE94 dimer was not disrupted by 
the addition of EDTA. There were two possible explanations for this. Either the dimer, present in 
solution, was not the one mediated by the Ni2+-ion, or the EDTA was not capable of removing the ion 
from the dimer interface. As the Ni2+-ion seemed to be quite accessible in the crystal structure (Figure 
113) and the affinity of Ni2+ to EDTA was most probably higher than to VirGE94, the first explanation 
was more probable. 
 
Figure 46: VirGE94 dialyzed against buffer a) without or b) with EDTA, separated on an S200 10/30 column. Elution profiles 
and c) a Coomassie stained SDS-gel of the two runs are shown. Elution fractions are color coded in the elution profiles and the 
gel. Elution volumes are indicated. Red arrows mark VirGE94. No significant differences were observed in the two preparations 
of the protein. 
To test if the other crystal contact, mediated by the VID, was responsible for the dimerization of 
VirGE94 in solution, SAXS experiments were performed. By comparing the theoretical scattering 
curves of the different possible crystallographic dimers with the experimental scattering data, it should 
have been possible to determine, which one was the dimer, present in solution. Another question that 
was addressed by this experiment was, where the VID was located in the full length protein. It might 
have occupied the same position, as in the crystal structure or it might have been attached to the side of 
a continued β-helical stem. It should have been possible to locate this domain, by calculating SAXS 
envelopes from the experimental scattering data. 
SAXS experiments were performed, using VirGE57, VirGE76, VirGE94 and two additional constructs: 
VirGK26 and VirGK34 (Figure 47 a). The origin of VirGK26 and VirGK34 is described in chapter 
4.1.4. The expected solution states of the constructs are shown in Figure 47 b. Of special interest was 
the VirGE76 construct, as it should have been possible to determine the position of the VID in the full 
length protein from its envelope. 
Results 
68 
 
Figure 47: a) Overview of the VirG-constructs used for SAXS experiments. b) Expected solution states of the constructs. 
The scattering curves and distance distribution functions of all five proteins are shown in Figure 48. The 
distance distribution functions of all constructs showed a bi- to multi modal distribution, which indicated 
that these proteins formed aggregates. The SAXS data were used to calculate the MW of the VirG-
constructs, which are shown in Table 17. VirGE57 was clearly monomeric and VirGE94 formed a dimer, 
which confirmed the results from SEC. VirGK34 also seemed to be dimeric in solution, while VirGE76 
and VirGK26 formed higher oligomers, which were most probably soluble aggregates. VirGE76 was 
clearly monomeric, when it eluted from the SEC column and VirGK26 was either a monomer or a dimer. 
Most probably the proteins aggregated, while being transported to the synchrotron for data collection, 
as the distance distribution functions of all proteins showed signs of aggregation (Figure 48). 
Table 17: MWs and the corresponding oligomerization states of the different VirG-constructs, calculated from the SAXS data. 
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Figure 48: (a), (b) VirGE57, (c), (d) VirGE94, (e), (f) VirGE76, (g), (h) VirGK26 and (i), (j) VirGK34 have been used in SAXS 
experiments. In the left column experimental (grey) and regularized (red) intensities are plotted against the scattering length s. 
In the right column particle distance distribution functions P(r) are shown. 
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To identify the dimer interface that was responsible for the solution state of VirGE94, the theoretical 
SAXS scattering curves of all possible crystallographic dimers were calculated and fitted to the 
experimental data. The dimer that was formed by the interaction of the VIDs resulted in the best fit with 
a χ2-value of 6.7 (Figure 49). The fit was good at lower scattering length, corresponding to lower 
resolutions, but deviated distinctly at higher scattering length and resolutions, indicating that the solution 
structure differed in details from the crystal structure. 
 
Figure 49: Fitting of the calculated SAXS scattering curve of the VirGE94 dimer, formed by the interaction of the VIDs (red), 
to the experimental scattering curve (grey). For the fit a χ2-value of 6.7 was obtained. 
Envelopes were calculated for VirGE57, VirGK34 and VirGE94 and models of the proteins were fitted 
into these envelopes (Figure 50). The VirGE94 envelope showed an elongated form, confirming the 
dimer formation via the VIDs, as also this dimer formed a long rod (Figure 50 c). A truncated model of 
VirGE94 was used to fit the experimental data of VirGE57 (Figure 50 a). No model was present for 
VirGK34, as it was not known if the additional N-terminal amino acids adopted a β-helical 
conformation. Thus a truncated VirGE94 model was used, lacking the additional N-terminal amino acids 
(Figure 50 b). 
All envelopes possessed a “tail”, which at least for VirGE94 was most probably an artifact of the 
calculation of the envelope, indicating that the protein was aggregated (personal communication with 
Dmitri Svergun from the EMBL Hamburg). This was in compliance with the distance distribution 
functions, which also indicated aggregation for all proteins (Figure 48). In the case of VirGE57 the tail 
could also have been interpreted as the remaining residues of the VID, which unfolded and formed an 
elongated string. Also for VirGK34, the tail might have been interpreted as the amino acids, missing 
from the model. However, as all proteins showed signs of aggregation, it was more probable that the tail 
was an artifact in all cases. 
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Figure 50: Envelopes calculated from the SAXS data and fitted structures or models for (a) VirGE57, (b) VirGK34 and (c) 
VirGE94. 
4.1.4 New VirG-constructs 
After the crystallization of VirGE94 the challenging task remained to identify soluble and crystallizable 
constructs of the more N-terminal parts of VirG, including the IcsB/ATG5 binding domain. As a first 
approach the boundaries of the VID were used as C-terminal boundaries for a number of new N-terminal 
constructs (VirGK9-K23). As there was no experimental data for convenient boundaries in the first 300 
amino acids of VirG, different N-terminal boundaries were chosen based on secondary and tertiary 
structure predictions (Figure 51). In 1 l scale test-expressions none of these constructs showed 
expression, not in the soluble and neither in the insoluble fraction (Figure 52). 
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Figure 51: Overview of the VirG-constructs K9-K23. 
 
 
Figure 52: Coomassie stained SDS-gels for 1 l scale test-expressions of VirG-constructs K9-K23. 1) insoluble fraction, 2) 
soluble protein fraction (elution fraction from His-affinity column), 3) soluble protein cleaved by TEV-protease. No protein 
expression was detected. 
The solubility of the constructs with N-termini between 53 and 281 was dramatically decreased. These 
results were in compliance with the results of the ESPRIT screening, where no soluble constructs with 
N-termini, preceding residue 340 were identified. Consequently in the next step it was tried to identify 
  Results 
  73 
soluble and crystallizable constructs with N-termini between the N-terminal boundaries of VirGE76 
(340) and VirGE94 (419), which both had been expressed solubly before. Limited proteolysis of 
VirGE76 was performed to identify suitable N-termini (Figure 53). Six stable fragments were chosen 
and their N-termini were determined by Edman degradation. Of the identified N-termini, G415 and S418 
were close to the N-terminus of the VID (N422), while S484 was close to its C-terminus (L483). 
Positions S349 and S383 were not located in the VID and thus were suitable N-termini for new 
constructs. 
 
Figure 53: Coomassie stained SDS-gel for the limited proteolysis of VirGE76, using following restriction enzymes from the 
Hampton Research Proti-Ace and Proti-Ace2 Kits: αC α-chymotrypsin, TR trypsin, EL elastase, PA papain, SU subtilisin, EG 
endoproteinase Glu-C, PK proteinase K, CL clostripain, PE pepsin, TH thermolysin, BR bromelain, AE actinase. The table 
shows the determined N-termini of the marked bands. 
New VirG-constructs were designed, using the two N-termini identified in the limited proteolysis 
experiment and three more N-termini, which were selected, using a rational approach, adding one 
predicted additional turn of the β-helix each to VirGE94 (VirGK28-K32). Additionally it was tested to 
remove the VID, to verify if the β-helix continued, upon its removal (VirGK33-K37). For this purpose 
several different linker length were tested to close the gap (VirGK24-K27) (Figure 54). The resulting 
14 new VirG-constructs were subjected to 1 l scale test-expressions (Figure 55). For all constructs 
soluble protein was obtained. VirGK34 and K37 showed the strongest expression. 
 
Figure 54: Overview of the VirG-constructs K24-K37. 
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Figure 55: Coomassie stained SDS-gels for 1 l scale test-expressions of VirG-constructs K24-K37. 1) insoluble fraction, 2) 
soluble protein fraction (elution fraction from His-affinity column), 3) soluble protein cleaved by TEV-protease. Protein 
expression was detected for all constructs, most prominent expression for VirGK34 and K37. Red arrows mark VirG protein 
bands. 
Subsequently the most promising of these constructs, namely VirGK25, K26 and K33-K37, were 
produced in 8 l large scale expressions. They were purified (Figure 56) and crystallization assays were 
set up. However, for none of these constructs initial crystallization conditions were identified. 
 
Figure 56: Coomassie stained SDS-gels showing samples from SEC for the VirG-constructs K25, K26, and K33-K37. All 
constructs were purified in varying purities and quantities. Red arrows mark VirG protein bands. 
Finally a number of new constructs were designed, using the same N-terminal boundaries as before 
(340, 349, 383), but a truncated C-terminus. In the crystal structures of VirGE94 and of the 
autochaperone domain, the 18 C-terminal amino acids were flexible and not visible. These 18 residues 
were truncated in the new constructs (VirGK41-K43). Additionally the VID domain was deleted in the 
constructs VirGK38-K40 (Figure 57). 1 l scale test-expressions of the new constructs were performed 
(Figure 58). Soluble protein expression was comparable to the previous VirG-constructs, hence the 18 
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missing amino acids did not seem to influence protein expression, but they still might have had an 
influence on the crystallizability of these constructs. However these constructs were not expressed and 
purified in large scale in the timeframe of this thesis anymore. In the future it would be worth to express 
and purify at least VirGK40, the best expressing of the new constructs, to test for crystallization 
conditions. 
 
Figure 57: Overview of the VirG-constructs K38-K43. 
 
 
Figure 58: Coomassie stained SDS-gels for 1 l scale test-expressions of VirG-constructs K38-K43. a) SDS-gel of the insoluble 
fraction, b) SDS-gel of the: 2) soluble protein fraction (elution fraction from His-affinity column), 3) soluble protein cleaved 
by TEV-protease. Protein expression was detected for all of the constructs, most prominent expression for VirGK40. Red 
arrows mark VirG protein bands. 
4.2 IcsB 
4.2.1 Testing of the initial IcsB-constructs 
The aim of this part of the work was the crystallization and the structural characterization of IcsB, which 
like for VirG required milligram amounts of soluble protein. Initially eleven truncated IcsB-constructs 
were designed, based on published domain boundaries and secondary structure predictions (IcsBK1-
K11) (Figure 59). IcsBwt and the eleven truncated constructs were cloned as His-tagged proteins and 
coexpressed with IpgA in Rosetta 2 (DE3) cells. To identify suitable expression conditions, test-
expressions were performed and all constructs except IcsBK4 were produced solubly and in high 
quantities (Figure 60). 
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Figure 59: Overview of the IcsB-constructs K1-K11. 
 
 
Figure 60: Coomassie stained SDS-gels for test-coexpressions of His-tagged IcsBwt/K1-K11 with IpgA. Only soluble protein 
fractions for the best expression condition are shown: TB, 20°C, 50 μM IPTG, overnight. Red arrows mark the corresponding 
IcsB-constructs, yellow arrows mark IpgA. Strong expression for all of the constructs except for IcsBK4 was observed. 
Most of the constructs were expressed and purified in large scale. Figure 61 shows the results of the 
purification of IcsBwt as an example. In Figure 61 b, a weak band with slightly lower MW than full 
length IcsB can be seen that coelutes in the same peak. This band was identified by tryptical digestion 
and mass spectrometry as mainly C-terminally truncated IcsB protein and is likely to be the result of 
premature termination of translation (Figure 66). 
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Figure 61: His-IcsBwt large scale expression and purification. As a first step the protein was purified, using a His-affinity 
column. In a second step the protein mixture was separated, using an S200 26/60 column. a) Coomassie stained SDS-gel of 
different steps in the His-affinity purification: 0, o.n.) samples taken directly from the culture before induction and after 
overnight expression, L) protein that was loaded to the column, FT) flow through of the column, P) pellet (insoluble protein), 
W) wash (30 mM imidazole), E11, E12) elution fractions (250 mM imidazole), E2) elution fraction (500 mM imidazole); b) 
Coomassie stained SDS-gel of different elution fractions from the S200 26/60 column. Elution fractions are color-coded and 
correspond to the fractions marked in c); c) Elution profile of the run on the S200 26/60 column. Elution volumes are indicated. 
Red arrows mark IcsBwt, orange arrows mark IpgA. 
In Figure 62 and overview of the IcsB-constructs is given, which were produced and purified in large 
scale. In all cases high quantities of pure and soluble protein were obtained. During SourceQ IEC always 
a part of IpgA was separated from IcsB and could be purified separately. In contrast, the separated IcsB-
constructs aggregated and could not be further used, indicating that IcsB was unstable without its 
chaperone IpgA. If IcsBwt was produced without coexpression of IpgA, soluble protein expression was 
lost. Hence IpgA was fundamental for the soluble expression and stabilization of IcsB. 
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Figure 62: Coomassie stained SDS-gels showing samples from SEC for IcsBwt and the constructs K1-K3, K5, K7-K9, K11 
and IpgA. All constructs were obtained in high purity and yield. Red arrows mark the corresponding IcsB-constructs, yellow 
arrows mark IpgA. 
Using the purified proteins, crystallization assays were set up, but no initial hits were obtained. In some 
cases crystalline material was observed, which always was identified as salt crystals. 
4.2.2 Different rescue strategies for crystallization 
As the initial crystallization screens didn’t yield any results, a number of rescue strategies were applied. 
The first was the generation, expression and purification of a set of surface entropy reduction (SER) 
mutants of IcsBwt [189]. Using the online SER-server [190] six positions, suitable for SER, have been 
identified (IcsBSER1-6) (Figure 63). Test-expressions showed that all six constructs expressed as good 
as IcsBwt (Figure 64). 
 
Figure 63: Overview of the IcsB-constructs SER1-6. 
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Figure 64: Coomassie stained SDS-gels for test-expressions of His-tagged IcsBSER1-6. Only soluble protein fractions for the 
best expression condition are shown: TB, 20°C, 50 μM IPTG, overnight. Red arrows mark the corresponding IcsB-constructs, 
yellow arrows mark IpgA. Strong expression was observed for all constructs. 
All SER-mutants were expressed and purified in large scale (Figure 65). Crystallization assays were set 
up, but no initial hits were obtained. 
 
Figure 65: Coomassie stained SDS-gels, showing samples from SEC for IcsBSER1-6. All constructs were obtained in high 
purity. Red arrows mark the corresponding IcsB-constructs, yellow arrows mark IpgA. 
As a second rescue strategy the methylation of surface lysines was tested. This approach was tested 
using IcsBK3. Only small amounts of protein precipitated during the methylation reaction and the final 
yields were high with 79%. Crystallization assays were set up, using the methylated protein, but also 
this approach didn’t result in any initial hits. 
In situ proteolysis [191] was tested as another means to crystallize IcsBwt. Trypsin, chymotrypsin, 
elastase, endoproteinase Glu-C and clostripain, in total five proteases, some of which produced stable 
fragments in limited proteolysis experiments (compare Figure 66), were used at concentrations of 1:1000 
to 1:10000. However, also this approach didn’t yield any initial hits. 
In another experiment, YCl3 was supplemented to several commercially available screens at a 
concentration of 100 μM. Yttrium is a transition metal with atomic number 39, hence its trivalent ion 
can provide orbitals for complex formation in different geometries. In these experiments individual IpgA 
or complexes of IpgA with small IcsB-constructs were used. IpgA had a low pI, meaning it was 
negatively charged at the pH-values, usually present in commercial screens. Hence the positively 
charged yttrium ions could have mediated crystal contacts between different copies of IpgA. Indeed the 
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growth of needle shaped crystals was observed over the course of several days to weeks, which were 
identified as salt crystals, in this case most probably yttrium salt crystals. 
The combination of all IcsB-constructs with all rescue strategies would have resulted in a number of 
experiments that one person wouldn’t have been able to handle anymore. For this reason, in a next step, 
new IcsB-constructs were designed, using boundaries based on experimental data. 
4.2.3 Design of new IcsB-constructs 
Limited proteolysis experiments were performed using IcsBwt, to identify suitable boundaries for the 
design of new IcsB-constructs. These experiments were done, using the Proti-Ace and Proti-Ace2 Kits 
of Hampton Research. Samples of the digested protein were analyzed on an SDS-gel and the results are 
shown in Figure 66. Several proteases produced stable fragments of IcsBwt, especially elastase (EL), 
endoproteinase Glu-C (EG-C), clostripain (CL), thermolysin (TH) and bromelain (BR). The N-terminal 
boundaries of the fragments were determined by Edman degradation and their MWs by mass 
spectrometry. For the fragments 3, 7 and 9 several different N-termini were identified, which meant that 
the band was composed of different fragments. Fragments 2 and 5 had an N-terminus before the start of 
the actual protein inside the His-tag or the linker. The C-terminal boundaries were calculated, using the 
N-termini and the MWs of the fragments. For fragment 9 the MW could not be determined, due to 
experimental problems with the sample. In all other cases the calculated C-termini and the according 
calculated MWs of the fragments are indicated. In most cases the experimental and the calculated MWs 
were similar. Interestingly, in the cases where several N-termini were determined, only the longest of 
the fragments yielded a plausible C-terminus, as if one of the other N-termini would have been used, the 
C-terminus of the fragment would have exceeded the full length protein, which was not possible. In 
these cases a ‘too big’ (tb) is indicated in the table in Figure 66 b. 
 
Figure 66: a) Coomassie stained SDS-gel for the limited proteolysis of IcsBwt, using following restriction enzymes from the 
Hampton Research Proti-Ace and Proti-Ace2 Kits: contr) control without enzyme, αC) α-chymotrypsin, TR) trypsin, EL) 
elastase, PA) papain, SU) subtilisin, EG) endoproteinase Glu-C, PK) proteinase K, CL) clostripain, PE) pepsin, TH) 
thermolysin, BR) bromelain, AE) actinase. b) N-termini, experimental MWs and calculated C-termini with corresponding 
theoretical MWs of the bands marked in a). See text for a more detailed explanation. 
To gain insight into the substructure of IcsB, aliquots of the full length protein were digested with 
elastase, endoproteinase Glu-C, clostripain, thermolysin and bromelain for one hour at 37°C. Afterwards 
the reaction mixture was separated on an S200 10/30 column. In all cases only a single peak eluted from 
the column at a volume of 13.9 ml. When it was analyzed on an SDS-gel, a number of protein fragments 
were identified in the according fractions. Hence IcsB maintained its tertiary structure, even when it was 
cut into several pieces. IcsB seemed to be a compact protein, exposing several loops to the solvent that 
were cut, but didn’t seem to contain loosely attached subdomains, which would have been separated 
from the protein upon digestion. 
  Results 
  81 
The boundaries, identified in the limited proteolysis experiment, were used to design new IcsB-
constructs (IcsBK12-K29, K32) (Figure 68). Test-expressions showed a widely varying amount of 
solubly expressed protein (Figure 68). Especially the constructs with C-terminal boundaries between 
391 and 464 didn’t express solubly. Maybe in these constructs some C-terminal domain that plays a role 
in the stability of IcsB, was disrupted. 
 
Figure 67: Overview of the IcsB-constructs K12-K29 and K32. 
 
 
Figure 68: Coomassie stained SDS-gels for test-expressions of IcsB-constructs K12-K29 and K32. Only soluble protein 
fractions for the best expression condition are shown: TB, 20°C, 50 μM IPTG, overnight. Red arrows mark the corresponding 
IcsB-constructs, yellow arrows mark IpgA. Strong expression for IcsBK16, K20, K24-K29, K32, weak expression for K17, 
K19 and no expression for the rest of the constructs was observed. 
Of the constructs that showed soluble protein expression, K16, K24, K26, K27, K29 and K32 were 
expressed and purified in large-scale (Figure 69). Crystallization assays were set up, but no initial 
crystallization conditions were identified. 
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Figure 69: Coomassie stained SDS-gels, showing samples from SEC for IcsBK16, K24, K26, K27, K29 and K32. All constructs 
were obtained in high purity. Red arrows mark the corresponding IcsB-constructs, yellow arrows mark IpgA. 
In a new approach the reconstitution of nearly full length IcsB from two protein fragments was tested. 
The region in between residues 196-230 was predicted as unfolded by DISOPRED2 and in limited 
proteolysis experiments a number of proteases cut in this region (176-236), indicating that it was flexible 
and accessible from the solvent. By limited proteolysis and SEC it was shown that IcsB maintained its 
tertiary structure upon digestion, indicating that fragments of the protein have an affinity for each other. 
Hence it was tried to remove the unfolded region from the protein, using two purified IcsB-constructs, 
the N-terminal fragment IcsBK3 (26-125) and the C-terminal fragment K24 (233-493), which should 
bind to each other to reconstitute nearly full length IcsB. The two proteins were mixed, incubated and 
separated on an S200 10/30 column. However, in contrast to previous results, the two fragments didn’t 
interact with each other. They eluted in two separate peaks, corresponding to the elution volumes of the 
individual proteins, and no additional peak, corresponding to the complex, appeared. 
In summary, 36 truncated or modified IcsB-constructs were tested and combined with different rescue 
strategies for crystallization, not leading to any initial crystallization condition. At this point further 
attempts to identify a crystallizable construct of IcsB were stopped and focus was lain on the biophysical 
characterization and interaction studies. 
4.2.4 Biophysical characterization of IcsB 
A thermofluor-assay was performed, using IcsBwt (in complex with IpgA) (Figure 70). The best buffer 
conditions for the complex were HEPES/TRIS pH 7.0-8.0 with ≥200 mM NaCl. In these conditions the 
complex had a melting temperature of around 50°C (Figure 70 b). At pH values below 5.0 the complex 
didn’t have distinct melting curves anymore and was probably denaturated. No stabilizing additives, 
except glycerol at concentrations from 5-20%, were identified. 
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Figure 70: Thermofluor-assay for IcsBwt (in complex with IpgA). a) Melting curves and b) melting peaks of a buffer screen. 
c) Melting curves and d) melting peaks of an additive screen. The complex had a melting temperature of about 50°C. 
 
Figure 71: Thermofluor-assay for individual IcsBwt and IpgA. a) Melting curves and b) melting peaks of IcsBwt in a buffer 
screen. The highest melting temperature is around 37°C. c) Melting curves and d) melting peaks of IpgA in a buffer screen. 
The highest melting temperature is around 72°C. 
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As has been described before, it was possible to separate the IcsB-IpgA complex, by SourceQ IEC. 
Individual IpgA remained soluble, while IcsB aggregated and ran in the void of an S200 16/60 column. 
The separated IcsB and IpgA were used for thermofluor-assays (Figure 71). Individual IcsB showed 
indistinct melting curves with only a minor maximum, indicating that it was mostly denatured already 
in the beginning. Still, a melting temperature of around 37°C was determined. Single IpgA had a melting 
temperature of around 72°C. The best buffer conditions were 50 mM HEPES pH 7.0 without NaCl for 
IcsB and 50 mM TRIS pH 8.0, 100 mM NaCl for IpgA. 
To test whether IcsBwt (in complex with IpgA) was properly folded, CD-spectra of the complex, as well 
as individual IpgA and IcsBK9 (169-494), a soluble C-terminal IcsB-construct that didn’t form a 
complex with IpgA, were recorded (Figure 72). The resulting ratios of secondary structure elements 
were not untypical, compared to other proteins [192]. 
 
Figure 72: CD-spectra of the four proteins or complexes: a) IcsBwt (in complex with IpgA), b) IpgA, c) IcsBK9 and d) IcsBwt 
(no IpgA). The spectra of the first three proteins IcsBwt (in complex with IpgA), IpgA and IcsBK9 were experimental CD-
spectra. The CD-spectrum of IcsBwt (no IpgA) was calculated by the subtraction of the two CD-spectra of IcsBwt (in complex 
with IpgA) and IpgA. Reeds method was used to calculate the ratios of secondary structure elements [193]. 
4.2.5 Mapping of the IpgA binding site 
In [131] it was shown that the smallest IpgA binding fragment of IcsB, spanned the residues 171-247. 
However in purifications of small N-terminal constructs of IcsB, comprising the first 125 residues, IpgA 
repeatedly copurified (Figure 62). This led to the hypothesis that the IcsB-CBD was actually located in 
the N-terminal part of IcsB. For this reason a number of IcsB-constructs, all coexpressed with IpgA, 
were purified and tested for the presence of IpgA in a systematic manner (Figure 73). N-terminal 
truncation of IcsB resulted in a loss of interaction with IpgA, even if only the first 168 amino acids were 
deleted (IcsBK9). On the other hand IpgA still copurified with all the C-terminally truncated IcsB-
constructs. The shortest construct of IcsB that copurified IpgA was IcsBK3 (26-125). 
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Figure 73: Coomassie stained SDS-gels for purifications of different His-tagged IcsB-constructs coexpressed with untagged 
IpgA. a) N-terminal truncations of IcsB, b) C-terminal truncations of IcsB with the indicated boundaries. c) A part of the IcsB-
constructs after SEC purification. Red arrows mark the corresponding IcsB-constructs, yellow arrows mark IpgA. IpgA 
copurifies with none of the N-terminally truncated constructs, except for IcsBK16, which only lacks the first five amino acids, 
but with all of the C-terminally truncated constructs. 
SAXS experiments were performed, using IcsBK3 (in complex with IpgA) and individual IpgA (Figure 
74). The distance distribution functions of both proteins were nearly unimodal, indicating that the 
proteins in solution were homogenous and didn’t form aggregates. The SAXS data were used to 
calculate the MW of both constructs, shown in Table 18. The MW of IpgA in solution corresponded to 
a dimer, while the MW of IcsBK3 corresponded to one molecule of IcsBK3, binding an IpgA dimer. 
Table 18: MWs and the corresponding oligomerization states of IpgA and IcsBK3 (in complex with IpgA), calculated from the 
SAXS data. 
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Figure 74: (a), (b) IpgA and (c), (d) IcsBK3 (in complex with IpgA) have been used in SAXS experiments. In the left column 
experimental (grey) and regularized (red) intensities are plotted against the scattering length s. In the right column particle 
distance distribution functions P(r) are shown. 
4.3 ATG5 
4.3.1 Purification and characterization of human ATG5 
Like for VirG and IcsB, the objective for ATG5 in this part of the work, was the crystallization and 
structural characterization, which required milligram amounts of protein. Initially only one human 
ATG5-construct was purified, the His-tagged full length protein. Test-expressions were performed 
(Figure 75) and the best expression condition was identified as expression in TB at 20°C overnight and 
induction with 200 µM IPTG. 
 
Figure 75: Coomassie stained SDS-gel for test-expressions of His-tagged ATG5. Only soluble protein fractions are shown. The 
best expression condition was: TB, 20°C, 200 μM IPTG, overnight. The red arrow marks ATG5. 
ATG5 was expressed and purified in large scale (Figure 76). About half of the protein was expressed in 
the insoluble fraction, while the other half expressed solubly. If the soluble protein was kept on ice for 
too long or if it was concentrated too high, heavy precipitation occurred. 
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Figure 76: ATG5 large scale expression and purification. First the protein was purified, using a His-affinity column, in a second 
step by SEC, using an S200 26/60 column. a) Coomassie stained SDS-gel of different steps in the His-affinity purification: 0, 
o.n.) samples taken directly from the culture before induction and after overnight expression, L) protein that was loaded to the 
column, FT) flow through of the column, P) pellet (insoluble protein); W) wash, E11, E12) elution fractions (250 mM 
imidazole), E2) elution fraction (500 mM imidazole); b) Coomassie stained SDS-gel of different elution fractions from the 
S200 26/60 column. Fractions are color-coded and correspond to the fractions marked in c). -TEV) cleavage control without 
protease, +TEV) cleaved protein; c) Elution profile of the run on the S200 26/60 column. Elution volumes are indicated. Red 
arrows mark ATG5. 
As the protein easily precipitated, a thermofluor-assay was performed to search for stabilizing buffer 
conditions (Figure 77). The best identified buffer conditions were 50 mM HEPES/TRIS pH 7.0-8.0, 
500 mM NaCl. Addition of 5-20% glycerol further stabilized ATG5. Finally a buffer of 50 mM HEPES 
pH 7.0, 500 mM NaCl and 5% glycerol was identified as the ideal buffer for the purification of ATG5. 
Using this buffer, precipitation of ATG5 was minimized. 
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Figure 77: Thermofluor-assay for ATG5. a) Melting curves and b) melting peaks of a buffer screen. c) Melting curves and d) 
melting peaks of an additive screen. ATG5 had a melting temperature of about 39°C in the buffer screen. Addition of 5-20% 
glycerol stabilized it up to 45°C. 
4.3.2 ATG5 crystallization and structure 
Crystallization setups were done for ATG5 and after several days very thin, needle shaped crystals were 
identified in condition 93 of the PEGs suite (0.2 M Li3citrate, 20% PEG 3350, 11 mg/ml, 4°C) (Figure 
78). The crystals in this condition were reproduced and optimized, using custom 96-well grid screens 
around this condition. Finally larger crystals were obtained in 24-well hanging drop setups (0.35 M 
Li3citrate, 32.2% PEG 3350, 10 mg/ml, 20°C). The crystals in the optimized condition were still needle 
shaped and mostly extremely thin, but several reached dimensions of up to 500x30x30 μm, which were 
suitable for data collection. 
 
Figure 78: ATG5 crystals. a) Condition 93 from PEGs suite (0.2 M Li3Citrate, 20% PEG 3350, 11 mg/ml, 4°C); b) reproduced 
in a 96-well grid-screen (0.325 M Li3Citrate, 24% PEG 3350, 10 mg/ml, 20°C). 
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The crystals diffracted to a resolution of around 4 Å in house. A dataset was collected, using the Pilatus 
2M detector at beamline PXIII of the SLS synchrotron at a wavelength of 1.000 Å and a temperature of 
100 K, where they diffracted to a resolution of around 3.1 Å. ATG5 crystallized in the P41212 space 
group with one molecule in the asymmetric unit. The structure was solved by molecular replacement, 
using ATG5 of the ATG5-12/16 complex from PDB-entry 4GDK as a search model. The structure of 
ATG5 is shown in Figure 79. 
 
 
 
 
 
Figure 79: Crystal structure of ATG5. 
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Table 19: Data collection and refinement statistics for ATG5. 
Data collection  
   X-ray source PXIII, SLS 
   Wavelength [Å] 1.000 
   Resolution [Å] 3.10 (3.21 – 3.10) 
   Space group P41212 
   Unit-cell parameters [Å] 75.0, 75.0, 115.3 
90.0, 90.0, 90.0 
   Rmerge 0.209 (0.801) 
   Rmeas 0.214 (0.817) 
   CC1/2 0.998 (0.970) 
   ‹I/σ(I)› 24.27 (6.27) 
   Completeness [%] 100.0 (100.0) 
   No. of reflections 160665 (16453) 
   Multiplicity 25.1 (26.5) 
Refinement  
   Resolution [Å] 53.0 – 3.10 
   No. of reflections 6398 (620) 
   Rwork 0.190 (0.265) 
   Rfree 0.218 (0.327) 
   Asymmetric unit 1 molecule 
   No. of atoms  
      Protein 2189 
      Ligands 0 
      Water 0 
   Average B factor [Å2]  
      Protein 33.1 
      Ligands / 
      Water / 
   R.m.s. deviations  
      Bond length [Å] 0.008 
      Bond angles [°] 1.29 
   Ramachandran favored [%] 98 
   Ramachandran outliers [%] 0.0 
 
ATG5 was used for SAXS experiments to determine its oligomerization state in solution (Figure 80 a, 
b). The distance distribution function was unimodal, indicating that the protein was homogenous in 
solution and didn’t form aggregates. Fitting of the calculated scattering curves of an ATG5 monomer to 
the experimental SAXS data, resulted in a good fit with a χ2-value of 2.8 (Figure 80 c), indicating that 
ATG5 was monomeric in solution. 
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Figure 80: ATG5 has been used in SAXS experiments. a) Experimental (grey) and regularized (red) intensities are plotted 
against the scattering length s. b) Particle distance distribution function P(r). c) Fitting of the calculated SAXS scattering curve 
of an ATG5 monomer (red) to the experimental scattering curve (grey). A good fit with a χ2-value of 2.8 was obtained. 
4.3.3 Function of the phosphorylation of threonine 75 
ATG5 residue T75 can be phosphorylated by the p38 MAP-Kinase, resulting in the inhibition of 
autophagy, by preventing the fusion of autophagosomes and lysosomes [162]. However, the mechanism 
of the inhibition has not been identified yet. One possible explanation might be that, by the 
phosphorylation of T75, the interaction of ATG5 with ATG16L1 or TECPR-1 is influenced, as they 
play major roles in the maturation of autophagosomes and their fusion with lysosomes [165]. A possible 
way to change the affinity of ATG5 to ATG16L1 or TECPR-1, might be a change in the tertiary structure 
of ATG5 upon phosphorylation of T75. 
To investigate the role of the phosphorylation of T75, two ATG5 mutants were prepared, T75E and 
T75A (Figure 81). Replacing threonine by glutamic acid results in a phosphomimetic mutant. The size 
and the charge of glutamic acid mimic a phosphorylated threonine. The alanine mutant served as a 
negative control, as alanine is uncharged and cannot be phosphorylated. Therefore the structure of the 
T75A mutant should resemble the structure of unphosphorylated ATG5 under all conditions. If the 
structures of both mutant forms of ATG5 were solved, an influence of the phosphomimetic mutation on 
the tertiary structure of ATG5 would have been revealed. Test-expressions were performed for the two 
mutant forms of ATG5 and both proteins expressed as good as or better than ATG5wt (Figure 82). 
Subsequently the two mutant forms were expressed and purified in large scale. 
 
Figure 81: Overview of the ATG5-constructs T75E and T75A. 
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Figure 82: Coomassie stained SDS-gels for test-expressions of ATG5wt, T75E and T75A. Only the soluble protein expression 
of the best expression condition is shown: TB, 50 μM IPTG, 20°C, overnight. Red arrows mark the corresponding ATG5-
constructs. The expression of the two mutant forms was stronger than the expression of ATG5wt. 
4.3.3.1 Crystallization and structure of ATG5T75E and T75A 
A completely new screening for crystallization conditions was performed for ATG5T75E and T75A, to 
exclude the possibility that, by using the same crystallization condition as for the ATG5wt, a certain 
conformation was imposed on the mutant forms. However, the only crystallization condition that yielded 
crystals was the one where already ATG5wt crystallized (0.2 M Li3citrate, 20% PEG 3350) (Figure 83). 
The crystals were reproduced in custom 96-well grid-screens around this condition and optimized in 24-
well hanging-drop setups to obtain larger crystals for data collection. The only difference compared to 
ATG5wt was, that for ATG5T75A, the crystallization setups had to be incubated at lower temperatures. 
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Figure 83: ATG5T75E and T75A crystals. a) T75E crystals reproduced in 96-well grid screen (0.35 M Li3citrate, 35% PEG 
3350, 5 mg/ml, 20°C), b) T75E crystals in hanging drop 24-well setups under optimized conditions (0.4 M Li3citrate, 31% PEG 
3350, 10 mg/ml, 20°C), c) T75A crystals reproduced in 96-well grid screen (0.35 M Li3citrate, 35% PEG 3350, 5 mg/ml, 4°C), 
d) T75A crystals in hanging drop 24-well plate setups under optimized conditions (0.45 M Li3citrate, 29% PEG 3350, 5 mg/ml, 
12°C). The form of the crystals and the optimized conditions were very similar to the crystals of ATG5wt. 
The crystals of both ATG5T75E and T75A diffracted to a resolution of around 4 Å in house. Data sets 
for both crystals were collected, using the Pilatus 6M detector of beamline P11 of the PETRA III 
synchrotron, at a wavelength of 1.033 and 1.000 Å respectively and a temperature of 100 K, where T75E 
diffracted to around 2.3 Å and T75A to around 2.7 Å. Like ATG5wt, both mutants crystallized in space 
group P41212 with one molecule in the asymmetric unit. The structures were solved by molecular 
replacement, using the same model as for the wild type form (ATG5 of the human ATG5-12/16 complex 
from PDB-entry 4GDK). The structures of ATG5T75E and T75A are shown in Figure 84 and Figure 
85. 
Results 
94 
 
Figure 84: Crystal structure of ATG5T75E. 
 
Figure 85: Crystal structure of ATG5T75A. 
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Table 20: Data collection and refinement statistics for ATG5T75E and T75A. 
Data collection ATG5T75E ATG5T75A 
   X-ray source P11, Petra III P11, Petra III 
   Wavelength [Å] 1.033 1.000 
   Resolution [Å] 2.30 (2.38 – 2.30) 2.70 (2.80 – 2.70) 
   Space group P41212 P41212 
   Unit-cell parameters [Å] 73.8, 73.8, 115.2 
90.0, 90.0, 90.0 
74.1, 74.1, 115.4 
90.0, 90.0, 90.0 
   Rmerge 0.119 (0.778) 0.132 (0.722) 
   Rmeas 0.121 (0.794) 0.135 (0.736) 
   CC1/2 0.999 (0.953) 0.999 (0.954) 
   ‹I/σ(I)› 23.70 (5.16) 26.37 (5.46) 
   Completeness [%] 99.9 (99.6) 100.0 (100.0) 
   No. of reflections 376765 (36314) 237959 (23696) 
   Multiplicity 25.6 (25.4) 25.5 (26.4) 
Refinement   
   Resolution [Å] 38.7 – 2.30 47.7 – 2.70 
   No. of reflections 14725 (1431) 9341 (898) 
   Rwork 0.178 (0.233) 0.186 (0.263) 
   Rfree 0.199 (0.285) 0.229 (0.359) 
   Asymmetric unit 1 molecule 1 molecule 
   No. of atoms   
      Protein 2205 2195 
      Ligands 0 0 
      Water 81 46 
   Average B factor [Å2]   
      Protein 37.6 37.5 
      Ligands / / 
      Water 37.7 32.2 
   R.m.s. deviations   
      Bond length [Å] 0.017 0.009 
      Bond angles [°] 1.68 1.39 
   Ramachandran favored [%] 99 99 
   Ramachandran outliers [%] 0.0 0.0 
 
The two mutant variants of ATG5 were crystallized, but no differences in the structures compared to 
ATG5wt were identified. However it was still possible that the binding of ATG16L1 was influenced by 
the phosphorylation of T75, e.g. by a destabilization of the tertiary structure of ATG5. For this reason, 
thermofluor-assay assays and limited proteolysis experiments were performed, using ATG5wt, T75E 
and T75A. 
4.3.3.2 ATG5 thermofluor-assay 
To identify a possible influence of T75 phosphorylation on the stability of ATG5, a thermofluor-assay 
was performed, using ATG5wt, T75E and T75A (Figure 86). The melting temperatures of all ATG5 
variants were in the range of 38-39°C. No significant influence of the phosphorylation of T75 on the 
thermostability of ATG5 was observed. 
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Figure 86: Thermofluor-assay for ATG5wt, T75E and T75A. a) Melting curves and b) melting peaks in 50 mM HEPES pH 7.0, 
500 mM NaCl, 5% glycerol. All ATG5 variants had melting temperatures of 38-39°C. 
4.3.3.3 ATG5 limited proteolysis 
In a last experiment the stability of the different ATG5 variants was probed by proteolytic digestion 
experiments (Figure 87).  If the tertiary structure of the mutants was destabilized, different proteolytic 
digestion patterns would have been expected, as parts of the protein would have been more flexible and 
accessible for the proteases. However, also in this experiment the different ATG5 variants behaved 
identical. No influence of the phosphorylation of T75 on the degradation patterns in the limited 
proteolysis experiment was observed. 
 
Figure 87: Coomassie stained SDS-gels for the limited proteolysis of a) ATG5wt, b) T75E and c) T75A, using following 
restriction enzymes from the Hampton Research Proti-Ace and Proti-Ace2 Kits: contr) no protease, αC) α-chymotrypsin, TR) 
trypsin, EL) elastase, PA) papain, SU) subtilisin, EG) endoproteinase Glu-C, PK) proteinase K, CL) clostripain, PE) pepsin, 
TH) thermolysin, BR) bromelain, AE) actinase. No differences in the degradation patterns were observed. 
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4.4 Interaction studies 
4.4.1 VirG interactions 
4.4.1.1 Interaction VirG – IcsB/ATG5 
For a detailed understanding of the molecular basis of the Shigella camouflage mechanism, the 
previously published interactions of VirG with IcsB and ATG5 were tested in pulldown experiments, 
using GST-tagged VirGK2/K3/K4/K6 and His-tagged IcsBwt/ATG5wt (Figure 88). Both the GST- and 
the His-tag were used for pulldowns, but no interactions were observed. A major problem was the weak 
expression of the GST-VirG-constructs. At the same time weak protein bands were observed in the 
negative controls, making the interpretation of the results difficult, because of the impossibility to 
distinguish between weak protein bands, resulting from weak expression and from unspecific binding 
to the affinity beads. 
 
Figure 88: Coomassie stained SDS-gels for pulldown interaction studies, using GST-VirGK2/K3/K4/K6 with His-
IcsBwt/ATG5wt. a) controls and His-pulldowns for VirGK2 and VirGK3, b) controls and His-pulldowns for VirGK4 and 
VirGK6, c) controls and GST-pulldowns for VirGK2 and VirGK3, d) controls and GST-pulldowns for VirGK4 and VirGK6. 
Red arrows mark the VirG-constructs, blue arrows IcsB and green arrows ATG5. No interactions were observed. 
In another approach the interaction between GST-tagged VirGK4/K6 and His-tagged IcsBwt/ATG5wt 
was tested, using blue native PAGE (Figure 89). The samples were mixed and analyzed on a gel. If a 
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complex had been formed, the appearance of a higher MW band would have been expected. However, 
it was not possible to observe the interactions. Again one problem was the low amount of available 
VirG-protein, as VirGK4 could not be detected on the gel. All other proteins were observed as individual 
proteins, but no complexes were detected. The only sign of a possible interaction was the vanishing of 
the VirGK6 band, when ATG5 was added. On the other hand, if all VirG protein was in a complex with 
ATG5, the appearance of a new band with a considerably higher MW would have been expected. 
 
Figure 89: Blue native PAGE interaction studies, using GST-VirGK4/K6 with His-IcsBwt/ATG5wt. Red arrows mark the 
VirG-constructs, blue arrows mark IcsB and green arrows mark ATG5. No interactions were observed. 
In the next step interaction of untagged VirGK3 and His-tagged IcsBwt/ATG5wt was tested, using an 
S200 16/60 column (Figure 90). The proteins were separated both individually and in all possible 
combinations. If a stable complex was formed, the emergence of an additional peak at a lower elution 
volume would have been expected. But again all proteins eluted in separate peaks and no additional 
peaks, corresponding to formed complexes, were observed. For individual VirGK3 two peaks were 
present. The higher peak with an elution volume of about 46 ml corresponded to VirGK3, the lower 
peak with an elution volume of about 81 ml corresponded to individual GST and TEV-protease that 
were separated in this run and were not present in later runs anymore. 
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Figure 90: SEC elution profiles from an S200 16/60 column for a) individual VirGK3 (red), His-IcsBwt (blue) and His-ATG5wt 
(green); b) mixed VirGK3 and IcsBwt; c) mixed VirGK3 and ATG5wt; d) mixed IcsBwt and ATG5wt. Vertical colored lines 
mark the position of individual protein peaks. The elution volumes are indicated. For individual VirGK3 two peaks were 
present. The higher peak at around 46 ml corresponded to VirGK3, the lower peak at around 81 ml corresponded to individual 
GST and TEV-protease that were separated in this run and were not present in later runs. No interactions were observed. 
In summary, using the constructs that were available before using the ESPRIT-system, the interactions 
of VirG to IcsB or ATG5 could not be observed. This might have been due to the formation of soluble 
aggregates by the VirG-constructs, as observed in SEC before, that obscured the interaction site. Another 
major problem was the low amount of available VirG protein. As the constructs that were obtained, 
using the ESPRIT-system, were expressed in higher quantities, soluble and presumably folded, further 
interaction studies were performed, using these new constructs. 
The interactions between VirG and IcsB/ATG5 were tested again in pulldown experiments, using 
untagged VirGE94/E76 and His-tagged IcsBwt/IcsBK9/ATG5wt (Figure 91). As the VirG-constructs 
were untagged, only pulldowns, using the His-tags were done. All proteins were present in sufficient 
amounts and unspecific binding of the VirG-constructs to the His-affinity beads was insignificant. Still 
no interactions between these VirG-constructs and IcsB or ATG5 were observed. 
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Figure 91: Coomassie stained SDS-gel for pulldown interaction studies, using untagged VirGE94/E76 with His-tagged 
IcsBwt/IcsBK9/ATG5wt. Red arrows mark the VirG-constructs, blue arrows mark the IcsB-constructs and green arrows mark 
ATG5. No interactions were observed. 
MST was used as a complementary method to verify these results. Labeled untagged VirGE94/E76 as 
well as unlabeled His-tagged IcsBwt/ATG5wt and GST as a negative control, were used in these 
experiments (Figure 92). For GST and ATG5 the curves showed a steep increase at high unlabeled 
protein concentrations. The reason for this might have been a higher viscosity of the solution, due to the 
very high protein concentration in the 0.1-1 mM range. No interactions of the VirG-constructs to GST 
or ATG5 were observed and also VirGE94 and IcsB did not interact. However, IcsB did interact with 
VirGE76 with a KD of 600±205 nM. 
 
Figure 92: MST interaction studies, using labeled VirGE94/E76 with unlabeled His-IcsBwt/ATG5wt and GST as a negative 
control. Most curves showed a steep increase at high unlabeled protein concentrations. An interaction of IcsBwt with VirGE76 
with a KD of 600±205 nM, but no interaction of IcsBwt with VirGE94 or of ATG5 with one of the VirG-constructs, was 
observed. 
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4.4.1.2 Interaction VirG – N-WASP 
N-WASP is a published interaction partner of VirG, which is essential for VirG’s function in ABM. In 
several publications, binding of different domains of VirG to N-WASP has been shown [85], [135], 
[145], [194]. Using the soluble VirG-constructs, obtained from the ESPRIT system, the interaction of 
VirG to N-WASP should have been further characterized. The expression of full length N-WASP 
protein is problematic as it tends to aggregate [195]. Hence several individual N-WASP-domains and 
domain-combinations were expressed as GST-fusion proteins in E. coli. Pulldowns were performed, 
using purified untagged VirGE57/E94/E76 and cell lysates from E. coli, producing GST-tagged N-
WASP-GBD/C/VVCA/VV (Figure 93). Expression of N-WASP-VVCA was weak, all other proteins 
were present in sufficient amounts. Unspecific interaction of the VirG-constructs with the GST-affinity 
beads was negligible. However, in the pulldowns only weak additional bands corresponding to the VirG-
constructs were detected, which were similar in strength to the negative controls. Hence no interactions 
between the VirG- and N-WASP-constructs were observed in these pulldowns. 
 
Figure 93: Coomassie stained SDS-gels for pulldown interaction studies, using VirGE57/E94/E76 with GST-N-WASP-
GBD/C/VV/VVCA. a) controls, b) pulldowns with GST-N-WASP-GBD/C, c) controls and pulldowns with GST-N-WASP-
VV/VVCA. No interactions were observed. 
MST was used to confirm these results. Labeled VirGE94/E76 with unlabeled GST-N-WASP-
GBD/C/VVCA/VV were used in these experiments (Figure 94). GST negative controls are shown in 
Figure 92. For none of the VirG-N-WASP combinations a clear sigmoidal binding curve was detected, 
hence no interactions were observed. 
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Figure 94: MST interaction studies, using labeled VirGE94/E76 with unlabeled GST-N-WASP-GBD/C/VV/VVCA. No 
sigmoidal binding curves were detected in these experiments, hence no interactions were observed. 
4.4.1.3 Interaction VirG – other proteins 
VirG is a protein that exploits the human actin polymerization system to permit ABM for Shigella. For 
this reason the interaction of VirGE76 with a number of proteins and domains of proteins, involved in 
or associated to the actin polymerization system, was tested. Pulldown studies were performed, using 
His-tagged VirGE76 with GST-tagged constructs of other proteins, comprising domains of N-WASP, 
Toca-1, Cip4, Cdc42 and a number of diaphanous formins (Figure 95). Some of the GST-tagged 
constructs, especially N-WASP-GBD and all Toca-1-constructs, bound unspecifically to His-affinity 
beads (Figure 95 a). Apart from this unspecific binding, no interactions between VirG and other protein 
constructs were observed. 
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Figure 95: Coomassie stained SDS-gels for pulldown interaction studies, using His-tagged VirGE76 with different GST-tagged 
constructs of N-WASP, Toca-1, Cip4, Cdc42 and several diaphanous formins. a) controls His-pulldown, b) controls GST-
pulldown, c) His-pulldowns, d) GST-pulldowns. No interactions were observed. 
4.4.2 IcsB interactions 
4.4.2.1 Interaction IcsB – Toca-1-HR1 
IcsB has been shown to interact with the HR1 domain of Toca-1, which has a function in the activation 
of N-WASP. To verify the interaction of IcsB and Toca-1, a pulldown experiment was performed, using 
His-tagged IcsBwt (1-494, in complex with IpgA) and IcsBK9 (169-494, no IpgA), as well as four GST-
tagged constructs of the Toca-1-HR1 domain (Toca-1K1-K4) and a GST-tagged construct of the HR1-
domain of Cip4 (Cip4K1) (Figure 96). The unspecific binding of GST-Toca-1K2, K4 and GST-Cip4K1 
to the His-affinity beads was problematic. Additionally the GST-constructs didn’t bind properly to the 
GST-affinity beads, rendering this half of the experiment not interpretable. Another problem was that 
IcsBK9 and the Toca-1/Cip4-constructs had nearly the same MW, which makes the detection of an 
interaction between these two proteins difficult. In the pulldowns, using the His-tagged IcsB-constructs, 
only the unspecific interactions were detected that were already observed in the controls, hence no 
interaction between IcsB and Toca-1 was observed. 
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Figure 96: Coomassie stained SDS-gels for pulldown interaction studies, using His-tagged IcsBwt/K9 with four GST-tagged 
constructs of Toca-1 and one GST-tagged construct of Cip4. a) controls, b) His-pulldowns, c) GST-pulldowns. Red arrows 
mark the IcsB-constructs, green arrows mark the Toca-1- and Cip4-constructs. No interaction was observed. 
As no clear interaction was detected, using the individual Toca-1-HR1 domain, in a second step 
pulldown experiments were performed, using His-tagged IcsBwt and IcsBK9, as well as the Toca-1-
constructs that were originally used to show this interaction (Toca-1K5-K7) [159] (Figure 97). All three 
GST-tagged Toca-1-constructs bound strongly and unspecifically to His-affinity beads, rendering the 
His-pulldowns not interpretable. In the GST-pulldowns, no additional bands corresponding to the IcsB-
constructs were detected, hence no interactions between IcsB and these Toca-1-constructs were 
observed. 
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Figure 97: Coomassie stained SDS-gels for pulldown interaction studies, using His-tagged IcsBwt/K9 with different GST-
tagged constructs of Toca-1. a) controls, b) His- and GST-pulldowns. Red arrows mark the IcsB-constructs, green arrows mark 
the Toca-1-constructs. No interactions were observed. 
Due to the problems in these experiments, the interaction of IcsBwt with a reduced number of Toca-1-
constructs, was reassessed in a later experiment, together with other proteins (Figure 103). Also in this 
pulldown experiment, the used GST-tagged Toca-1-constructs showed a strong unspecific binding to 
His-affinity beads and no interactions were observed. 
4.4.2.2 Interaction IcsB – Cholesterol 
IcsB had been shown to interact with cholesterol through its cholesterol binding domain, located 
between residues 288-351 [154]. This interaction was tested, using dehydroergosterol (DHE), a 
fluorescent cholesterol analogon. Cholesterol and DHE are both virtually insoluble in water, hence DHE 
was solubilized, using methyl-β-cyclodextrin, a cyclic compound composed of seven glucose moieties, 
which can harbor one molecule of cholesterol [196]. The solubilized DHE was mixed with IcsBwt (in 
complex with IpgA), incubated and separated on an S200 10/30 column. It was not possible to detect 
the absorption of DHE at 324 nm. Possible reasons for this result might be that the solubilization of 
DHE did not work or that DHE did not bind to IcsB under the used conditions. In the former case DHE 
might not have been available for binding to IcsB, in the latter its fluorescence would have been 
quenched, due to the aqueous environment. Consequently the interaction of IcsB with DHE could not 
be verified. 
4.4.2.3 Interaction IcsB – N-WASP 
Phyre2 [197] was used to predict the tertiary structure of IcsB. The quality of the resulting model was 
poor, as no homologues structures were known. Still, a stretch in IcsB, comprising residues 99-130, was 
identified to show homology to a stretch in E. coli EspFU, comprising residues 73-102, where it was 
responsible for the activation of N-WASP, by binding to the N-WASP-GBD [198]. To test if in IcsB 
this stretch also interacted with the N-WASP-GBD, two IcsB-constructs were prepared, the first 
covering the IcsB region corresponding to the EspFU N-WASP binding region (IcsBK30, 104-130), the 
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second covering additional regions N- and C-terminal of the binding region (IcsBK31, 99-136). 
Pulldown experiments were performed, using His-tagged N-WASP-GBD, as well as GST-tagged 
IcsBK30, IcsBK31 and N-WASP-C as a positive control (Figure 98). GST-IcsBK30, but not GST-
IcsBK31, bound unspecifically to the His-affinity beads. The GBD and the C-domain of N-WASP, 
which served as a positive control for binding, clearly interacted in the His-pulldowns, while in the GST-
pulldowns no interaction was observed. This might indicate a sterical problem for the interaction of the 
GBD and the C-domain, upon binding of the GST-tag to the GST-affinity beads. Between the tested 
IcsB-constructs and the N-WASP-GBD, no interactions were observed. 
 
Figure 98: Coomassie stained SDS-gel for pulldown interaction studies, using His-tagged N-WASP-GBD with GST-tagged 
IcsBK30/K31/N-WASP-C. Except for the binding of N-WASP-GBD (red arrow) to N-WASP-C (green arrow), no interactions 
were observed. 
 
 
Figure 99: Coomassie stained SDS-gels for pulldown interaction studies, using GST- or His-tagged N-WASP-GBD with His-
tagged IcsBwt/IcsBK9 or GST-tagged IcsBK30/K31/N-WASP-C. a) controls, one gel with His-, one with GST-pulldowns. b) 
pulldowns. Except for the binding of N-WASP-GBD (red arrow) to N-WASP-C (green arrow), no interactions were observed. 
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One problem might have been that the IcsB-constructs were too limited and other regions were important 
for the interaction. For this reason in a follow-up experiment His-tagged IcsBwt (1-494, in complex with 
IpgA) and IcsBK9 (169-494, no IcsB) were tested for binding to the N-WASP-GBD (Figure 99). GST-
IcsBK30 again bound unspecifically to the His-affinity beads. Another problem was the weak expression 
of IcsBwt, IcsBK9 and IcsBK31. Binding was detected between the N-WASP-GBD and C-domain, 
which served as a positive control again. However, no interactions were observed between the N-WASP-
GBD and the IcsB-constructs. 
In a last experiment the interaction of IcsB and the N-WASP-GBD was tested, using a complementary 
method. Normally the N-WASP-GBD is disordered and only folds upon binding of an interaction 
partner, like the N-WASP-C domain or EspFU. This property was used in a thermofluor-assay. For an 
unfolded N-WASP-GBD, no distinct melting curve or a low melting temperature would be expected, 
while for the folded domain a distinct melting curve with a higher melting point would be expected. 
Three different fusion proteins of N-WASP-GBD and IcsBK30/IcsBK31/N-WASP-C were created, 
based on the constructs published in [198]. The GBD-C fusion protein served as a positive control for 
binding, while the individual GBD served as a negative control. First the constructs were purified. 
Unfortunately the GBD-C fusion protein, the positive control for binding, was expressed poorly and 
could not be purified in sufficient amounts, even though it showed reasonable expression levels in test-
expressions (Figure 100). 
 
Figure 100: Coomassie stained SDS-gel of different N-WASP-GBD fusion proteins after His-affinity purification. 1) N-WASP-
GBD, 2) N-WASP-GBD–N-WASP-C, 3) N-WASP-GBD–IcsBK30, 4) N-WASP-GBD–IcsBK31. 
The purified proteins were used in a thermofluor-assay (Figure 101). The individual N-WASP-GBD and 
the N-WASP-GBD–IcsBK30 fusion protein didn’t show distinct melting curves, hence their GBDs were 
probably unfolded. But the melting curve of the N-WASP-GBD–IcsBK31 fusion protein showed a slight 
inflection point, corresponding to a melting temperature of about 50°C. This indicated that the longer 
IcsBK31 construct might have interacted with the GBD of N-WASP and stabilized it. However, without 
the positive control for binding, it was difficult to evaluate the plausibility of the results. 
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Figure 101: Thermofluor-assay with different N-WASP-GBD fusion proteins. For all proteins a buffer screen was performed. 
a) Melting curves and b) melting peaks for N-WASP-GBD. c) Melting curves and d) melting peaks for N-WASP-GBD–
IcsBK30 fusion protein. e) Melting curves and f) melting peaks for N-WASP-GBD–IcsBK31 fusion protein. GBD–IcsBK31 
showed a slight inflection point (red arrow), corresponding to a melting temperature of about 50°C. 
4.4.2.4 Interaction IcsB – Diaphanous formins 
Diaphanous formins contain a GBD and are autoinhibited in a similar way as N-WASP. Diaph1 and 
Diaph2 are reported to be essential for protrusion formation and IpgB2 has been shown to activate them 
[90]. As IcsB might have interacted with the N-WASP-GBD, here the interaction of His-/ZZ-His-tagged 
IcsBwt, IcsBK9, K30 and K31 with the GST-tagged GBDs of five different diaphanous formins were 
tested in pulldown-experiments (Figure 102). Unfortunately the GBD of Diaph1, which has been shown 
to be involved in the formation of Shigella protrusions [90], was not included in this experiment, due to 
prolonged cloning problems. Generally, the expression of the GBDs was weak. GST-Fmnl2-GBD was 
produced slightly better than the other constructs, but bound unspecifically to the His-affinity beads. No 
interactions between the IcsB-construct and the diaphanous formin GBDs were observed. 
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Figure 102: Coomassie stained SDS-gels for pulldown interaction studies, using His-tagged IcsBwt/IcsBK9 and ZZHis-tagged 
IcsBK30, K31 with GST-tagged constructs of Diaph2/Daam2/Fhod1/Fmnl2/Fmnl3. a) controls, one gel with His-, one with 
GST-pulldowns, b) His-pulldowns, c) GST-pulldowns. Except for the unspecific binding of GST-Fmnl2-GBD to the His-
affinity beads, no interactions were observed. 
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4.4.2.5 Interaction IcsB – other proteins 
In a last pulldown experiment, possible interactions of His-tagged IcsBwt with GST-tagged Diaph3-
GBD, a diaphanous formin, and Cdc42, a small Rho-GTPase that controls the turnover of the actin-
cytoskeleton, were tested. At the same time, some of the already tested interactions were reassessed, to 
confirm the results of the previous pulldown experiments. However, no interactions between IcsBwt 
and any of the tested constructs were observed (Figure 103). 
 
Figure 103: Coomassie stained SDS-gels for pulldown interaction studies, using His-IcsBwt with different GST-tagged 
constructs of N-WASP/Toca-1/Cip4/Cdc42 and several diaphanous formins. a) controls, His-pulldown, b) controls, GST-
pulldown, c) His-pulldowns, d) GST-pulldowns. No interactions were observed. 
4.4.3 Interaction ATG5 – ATG16L1 
It was hypothized that the phosphorylation of ATG5 residue T75 might have an influence on the affinity 
of ATG5 to ATG16L1 or TECPR-1. For this reason, here the interaction of ATG5 and ATG16L1 was 
tested, using ITC and BLI. ATG5wt, T75E and T75A, as well as a synthetic ATG16L1 peptide, 
comprising residues 11-43, and two GST-ATG16L1 fusion proteins, comprising residues 1-30 and 1-43, 
were used in these experiments. 
  Results 
  111 
The results of the ITC experiments are shown in Figure 105. Clearly, in all experiments interaction of 
ATG5 and ATG16L1 was shown. The ATG16L1(11-43) peptide interacted with all forms of ATG5 
with an affinity of about 1 μM (Figure 105 a-c). For GST-ATG16L1(1-43) the interaction with 
ATG5T75A was not assessed. Binding affinities to ATG5wt and T75E were in the range of 200-300 nM 
(Figure 105 d-e). Finally GST-ATG16L1(1-30) interacted with all variants of ATG5 with an affinity in 
the range of 10-20 nM (Figure 105 f-h). The controls showed no interaction between ATG5wt and GST 
(Figure 104 a) and no significant injection heat was detected, while injecting ATG16L1(11-43) peptide 
into pure buffer (Figure 104 b). Table 21 shows an overview of the resulting affinities. 
 
Figure 104: ITC interaction controls. No binding was observed between ATG5wt and individual GST. Only small amounts of 
heat were produced by injecting ATG16L1(11-43) peptide into pure buffer (compare scales with Figure 105). 
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Figure 105: ITC interaction studies, using ATG5wt, T75E and T75A with ATG16L1(11-43), GST-ATG16L1(1-43) and GST-
ATG16L1(1-30) as indicated in the table together with the resulting KD values. 
To confirm these results, the binding studies were repeated, using BLI as a complementary method. The 
His-tagged ATG5-constructs were coupled to anti-His tips. GST-ATG16L1(1-30) interacted 
specifically with all ATG5 variants with a high affinity of 42-50 nM (Figure 106, Table 21). Every 
experiment was run in triplets to obtain statistical significance. GST-ATG16L1(1-43) interacted 
unspecifically with the tips and could therefore not be used in BLI experiments. The synthetic peptide 
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ATG16L1(11-43) wasn’t used neither, as BLI was sensitive for size differences and the MW of the 
peptide was only 4.3 kDa, which corresponded to only 12% of the MW of ATG5 (compared to 87-91% 
for the GST fusion proteins). In a control experiment individual GST didn’t bind to the tips or to any of 
the ATG5 variants. 
 
Figure 106: BLI interaction studies, using a) ATG5wt, b) T75E and c) T75A with GST-ATG16L1(1-30). Every experiment 
was run in triplets, but only the results of a single experiment are shown here. The KD-values of the individual experiments are 
indicated in the graphs, the averaged KD-values are indicated in Table 21. 
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5 Discussion 
5.1 VirG 
One objective of this work was the structural characterization of Shigella VirG, the outer membrane 
protein that is responsible for ABM. To set up crystallization experiments, milligram amounts of this 
protein were necessary. For this reason test-expressions of initially eight different constructs (Figure 28) 
were performed to identify optimal expression conditions. They were expressed as Strep- and as GST-
tagged fusion proteins (Figure 29). Also coexpression of the binding partners ATG5 and IcsB was tried 
(Figure 30) as well as periplasmic expression (Figure 31), but in all cases only low protein yields were 
obtained. In large scale expressions the soluble protein proved to form aggregates, not suitable for 
crystallization experiments (Figure 32-Figure 35). 
For this reason the ESPRIT system was used to screen for soluble constructs of VirG. 18 interesting 
constructs, covering regions that were not structurally characterized before, were identified, 13 
containing the IcsB/ATG5 binding domain at least partially (Figure 36-Figure 39, Table 15). In Figure 
107 the distribution of the N-termini of all VirG-constructs, resulting from ESPRIT screening, is shown. 
The biggest cluster of constructs contained N-termini between residues 590-640, corresponding to the 
autochaperone domain. Another cluster of constructs contained N-termini between residues 340-380, 
indicating that proteins with these N-termini were also stable. Finally a number of constructs didn’t 
cluster, but were evenly distributed between residues 300 and 670. No constructs with N-termini before 
residue 340 were identified, except for the two constructs starting at residue 77 and 303, which carried 
a frame shift mutation in the beginning. Consequently constructs, extending further to the N-terminus 
than residue 340, were most probably unstable. 
 
Figure 107: Histogram of the distribution of N-terminal residues in the VirG-constructs, obtained by ESPRIT. Many constructs 
began between residues 590-640, corresponding to the autochaperone domain. Another cluster of constructs began between 
residues 340-380. 
Three of the ESPRIT-constructs, VirGE57, E94 and E76 were expressed and purified, which proved to 
be soluble and homogenous on SEC (Figure 40-Figure 43). VirGE94 crystallized (Figure 44) and the 
structure of this construct was solved (Figure 45). 
5.1.1 VirGE94 structure 
The structure of VirGE94 was composed of the C-terminal autochaperone domain, comprising residues 
591-740 (blue in Figure 45), an intermediate part, comprising residues 484-590, that extended the β-
helix by about four turns (green in Figure 45) and an N-terminal region, comprising residues 422-483, 
that formed the VID (orange in Figure 45). 
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The autochaperone domain was present in a conformation that was very similar to the published 
structure of the autochaperone domain (Figure 108 a). RMSD-Values were 0.45 Å for all atoms and 
0.37 Å for the backbone residues. The major difference between the two structures was the conformation 
of an N-terminal loop, marked by an arrow in Figure 108 a. In the previously published structure of the 
isolated autochaperone domain the N-terminus was involved in a number of crystal contacts (Figure 108 
b). The N-terminal loop itself was not involved, still these close by contacts probably influenced its 
conformation. In the VirGE94 crystal structure this loop did not contact symmetry related molecules, so 
the present conformation of the loop was likely to be the result of long range interactions and of the 
continuation of the β-helix. 
 
Figure 108: a) Comparison of the autochaperone domains of VirGE94 (blue) and the previously published structure from PDB-
entry 3ML3 (red). The major difference was the conformation of an N-terminal loop (marked by a black arrow). The 
continuation of the β-helix in VirGE94 is shown in green. b) The N-terminus of the 3ML3 structure was involved in a number 
of crystal contacts (yellow dotted lines) with a symmetry related molecule (pink) that were likely to influence the conformation 
of this loop. 
The most N-terminal part of VirGE94, comprising residues 422-483, formed a previously unknown 
domain, which we termed the VID and which consisted of two opposing β-sheets and a short α-helix in 
a connecting loop. The first β-sheet comprised two short parallel β-strands, while the second β-sheet 
comprised three antiparallel β-strands. A magnification of the structure of the VID and a schematic view 
on its fold is shown in Figure 109. 
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Figure 109: a) The structure of the VID, which consisted of two opposing β-sheets, the first comprising two short parallel β-
strands, the second comprising three antiparallel β-strands, and a short α-helix in a connecting loop. b) A schematic view on 
the fold of the VID. The secondary structure elements are numbered in both panels accordingly. 
The VID was located on top of the β-helix. The interface between the VID and the β-helix was mainly 
formed by hydrophobic residues, namely W432, L460, L461, I466, Y468, L483 and W485 on the side 
of the VID, as well as F496, L498, L504, V506 and L510 on the β-helical side (Figure 110). 
Consequently the interaction between the β-helix and the VID in the observed fashion, shielded the 
hydrophobic residues on both sides from the contact with the solvent. 
 
Figure 110: On the left the interface between the VID (orange) and the β-helix (green) is shown, which was mainly formed by 
hydrophobic residues. On the right the interface was opened by a 90° turn of the VID and both faces are shown for clarity. 
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A loop comprising residues 514-521 was flexible and its electron density was poorly defined, especially 
in chain B. In chain A the density was slightly more pronounced, probably due to the different 
surroundings, given the fact that in both cases the loop was not involved in crystal contacts. For either 
loop the backbone was traced but several side chains were completely invisible. Residue 758 was the 
C-terminus of VirGE94, but in the crystal structure only the amino acids up to residue 740 were visible. 
This indicated that the last 18 amino acids were flexible and might have formed a linker that connected 
the extracellular α-domain to the β-barrel membrane anchor. 
A negatively charged cleft was formed by the four asparte residues D487, D489, D491 and D523, which 
were located in two extended loop regions at the N-terminus of the β-helix ((2) in Figure 111). This cleft 
might have had a function in the interaction with other compounds or proteins. It was clearly distinct 
from the polar localization region, which was located in the β-helical part of the structure below, where 
it comprised about two β-helical turns. In this region a negatively charged cleft was located that was 
formed between extended loops of the β-helix ((1) in Figure 111). The negative charge resulted from 
the three glutamate residues E499, E502 and E532. This cleft might be involved in the binding of an 
unknown factor that leads to the unipolar localization of VirG in the bacterial periplasm. The VID 
showed a mixed surface charge. A strongly positively charged patch ((3) in Figure 111) was formed by 
the three lysines K424, K438 and K478 and might be important for the function of the VID. 
 
Figure 111: VirGE94 electrostatic surface potential, calculated, using APBS [199] [200]. Potentials between -3 kT/e (red) and 
+3 kT/e (blue) are color coded. Prominent features were a negatively charged cleft in the polar localization region (1), a second 
negatively charged cleft (2) and a positively charged patch in the VID (3). For orientation on the left a cartoon representation 
of VirGE94 according to the leftmost surface potential is shown. 
The structures of a number of autotransporter proteins, different from VirG, had previously been 
published, including adhesins, serine proteases and a pore forming exo-toxin (Figure 112). They all had 
a central β-helix in common, which mainly acted as a rigid scaffold. Additional domains were attached 
to this scaffold in a modular fashion that exerted different protein specific functions. The Bordetella 
pertussis adhesin P.69 pertactin contained a long flexible loop that mediated the interaction with 
epithelial cells. In all five serine protease structures a large domain, containing the protease function, 
was present, which was attached next to the N-terminus of the β-helical stem, as well as a number of 
other domains of unknown function, designated domains 2 to 4. The Helicobacter pylori pore forming 
exo-toxin VacA contained an unusual domain, extending its C-terminus (Figure 112). 
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Figure 112: Overview of the known structures of different autotransporter proteins. For each structure the organism, the protein 
name and the PDB accession code are indicated. The β-helical stem (green), the autochaperone domain (blue) and different 
functional domains are highlighted in colors, where appropriate. In the structure of the adhesin P.69 pertactin, the orange loop 
contains the binding motif. In the serine-protease structures domain 1 (orange, the protease-domain), domain 2 (cyan), domain 
3 (purple) and domain 4 (yellow) are highlighted. The structures are aligned, so that the N-termini are located at the top and 
the C-termini at the bottom. The membrane anchor domains, which insert into the outer bacterial membrane, follow at the C-
terminus, hence they would be located at the bottom of these structures. 
Compared to these known autotransporter structures, the autochaperone domain and the β-helical part 
of the VirGE94 structure were not unusual, as similar motifs were present in nearly all structures. 
However, in none of these structures a domain sitting on top of the β-helical backbone had been 
observed. Additional domains were rather attached to the side of the β-helical stem. As the VirGE94 
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construct did not cover the complete VirG α-domain, this raised the question, if the VID normally was 
located on top of the β-helix, as seen in the VirGE94 structure, or if it was attached to the side of an 
extended β-helical backbone, as seen in the structures of many other autotransporter proteins. This 
question is addressed in chapter 5.1.3. 
5.1.2 VirGE94 oligomerization state 
VirGE94 was dimeric in solution as shown by SEC (Figure 41). Two different crystal contacts were 
identified that might have been responsible for the dimerization. The first of these contacts was mediated 
by a heavy metal ion. As there were no heavy metals present in the buffers during purification or in the 
crystallization condition, the first possibility was that it was copurified from E. coli and the second 
possibility was that VirG had stripped off a Ni2+-ion during His-affinity purification. When a Ni2+-ion 
was placed into the density, it fitted perfectly, not leaving any unexplained electron density (Figure 113 
a). It contacted residues H669 and D701 in both VirGE94 molecules. The aspartates contacted and 
neutralized the charge of the Ni2+-ion, while the histidines complexed it. Consequently it was four times 
coordinated with distances to the aspartate δ-oxygens of 1.91/2.03 Å and to the histidine ε-nitrogens of 
1.99/2.04 Å, which was quite close but had been observed before in other structures [201] (Figure 113 
b). The B-factors of the Ni2+-ion and the surrounding amino acids were of the same magnitude in a range 
between 20 and 28 Å2, supporting the placement of the Ni2+-ion. However, when the Ni2+-ion was 
removed by dialysis with EDTA, VirGE94 still formed dimers in solution, as shown by SEC (Figure 
46), indicating that this crystal contact was not responsible for the observed dimer formation. 
 
Figure 113: a) In the VirGE94 crystal structure a Ni2+-ion (green sphere) was bound in between two symmetry mates of 
VirGE94 (one colored in blue, green and orange, the other in purple). It contacted residues H669 and D701 in both molecules. 
The inset shows a magnification of the contact area with a 2Fo-Fc electron density map (grey) contoured at a level of 1.0 σ. b) 
A schematic view of the involved contacts, including the binding distances. 
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The second crystal contact that might have been responsible for VirGE94 dimerization, was an 
interaction of the VIDs from two symmetry related copies of VirGE94, which were rotated by 180° 
(Figure 114). The two VIDs formed an intermolecular β-sheet primarily by contacts between the two 
protein backbones. The only side chains that were involved in this interaction, were the side chains of 
S441 from both molecules. 
 
Figure 114: The VID (orange) contacted a symmetry related copy of itself, by the formation of an intermolecular β-sheet. The 
inset shows a detailed view on the participating residues. 
To test whether this second crystal contact, mediated by the interaction of the VIDs, was responsible for 
the dimer formation of VirGE94 in solution, a SAXS experiment was performed (Figure 48). The MW 
of VirGE94 was calculated from the SAXS data and confirmed that VirGE94 was dimeric in solution 
(Table 17). The theoretical scattering curves of all possible crystallographic dimers were calculated and 
fitted to the experimental data. The dimer, formed by the interaction of the VIDs, resulted in the best fit 
(Figure 49) and also fitted into the envelope, calculated from the SAXS data, which had a similar 
elongated form (Figure 50 c). Also the results from the PISA server [202] suggested, that this dimer 
with an interface area of 679 Å2 might have been stable in solution. Together these results confirmed 
that the VirGE94 dimer was formed by the interaction of the VIDs. 
However, it was unlikely that the dimerization via the VIDs had an in vivo function. Normally the VirG 
proteins were located on the surface of the bacterial outer membrane, oriented in the same direction. 
Thus the formation of dimers by an interaction of the VIDs would have required a rotational freedom of 
about 90° to arrange the VIDs in a fashion, suitable for interaction (Figure 115). Additionally the longer 
VirgE76 construct was monomeric in solution, as shown by SEC (Figure 41), indicating that the 
dimerization interface might not have been accessible in longer VirG-constructs and in the full length 
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VirG α-domain. Together these results indicated that the dimerization via the VIDs was an artifact of 
the VirGE94 construct. 
 
Figure 115: a) Scheme of the VirE94 dimer in solution. b) For the dimerization of VirG on the outer bacterial membrane, the 
VIDs would have required a rotational freedom of about 90°. The continuation of the VirG α-domain is indicated by black dots. 
5.1.3 Localization of the VID 
In contrast to many autotransporter proteins, where functional domains were attached to the side of an 
elongated β-helical stem (compare Figure 112), in the crystal structure of VirGE94, the VID was located 
on top of the β-helix. However, VirGE94 lacked the N-terminal half of the α-domain that might have 
formed a continuation of the β-helix. This raised the question of the position of the VID in the full length 
protein. Different scenarios were imaginable (Figure 116). The VID might have been attached to the 
side of a continued β-helical stem, like in other autotransporter proteins. In this case, in the truncated 
VirGE94 it might have moved to the unoccupied space on the top of the β-helix, to shield its hydrophobic 
interior from the solvent (Figure 116 a). Other possible locations of the VID in full length VirG were on 
top of the β-helix, like in the VirGE94 crystal structure (Figure 116 b), or it might have been aligned 
with the β-helix, to form a continued β-helical stem (Figure 116 c). 
 
Figure 116: Models for the localization of the VID in the full length VirG α-domain. a) In full length VirG the VID (orange) 
might have been attached to the side of an extended β-helical stem (dark and light green). In VirGE94 the N-terminal half of 
the β-helix (light green) was truncated, hence the VID could have moved to the top of the C-terminal part of the β-helix (dark 
green) to shield its hydrophobic interior. At the bottom the autochaperone domain is shown (blue). b) The VID might have 
been located on top of the β-helix, like in the VirGE94 crystal structure, and the β-helix continues elsewhere (indicated by the 
black dots). c) The VID might have been aligned with the β-helix to form a continued β-helical stem. 
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A structure prediction of the VirG passenger domain by the Phyre2 server [197] showed a long β-helical 
stem and two domains attached to its side (orange and cyan in Figure 117). One of the domains in the 
Phyre2 prediction (orange in Figure 117) had residue 420 as N-terminus, which was nearly identical to 
the N-terminal boundary of the VID. In the prediction, this domain was composed of two separate chains 
(residues 420-456 and 497-534) that extruded from different loops in the β-helix, while in the crystal 
structure the VID was composed of a single chain. Also limited proteolysis experiments suggested that 
residues 420 and 485 might have been the boundaries of a domain in VirG (Figure 53). These indices 
confirmed the presence of the previously unknown domain in VirG. They also suggested that the VID 
corresponded to the orange domain in the Phyre2 prediction and might have been located at the side of 
an extended β-helix. 
 
Figure 117: Phyre2 prediction of the structure of the passenger domain of VirG [197]. Models, used by Phyre2, were the 
structure of the VirG autochaperone domain (PDB-entry 3ML3) and the published structures of different autotransporter 
proteins (PDB-entries 1DAB, 3AK5, 3H09, 3SYJ, 4OM9). Blue: autochaperone domain, green: β-helical stem, yellow: N-
terminal signal peptide for sec-pathway, orange and cyan: two domains attached to the side of the β-helical stem. 
The question was addressed experimentally by a SAXS experiment, using VirGE57, E76, E94, K26 and 
K34. The expected solution states of the constructs are shown in Figure 47 b. To locate the VID in these 
constructs, their envelopes were calculated from the experimental scattering data (Figure 50). The 
envelope of VirGE76 was of special interest. It better resembled the full length VirG α-domain than 
VirGE94, as it contained the VID probably together with an extended β-helix. 
VirGE94 was dimeric and a model of a VirGE94 dimer, formed by the interaction of the VIDs, fitted 
perfectly into the calculated envelope (Figure 50 c). The VID was located on top of the β-helix as in the 
crystal structure. For VirGE57 a truncated model of VirGE94 was fitted into the envelope (Figure 50 a). 
In this construct the VID was not complete, hence it was probably unfolded and its conformation and 
position were not significant. In VirGE34 the VID was deleted to test if further N-terminal regions of 
VirG would fold into a continued β-helix. A model of VirGE94, where the VID was deleted and which 
lacked the additional N-terminal amino acids, was fitted into the envelope (Figure 50 b). The 
unexplained volume at the N-terminus might have been attributed to the amino acids missing from the 
model, but it was not possible to determine their conformation. As the VID was deleted, no conclusions 
about its position could be drawn from the data of this construct. Unluckily the most important construct 
VirGE76 was aggregated and no envelope could be calculated. Also the other constructs showed signs 
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of aggregation first in their distance distribution functions (compare Figure 48) and second in the form 
of tails, extruding from the envelopes (compare Figure 50). 
Consequently the question of the position of the VID in full length VirG could not finally be answered, 
as the SAXS data for the VirGE76 construct was missing. All scenarios were still possible. 
5.1.4 Function of the VID 
The structure of the VID was employed for the search of similar protein structures, using the DALI 
server [203] and PDBeFold [204]. A number of domains with similar folds were identified by the DALI 
server. Surprisingly the fold of the VID was similar to the fold of the autochaperone domains of different 
autotransporter proteins (Figure 119). 
When the fold of the VID was compared to other folds associated with the β-helical backbones of known 
autotransporter proteins, it was clearly similar to the autochaperone domain fold, but distinct from all 
other folds (Figure 118). 
 
Figure 118: Different folds, associated with the β-helical structures of autotransporters. a) parallel β-helix, b) β-helical kink 
(PDB-entry 4KH3), c) N-terminal cap (PDB-entries 1WXR, 3H09, 3SYJ, 3SZE), d) C-terminal autochaperone domain (PDB-
entries 1DAB, 1WXR, 2IOU, 2QV3, 3H09, 3SYJ, 3SZE, 4OM9), e) C-terminus (PDB-entry 4MR0), f) VID of VirGE94. The 
fold of the VID is clearly similar to the fold of the autochaperone domain, but distinct from all other folds. 
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Figure 119: a) The best hit for a protein with similar fold, identified using the DALI server, was the autochaperone domain of 
B. pertussis P.69 pertactin (PDB-entry 1DAB) with an RMSD-value of 2.7. An overlay of the VID with the whole protein 
structure is shown. The inset shows a magnification of the VID (orange) and the P.69 autochaperone domain (blue). A scheme 
of the fold of the P.69 autochaperone domain is shown on the right, which is similar to the fold of the VID (compare with g)). 
A number of other autochaperone domains have also been identified by the DALI server, including the autochaperone domains 
of b) E. coli Hbp (PDB-entry 1WXR), c) B. bronchiseptica Prn-E (PDB-entry 2IOU), d) H. pylori VacA (PDB-entry 2QV3) 
and e) H. influenza IgA1 (PDB-entry 3H09). Overlays of the structures of the autochaperone domains (blue) with the VID 
(orange) are shown for all structures, above a scheme of the fold of the according autochaperone domain. All folds were similar 
to the fold of the VID (compare with g)), even if in the case of VacA an additional domain and different secondary structure 
elements were inserted. f) The VirG autochaperone domain had not been identified by the DALI server, still a structural 
alignment and the scheme of the fold showed the similarity to the VID. g) Scheme of the fold of the VID the VirGE94 structure. 
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Conclusively the VID might have acted as a second autochaperone domain, which nucleated the fold of 
the N-terminal continuation of the β-helix. Consequently the interface, which formed the dimer in 
VirGE94, would not have been accessible anymore in N-terminally elongated VirG-constructs and in 
the full length VirG α-domain. The fact that only VirGE94 dimerized, but the shorter VirGE57 and also 
the longer VirGE76 were monomeric, supported this hypothesis (Figure 41). An autochaperone domain 
function of the VID created new possibilities for the conformation of the VirG α-domain (Figure 120). 
One scenario was that the VID might have been located as in the VirGE94 crystal structure, and 
introduced a 90° kink into the protein backbone (Figure 120 a). It might also have been located to the 
side of a continued β-helical backbone and nucleate the fold of a separate β-helical domain there (Figure 
120 b). A last possibility was the formation of a continued β-helix, similar to other autotransporter 
proteins (Figure 120 c). A kink in the β-helical backbone would not have been too extraordinary, as a 
nearly 90° kink, which was formed by other means, had already been observed in the Ag43a crystal 
structure (Figure 112). 
 
Figure 120: Schemes of possible conformations of the VirG α-domain. a) If the VID was located, like in the VirGE94 crystal 
structure, it might have introduced a 90° kink in the β-helix. b) If the VID was located at the side of a continued β-helical stem, 
it might have nucleated the formation of a separate β-helical domain there. c) The VID might have formed a continuation of 
the β-helix. 
5.1.5 Interaction studies 
The previously published interactions of VirG with IcsB and ATG5, which were the basis of the Shigella 
camouflage mechanism, were evaluated here, using various protein constructs and methods, for a more 
detailed understanding. The interactions of the initial VirG-constructs were assessed in pulldown 
experiments (Figure 88), by blue native PAGE (Figure 89) and by SEC (Figure 90), but binding of IcsB 
or ATG5 was not observed. The major problems were the low available amounts of VirG protein and 
the fact that it was aggregated, as shown by SEC. 
For this reason the interaction of VirG with IcsB and ATG5 was reassessed, using the soluble and 
homogenous VirGE94 and E76 constructs, which resulted from the ESPRIT screening. Still in pulldown 
experiments no interactions with IcsB or ATG5 were observed (Figure 91), but using MST as a 
complementary method an interaction of VirGE76 and IcsBwt (in complex with IpgA) with a KD of 
600±205 nM, but not of VirGE94 and IcsBwt, was observed (Figure 92). This was not surprising as 
VirGE94 contained only the last 15 amino acids of the IcsB/ATG5 binding domain, while VirGE76 
contained nearly the full domain, except for the first 20 amino acids. However, it was strange that an 
interaction with a KD of 600 nM was not observable in the pulldown interaction studies. The reason 
might have been that VirG was untagged and pulldowns could only be performed, using the His-tag of 
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IcsB. By binding IcsB to the affinity beads, the VirG binding site might have been blocked. Still the 
interaction between VirGE76 and IcsB should be considered as uncertain, until being validated by an 
independent method. In the case of ATG5 no clear interaction to VirGE76 or VirGE94 was detected, 
indicating that either ATG5 did not directly bind to VirG or that the ATG5 binding site included residues 
320-339 of the previously reported interaction motif, which were not included in the soluble constructs, 
identified by ESPRIT and used in these experiments. 
VirG has been shown to be an activator of N-WASP in a fashion similar to Cdc42. Still it is quite unclear 
which domains of N-WASP and VirG are involved in their interaction. Binding of N-WASP-PH/IQ 
[194], -GBD [85] and -V [145] to VirG has been shown. At the same time three different interaction 
regions in VirG have been shown to bind to N-WASP and N-WASP interacts with different VirG 
molecules at the same time [135]. To further investigate the interaction between N-WASP and VirG, 
pulldowns (Figure 93) and MST experiments (Figure 94) were performed, but no interactions were 
observed. This did not mean that there was no interaction between VirG and N-WASP. Only the 
individual N-WASP domain has been used in these experiments and VirGE76 only covered N-WASP 
interaction regions III and II (except for the first ten amino acids), but not N-WASP interaction region 
I, which might have been important for this interaction. A VirG-construct covering N-WASP interaction 
regions I and II was the first one, for which in vitro interaction with N-WASP had been shown [146]. 
Hence the constructs, used in these experiments, might have been too limited to allow for the interaction 
of VirG and N-WASP. 
Finally a pulldown experiment was performed to test the interaction of VirG to other proteins involved 
in or associated with the actin polymerization system. The tested interaction partners were domains of 
N-WASP, Toca-1, Cip4, Cdc42 and a number of diaphanous formins (Figure 95). No interactions 
between VirGE76 and these constructs were observed. However, as VirGE76 covered only a part of the 
VirG α-domain and only individual domains of the potential binding partners were used, an interaction 
between full length VirG and the respective proteins cannot be excluded here. 
5.2 IcsB 
IcsB was the second target that should be structurally characterized in this work. Initially twelve 
different constructs were used, which were expressed and purified in high quantities (Figure 59-Figure 
62). The proteins were soluble and homogenous, but no initial crystallization conditions were identified. 
Different rescue strategies like SER (Figure 63-Figure 65), methylation of surface lysines and in situ 
proteolysis were applied, but didn’t lead to crystal formation either. A limited proteolysis experiment 
was used to identify suitable boundaries for new constructs (Figure 66). Using these boundaries, 19 new 
constructs were designed (Figure 67). Proteins were expressed and purified, but again no initial 
crystallization conditions were identified (Figure 68, Figure 69). At this point attempts to crystallize 
IcsB were stopped and the purified proteins were used to characterize IcsB. 
5.2.1 Biophysical characterization 
The purified IcsB-IpgA complexes were homogenous and soluble, as shown by SEC. Using SourceQ 
IEC, IpgA was partially separated from IcsB. The resulting individual IcsB proteins, which contained 
the CBD, were unstable, as they aggregated, as shown by SEC. In contrast, individual IpgA remained 
soluble and homogenous. The reason for the lability of individual IcsB was the presence of the CBD. 
IcsB-constructs, lacking the CBD, were soluble and stable without IpgA. On the other hand, expression 
of the CBD (11 kDa) fused to GST as a solubility tag (28 kDa) without coexpressed IpgA, resulted in 
the complete aggregation of the fusion construct. The absence of expression for IcsB protein constructs, 
including the CBD, without coexpressed IpgA, was in compliance with these results. Taken together, 
these results indicated that the presence of the CBD destabilized the IcsB protein, while it was stabilized 
by the presence of IpgA. 
  Discussion 
  127 
Upon secretion by the TTSS, IpgA is stripped off, resulting in the export of IcsB, including the CBD, to 
the cytoplasm of human cells. Hence the CBD might have an in vivo function that needs further 
investigation. Possibly it is a protein interaction domain that is stabilized, upon binding of an interaction 
partner derived from the host. 
Thermofluor-assays showed that the IcsB-IpgA complex had an intermediate melting temperature of 
50°C, compared to the melting temperatures of individual IcsB of 37°C and the melting temperature of 
individual IpgA of 72°C (Figure 70, Figure 71). This result supported the stabilizing function of IpgA. 
A melting temperature, close to the human body temperature, might be important for the function of 
IcsB, by providing a high degree of flexibility to the protein, while it is stabilized by IpgA as long as it 
resides inside the bacterial cell, to prevent degradation. 
CD-spectroscopy was used to determine the secondary structure composition of IcsB (Figure 72). 
Interestingly the fraction of random coil rose from 25% to 37% upon subtraction of the spectrum of 
IpgA from the spectrum of the IcsB-IpgA complex. This major fraction of random coil in IcsB, might 
be the reason for the bad crystallization behavior of all IcsB-constructs. These results were in agreement 
with the findings from [205], where IcsB was shown to contain natively unfolded regions by NMR and 
that it was no suitable target for crystallography. 
5.2.2 Mapping of the IpgA binding site 
Previously, IcsB residues 171-247 had been shown to contain the minimal CBD [131]. However, in this 
work N-terminal IcsB-constructs, comprising the first 125 residues, repeatedly copurified IpgA (Figure 
62). This led to the hypothesis that the CBD was actually located in the N-terminal part of IcsB. Using 
the IcsB-constructs, generated in this work, the CBD was mapped in pulldown experiments (Figure 73). 
The minimal fragment of IcsB that copurified IpgA was IcsBK3, spanning residues 26-125. 
The CBDs of several TTSS effector proteins were located in the N-terminal region of their respective 
target proteins [206]–[208]. Using SIB-MyHits (Pfam) [209], [210], a stretch in IcsB, comprising 
residues 33-115, was predicted to contain a SicP binding site [153]. SicP was the chaperone of SptP, a 
TTSS effector protein in Salmonella typhimurium [206]. IcsB 33-115 shared 27% sequence identity 
(51% similarity) with SptP 44-121, the SicP binding site in SptP. The chaperones IpgA and SicP shared 
20% sequence identity (34% similarity). These significant sequence conservations supported the 
hypothesis. 
A limited proteolysis experiment has been performed to identify suitable boundaries for new IcsB-
constructs. The identified N- and C-terminal boundaries of the fragments, were marked in a PSIPRED 
secondary structure prediction of IcsB [211] (Figure 121). Most cleavage sites were close to the N- and 
C-terminus and in a region around a presumably unfolded stretch (predicted by DISOPRED2 [212]). 
Some single cleavage sites were located in the C-terminal part of IcsB. Interestingly, no cleavage site 
was identified in an N-terminal region spanning residues 10-175, indicating that this region was 
protected from cleavage, complying with the previous results. 
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Figure 121: Mapping of the N- and C-terminal cleavage sites, determined in a limited proteolysis experiment, on a PSIPRED 
secondary structure prediction of IcsB. Green arrows indicate N-terminal fragment boundaries, red arrows indicate C-terminal 
boundaries. Red boxes indicate regions that were predicted as unfolded by DISOPRED2. 
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Finally a SAXS experiment was performed, using an IcsBK3-IpgA complex as well as individual IpgA 
(Figure 74). The SAXS data were used to determine the MW of the proteins (Table 18). The MW of 
IpgA corresponded to a dimer, while the MW of the IcsBK3-IpgA complex corresponded to one 
molecule of IcsBK3, binding a dimer of IpgA. 
The structures of a number of TTSS effector proteins in complex with their respective chaperones were 
deposited in the PDB. An overview of these structures is given in Figure 122. Two models were created 
from each structure, one containing a chaperone dimer, the other containing a chaperone dimer bound 
to the CBD of their respective effector protein. These models were fitted to the experimental scattering 
curves. The χ2-values of the resulting fits are shown in Figure 123. Fitting of the chaperone dimer models 
to the SAXS data of IpgA, consistently resulted in good fits with χ2-values smaller than 4. If the same 
models were fitted to the SAXS data of the IcsBK3-IpgA complex, the χ2-values in most cases were 
considerably higher, reaching values of 6-14. Fitting of the chaperone-effector complexes to the SAXS 
data of the IcsBK3-IpgA complex, resulted in much lower χ2-values again, similar to those, obtained for 
the fit of the chaperone dimers to the SAXS data of IpgA. These results confirmed that IpgA formed a 
typical chaperone dimer, while IcsBK3-IpgA formed a chaperone-effector complex, where one 
molecule of IcsBK3 bound a dimer of IpgA. 
 
Figure 122: Overview of the known structures of different class I TTSS chaperone-effector complexes. For each structure the 
organism, the chaperone and effector names as well as the PDB accession code are indicated. The chaperone dimers are shown 
in green and blue, the CBD of the effector is shown in purple. 
 
Discussion 
130 
 
Figure 123: Fitting of different known TTSS chaperone-effector complexes to the experimental SAXS data of IpgA and of the 
IcsBK3-IpgA complex. a) blue bars: fitting of chaperone dimers to IpgA SAXS data, b) red bars: fitting of chaperone dimers 
to IcsBK3-IpgA SAXS data, green bars: fitting of chaperone effector complexes to IcsBK3-IpgA SAXS data. These results 
confirmed that IpgA formed a chaperone dimer in solution, while IcsBK3-IpgA formed a chaperone-effector complex. 
Conclusively, the results presented here show that the IcsB-CBD is located in the N-terminal region, 
between residues 26-125, as shown by the pulldown experiments. SAXS experiments confirmed that an 
IpgA dimer was binding in this region, which is typical also in other TTSS chaperone-effector 
complexes. 
5.2.3 Interaction studies 
Interaction studies with published binding partners of IcsB were performed for the further 
characterization of IcsB. The reported interaction of IcsB with Toca-1 was tested in pulldown 
experiments, but could not be confirmed (Figure 96, Figure 97, Figure 103). In the original publication 
the interaction of IcsB and Toca-1 had been shown by immunoprecipitation from human cell lysates and 
Western blotting, and was confirmed by the coprecipitation of MBP-IcsB (no IpgA) and His-Toca-
1(105-477) from E. coli lysates and Western blotting, which mostly excluded the possibility that a third 
interaction partner was involved. This leaves several possibilities, why the interaction could not be 
shown here. One reason might have been the presence of IpgA, which complexed IcsB. If the N-terminal 
part of IcsB was involved in the observed interaction, the presence of IpgA might have blocked it. Also 
in this work Toca-1(1-293) and (245-477) (the core IcsB binding domain), but not the longer construct 
(105-477) have been used, leaving the possibility that Toca-1 residues 105-244 were involved in the 
interaction. In the publication the interaction was shown by Western blotting, while here pulldown 
experiments and Coomassie stained gels were used. If the interaction was weak, it might have been 
disrupted by the washing steps, applied in the pulldowns, and might not have been detectable on 
Coomassie stained SDS-gels anymore. Also a major problem in the pulldown experiments was the 
strong and unspecific binding of GST-tagged Toca-1-constructs to His-affinity beads, which might have 
obscured an interaction. 
Another published interaction partner of IcsB was cholesterol. This interaction was tested, using DHE, 
a fluorescent cholesterol analogon, in SEC. However, the interaction could not be confirmed. One 
problem might have been that DHE, like cholesterol, was virtually insoluble in water. For this reason 
methyl-β-cyclodextrin, a cyclic compound composed of seven glucose moieties, was used to solubilize 
DHE. If the solubilization didn’t work, DHE might not have been available for interaction with IcsB. 
Another possibility was that the differences in the structure between cholesterol and DHE prevented the 
interaction. 
A third potential interaction partner has been identified in this work. Phyre2 [197] was used to predict 
the tertiary structure of IcsB. The quality of the resulting model was poor, as no homologues structures 
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were known. Still, a stretch in IcsB, comprising residues 99-130, was shown to be homologues to a 
stretch in E. coli EspFU, comprising residues 73-102. These two regions shared 30% identity (46% 
similarity). A more truncated core region, comprising residues 106-130 in IcsB and 75-99 in EspFU, 
even shared 41% identity (63% similarity) (Figure 124). 
 
Figure 124: Alignment of IcsB(106-130) and EspFU(75-99). These two regions shared 41% identity (63% similarity). 
EspFU is an activator of N-WASP and a TTSS effector protein from entero hemorrhagic E. coli (EHEC). 
In its inactive state N-WASP is autoinhibited by an intramolecular interaction of the GBD with the C-
region of the VCA-domain. EspFU binds competitively to the GBD, releasing the VCA-domain, which 
in turn activates the Arp2/3-complex. The direct interaction of EspFU with the WASP-GBD has been 
proven, by solving the solution structure of the complex by NMR (PDB-entry 2K42) [198]. EspFU is 
composed of an N-terminal signal peptide, followed by 2-7 nearly identical 47 amino acid repeats. Every 
repeat consists of a 27 aa N-terminal hydrophobic stretch and a 20 aa C-terminal proline rich region. 
The first 33 aa, which comprise the whole hydrophobic region and the first part of the proline rich region, 
are sufficient to effectively activate N-WASP [198]. The IcsB core region, identified above, 
corresponded to a stretch in EspFU, covering all the hydrophobic part of one repeat, except for the first 
two amino acids. For this reason it was hypothized that IcsB might bind and activate N-WASP. 
For this reason the two IcsB-constructs K30(104-130) and K31(99-136) were designed and tested 
together with IcsBwt (1-494, in complex with IpgA) and K9 (169-494, no IpgA) in pulldown 
experiments for interaction with the N-WASP-GBD (Figure 98, Figure 99, Figure 103). However, no 
interactions were observed. The presence of IpgA, complexed to IcsBwt, might have been problematic. 
The predicted N-WASP binding site (104-130) partially overlapped with the CBD (33-115). One 
solution might have been the coexpression of IcsBwt and the N-WASP-GBD, which has not been tested 
here. The constructs IcsBK30 and K31 also might have been too limited to support interaction with the 
N-WASP-GBD. In an independent approach N-WASP-GBD – IcsBK30/K31 fusion proteins were 
tested for interaction, using a thermofluor-assay (Figure 100, Figure 101). Here, for IcsBK31 and the N-
WASP-GBD, indications for an interaction have been observed. Interestingly, in contrast to IcsBK30, 
IcsBK31 included IcsB residue W135, which was in a similar position as EspFU residue W105 that had 
been shown to contribute to a higher affinity N-WASP interaction [213]. Unfortunately, in this 
experiment the positive control did not work, hence the interaction between IcsB and the N-WASP-
GBD should be considered as uncertain, until being validated by an independent method. 
Like N-WASP, diaphanous formins contain a GBD and are autoinhibited by an intramolecular 
interaction. Diaph1 has been shown to be involved in the formation of Shigella protrusions [90]. As an 
interaction of IcsB and the N-WASP-GBD was hypothized, also the interactions of IcsB and the GBDs 
of different diaphanous formins were tested in pulldown experiments (Figure 102, Figure 103). Also 
here, no interactions were observed, possibly due to the weak soluble expression of most of the GBD-
constructs. 
Finally IcsB contained a predicted RID [153]. For this reason the interaction of IcsB and Cdc42 was 
tested in a pulldown experiment (Figure 103), but no interaction was observed. 
In summary, a potential interaction of IcsB and the N-WASP-GBD has been shown, apart from the 
potential interaction of IcsB and VirG that was described in chapter 5.1.5. The presence of complexed 
IpgA in IcsBwt might have been problematic, as interactions with the N-terminal part of IcsB would 
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likely have been missed. Also in most cases, interactions were tested, using individual domains of the 
binding partners, which might not have been sufficient for interaction with IcsB. 
5.3 ATG5 
5.3.1 ATG5 structure 
Initially only one ATG5-construct, ATG5wt, was expressed and purified (Figure 75, Figure 76). 
Subsequently ATG5wt was crystallized in November 2012 (Figure 78) and its structure was solved in 
April 2013 (Figure 79). At the beginning of this work, only two structures from December 2006 of S. 
cerevisiae Atg5 in complex with N-terminal fragments of Atg16 were known (PDB-entries 2DYM, 
2DYO). Hence, the structural characterization of human ATG5 in this work was a logical objective. In 
August 2012 the structure of Kluyveromyces marxianus Atg5 was published (PDB-entry 3VQI), 
followed by the first human ATG5 structure in complex with ATG12 and an N-terminal fragment of 
ATG16L1 (PDB-entries 4GDK, 4GDL) and the homologues S. cerevisiae complex (PDB-entry 3W1S) 
in December 2012. At this point ATG5 has already been crystallized. The structure of individual ATG5 
was interesting to evaluate possible conformational changes of the ATG5 mutants T75E and T75A, as 
well as in a potential VirG-ATG5 complex. In the published complex structure, conformational changes 
might have been imposed on ATG5. The structures of individual ATG5wt and the mutant forms were 
solved between April and December 2013. In November 2013 the structure of the human ATG5-12/16 
complex, binding a fragment of ATG3 was reported (PDB-entry 4NAW) and only recently in March 
2015 the structures of human ATG5 in complex an N-terminal fragment of ATG16L1 (PDB-entry 
4TQ0) and the AFIM of TECPR1 were published (PDB-entry 4TQ1). 
The structure of individual ATG5, solved in this work, is shown in Figure 79. Similar to S. cerevisiae 
Atg5 (Figure 15), human ATG5 consisted of two UFDs and an α-helical bundle region. The first and 
the last three amino acids were not modelled, due to missing electron density. Additionally, an internal 
loop comprising residues 228-234 was not modelled for the same reason. Most probably these residues 
were flexible and therefore not visible in the electron density map. 
The peptide bond between residues L96 and P97 was in the cis-form, which is not unusual for a peptide 
bond, involving a proline residue. The resolution of 3.1 Å was not sufficient to determine the correctness 
of the cis- or trans-configuration, but the cis-peptide was already present in the molecular replacement 
search model, which was determined at a resolution of 2.6 Å. A human ATG5 structure published in 
2013 (PDB-entry 4NAW) with a resolution of 2.2 Å also showed the cis-peptide, which was stabilized 
by an octahedrally coordinated ion (Figure 125). This ion contacted the backbone oxygens of A95 and 
P97, as well as the side chain of N99, thereby stabilizing the cis-configuration. The other three 
coordination sites were occupied by water molecules. The nature of this ion was not further specified in 
the PDB-file or the according publication [214]. 
The structure of individual ATG5 was very similar to the structure of ATG5 in the published human 
ATG5-12/16 complex  (PDB-entry 4GDK) [215] with RMSD-values of 0.41 Å for the backbone 
residues and 0.47 Å for all atoms. Hence no conformational changes of ATG5, upon complex formation 
were observed. Human ATG5 shared 24% identity (42% similarity) with S. cerevisiae Atg5 and 24% 
identity (40% similarity) with K. marxianus Atg5. The RMSD-values were 1.41 Å for the backbone 
residues and 1.59 Å for all atoms for S. cerevisiae (PDB-entry 2DYM) and 1.74 Å for the backbone 
residues and 1.78 Å for all atoms for K. marxianus (PDB-entry 3VQI). The structures of the different 
ATG5 homologues were closely related. 
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Figure 125: The cis-peptide bond (dashed black line) between residues L96 and P97 from PDB-entry 4NAW. The cis-
configuration is stabilized by an unspecified ion, which contacts the backbone oxygens of A95 and P97, as well as the sidechain 
oxygen of N99. Three water molecules complete an octahedral coordination sphere. 
A SAXS experiment was performed to determine the oligomerization state of ATG5 in solution (Figure 
80). From the SAXS data, a MW of 39.8 kDa was determined, which corresponded to the MW of an 
ATG5 monomer of 33.1 kDa with a deviation of 20%. Fitting of the calculated scattering curves of an 
ATG5 monomer to the experimental scattering curves resulted in a good fit with a χ2-value of 2.8 (Figure 
80 c). At larger angles, corresponding to higher resolution, the calculated scattering curve didn’t fit the 
experimental curve perfectly. The reason might have been, that the overall shape of ATG5 in solution 
and the ATG5 crystal structure was similar, but differed in details. The PISA server confirmed that 
ATG5 probably did not form oligomers. Taken these results together, ATG5 was probably monomeric 
in solution. 
5.3.2 ATG5 phosphomimetic mutants structure 
ATG5 residue T75 can be phosphorylated, resulting in the inhibition of the fusion of autophagosomes 
and lysosomes, thus inhibiting autophagy. ATG5 T75 was conserved across the kingdom of animals. In 
fungi and yeast it was usually replaced by hydrophobic amino acids like valine and isoleucine, only S. 
cerevisiae had a threonine in this position. In plants it was replaced by other amino acids, like 
phenylalanine in A. thaliana and leucine in rice. The structures of two ATG5 homologues were available 
in the PDB. In S. cerevisiae Atg5 T79 occupied the same space as T75 in the human form. Interestingly, 
in K. marxianus, also a yeast, Atg5 residue E78 replaced T75, which resembled the phosphomimetic 
mutant of the human form. 
One possible effect of T75 phosphorylation was a changed affinity of ATG5 for ATG16L1 or TECPR-
1, by influencing its conformation. To investigate the influence of T75 phosphorylation on the ATG5 
structure, a phosphomimetic T75E mutant as well as a T75A negative control were generated. These 
two constructs were expressed, purified, crystallized and their structures were solved (Figure 81-Figure 
85). 
The structures of ATG5wt, T75E and T75A were extremely similar (Figure 126). RMSD-values for the 
backbone residues were 0.24 Å for T75E compared to wt and 0.22 Å for T75A compared to wt. For all 
atoms the values were 0.27 Å and 0.25 Å for T75E and T75A compared to wt respectively. Minor 
differences to the wild type structure were seen only in surface exposed loops and side chains, which 
had a higher degree of freedom. Like for the structure of ATG5wt, in T75E and T75A the first and the 
last three amino acids were not modelled, as well as an internal loop comprising residues 229-234, due 
to missing electron density, which indicated that these residues were flexible. 
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Figure 126: ATG5 structures: wt (green), T75E (blue), T75A (red). Minor differences were observed in the conformation of 
some surface loops. The inset shows the surrounding of residue 75, which is shown as a stick model for the three ATG5 variants. 
In comparison, the structures were extremely similar, also in proximity to the mutation. 
The mutations were clearly visible in the electron density maps (Figure 127 a-c). If in ATG5T75E a 
threonine was modelled instead of the glutamate at position 75, additional unexplained electron density 
appeared around this residue (Figure 127 d). If a threonine was modelled instead of an alanine at position 
75 in ATG5T75A, negative difference electron density appeared in proximity, indicating that no side 
chain atoms beyond Cβ were present (Figure 127 e). This data confirmed the presence of the mutations. 
 
Figure 127: Electron density maps around residue 75. 2Fo-Fc maps are shown in grey and are contoured at a level of 1.0 σ. Fo-
Fc maps are shown in green and red and are contoured at a level of +3.0 and -3.0 σ respectively. a) ATG5wt, b) ATG5T75E, 
c) ATG5T75A, d) ATG5T75E, residue 75 is modelled as a threonine, e) ATG5T75A, residue 75 is modelled as a threonine. 
The results confirmed that the mutations were present in the respective structures. 
In summary the different mutant variants of ATG5 were crystallized and the mutations were visible in 
their crystal structures. No influence of the phosphomimetic mutation T75E on the structure of ATG5 
was observed, indicating that the phosphorylation of ATG5 probably wouldn’t change its structure. 
However, a direct influence of the phosphorylation of T75 on the binding of ATG16 was still possible, 
for instance by the destabilization of the tertiary structure of ATG5, which was not necessarily 
observable in the crystal structure. To address this question, the different ATG5 variants were examined 
for their biophysical properties by a thermofluor-assay (Figure 86) and limited proteolysis (Figure 87), 
but also in these experiments the three mutant ATG5 forms had identical properties. The melting 
temperatures of all ATG5 variants were in the range of 38-39°C and no differences in the degradation 
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patterns of the limited proteolysis experiment were observed. These results indicated that the T75 
phosphorylation didn’t destabilize ATG5. 
5.3.3 Interaction ATG5 – ATG16L1 
To test whether there was any influence of the T75 phosphorylation on the binding of ATG16, in the 
next steps binding studies of the different ATG5 variants with different ATG16 peptides, all comprising 
the ATG16 AFIM, were performed. In ITC experiments all ATG5 variants bound the ATG16L1(11-43) 
peptide with an affinity of about 1000 nM, the GST-ATG16L1(1-43) fusion protein with an affinity of 
about 300 nM and the GST-ATG16L1(1-30) fusion protein with an affinity of about 20 nM (Figure 105, 
Table 21). 
Table 21: Binding affinities of the different ATG5 variants to the different ATG16L1 variants, used in ITC and BLI 
experiments. BLI experiments were run in triplets, so the indicated KD-value are averages with standard deviations. No 
differences in the binding affinities of ATG16L1 to the different ATG5 variants were detected. 
 
Interestingly the affinity of the GST-ATG16L1(1-30) fusion protein to ATG5 (10 nM magnitude) was 
higher than the affinity of GST-ATG16L1(1-43) fusion protein (100 nM magnitude) and 
ATG16L1(11-43) peptide (1000 nM magnitude). The structure of an N-terminal fragment of ATG16L1 
in complex with ATG5 had previously been published (Figure 128). Most polar interactions were 
present between ATG5 and ATG16L1 residues 10-30. Apart from these, there were only two further 
contacts: ATG16L1 Y39 contacted the backbone oxygen of ATG5 P34 and ATG16L1 N40 contacted 
the side chain of ATG5 Y35. All residues of the ATG16L1 AFIM formed an α-helix, with a visible kink 
approximately at residue 30. The two contacts of the ATG16L1 residues 39 and 40 might have forced 
the helix in such a kinked conformation, thereby applying stress on the N-terminal part of the helix. This 
could have weakened the overall affinity of ATG16L1 to ATG5 and might have explained why the 1-30 
construct had a higher affinity than the 1-43 construct. However, it did not explain the 10x lower affinity 
of ATG16L1(11-43) compared to GST-ATG16L1(1-43). Even though, individual GST did not interact 
with ATG5 in a control experiment, the presence of GST might have had an influence on the interaction 
of the fused ATG16L1 peptide with ATG5, by increasing the solubility of the peptide or by stabilizing 
the conformation of the α-helix. Also ATG16L1 residues 1-10 might have had an influence on the 
interaction with ATG5. 
Discussion 
136 
 
Figure 128: Human ATG5 (green), ATG12 (purple) and ATG16L1 (orange) from PDB-entry 4GDK. ATG5 residues T75 is 
highlighted in red. The inset shows the contacts between ATG5 and ATG16L1 (yellow dotted lines). The ATG16L1 residues, 
implicated in the interaction, are indicated below. 
A part of the results from the ITC experiments were confirmed by BLI experiments, where all ATG5 
variants bound the GST-ATG16L1(1-30) fusion protein with an affinity of about 50 nM (Table 21). This 
was lower than the about 20 nM measured by ITC, but still of the same magnitude. ITC is a method, 
where proteins interact free in solution, while for using BLI one of the binding partners has to be 
immobilized on a surface. Therefore diffusion is limited in BLI experiments and the resulting binding 
affinities can differ from the values obtained by other methods. 
In conclusion all ATG5 variants showed similar binding affinities to the different ATG16L1 variants, 
used in these experiments. Hence the phosphorylation of T75 did not have a direct effect on the binding 
of ATG16L1. As can be seen in Figure 128, T75 and the binding site of ATG16L1 lie on the surface of 
ATG5, separated by an angle of about 90°. A direct influence of the phosphorylation of T75 on the 
binding of ATG16L1 would most probably have had to be transmitted by a conformational change, 
which was not observed in the crystal structures, or by long range charged interactions. With the data 
presented here, a direct influence of the T75 phosphorylation on the ATG16L1 interaction in vitro could 
be excluded. Therefore the phosphorylation of ATG5 T75 must have had a different, less direct effect 
on autophagy, probably by influencing the interaction of ATG5 with one of its many binding partners, 
not covered in this work.  
  Conclusions and Outlook 
  137 
6 Conclusions and Outlook 
The main objective of this work, the characterization of the binding interfaces of VirG/IcsB and 
VirG/ATG5 for the identification of an inhibitor of the Shigella camouflage mechanism, has not been 
accomplished. The main problem was the difficult expression of the VirG protein, but also the late 
identification of the putative VirGE76-IcsB interaction and the missing interaction between VirG and 
ATG5. However, some important steps have been taken on the way to a better understanding of the 
Shigella camouflage mechanism. 
Eight initial VirG-constructs were expressed as Strep- and GST-tagged proteins, but soluble protein 
expression was low. In further experiments these eight constructs were coexpressed with the published 
interaction partners IcsB and ATG5, as well as periplasmically expressed, without an improvement of 
the soluble protein yield. SEC showed that the fraction of solubly expressed protein formed aggregates 
and was therefore not suitable to set up crystallization experiments. For this reason the ESPRIT system 
was deployed to screen for soluble VirG-constructs, resulting in the identification of 18 interesting 
constructs that covered parts of VirG, where no structural information was available before, 13 of which 
covered parts of the IcsB/ATG5 binding domain. One of these constructs, VirGE76, comprising residues 
340-758, was expressed solubly and was used in interaction studies with IcsB and ATG5, as it contained 
the whole IcsB/ATG5 binding domain, except for the first 20 aa. Another ESPRIT-construct, VirGE94, 
comprising residues 419-758, was crystallized and its structure was solved. 
The VirGE94 structure contained the previously published structure of the VirG autochaperone domain, 
a continuation of the β-helix by about four turns and a previously unknown domain, here termed the 
VirG insertion domain (VID), sitting on top of the β-helix. The previously described polar localization 
region has been identified to be part of the β-helical backbone of VirG. It contained a negatively charged 
pocket that might be involved in the interaction with an unknown binding partner that is responsible for 
the unipolar localization of VirG. The VID interacted with the β-helical backbone via a hydrophobic 
interface. The fold of the VID was identified by the DALI server to be similar to the folds of the 
autochaperone domains of different autotransporter proteins. For this reason a potential function as a 
second autochaperone domain, nucleating the fold of a continuation of the β-helix, has been postulated. 
If the location and conformation of the VID in the full length VirG α-domain was similar to its position 
in the VirGE94 crystal structure, it would have introduced a 90° kink in the β-helical backbone. SAXS 
experiments to elucidate the position of the VID in the longer VirGE76 construct were not successful, 
due to aggregation of the protein. However, SAXS data confirmed that VirGE94 formed dimers in 
solution, which were mediated by the interaction of the VIDs. This dimerization of VirGE94 was most 
probably an artifact of this construct that does not have an in vivo function in the previously described 
oligomerization of VirG on the outer bacterial membrane. The reason for this assumption is that in the 
longer VirGE76 construct, dimerization was abolished, which might be explained by an autochaperone 
function of the VID, as the dimerization interface would be blocked by the following turns of the β-
helix. 
The autochaperone domain was identified to be essential for the stability of the VirG α-domain, as no 
soluble expression of constructs, lacking this domain, has been observed. On the other hand, N-terminal 
residues prior to 340 were found to destabilize the VirG α-domain, as the ESPRIT screening didn’t yield 
constructs with N-termini in this region and also other constructs with N-termini in this section did not 
express solubly. Finally 35 new VirG-constructs were designed to elucidate the structure of further N-
terminal parts of the VirG α-domain, but none of them crystallized. 
Initially twelve different constructs of IcsB were expressed and purified, which mostly yielded high 
amounts of pure and soluble protein, but didn’t crystallize. The application of different rescue strategies 
like surface entropy reduction, surface lysine methylation and in situ proteolysis didn’t improve the 
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crystallizability. 19 new constructs were designed, based on experimentally determined boundaries from 
limited proteolysis, but didn’t crystallize either. CD-spectroscopy results showed that IcsB contains a 
major fraction of random coil secondary structure elements, which might have hindered crystallization. 
The IcsB-CBD has been mapped to residues 26-125 in pulldown experiments, which were confirmed 
by a bioinformatics prediction, SAXS experiments and by the protection of the binding site in a limited 
proteolysis experiment. The position of the CBD is in conflict with the previously published binding 
site between residues 171-247. However, due to the multitude of methods used in this work, the N-
terminal position of the CBD is more probable. 
The presence of the CBD destabilized the respective IcsB-constructs, if IpgA was not coexpressed. A 
GST-tagged IcsB-construct, covering the CBD, aggregated, even though the IcsB-construct was small 
compared to the solubility tag GST. On the other hand, IcsB-constructs, lacking the CBD, were 
expressed solubly in the absence of IpgA. These results were confirmed, by the formation of aggregates 
of IcsB, upon removal of IpgA by IEC, and by thermofluor-assays, where the IcsB-IpgA complex had 
an intermediate melting temperature of 50°C, between the melting temperatures of individual IcsB at 
37°C and IpgA at 72°C. As IpgA is stripped off IcsB, upon secretion by the TTSS, the CBD might have 
an important in vivo function, which needs further characterization. 
C-terminally truncated constructs of IcsB could not be expressed solubly, indicating the presence of a 
C-terminal domain, important for the stability of IcsB. The interaction of IcsB with the published 
interaction partners Toca-1 and cholesterol could not be confirmed, which might have been an effect of 
the limitations of the IcsB-constructs used in this work (complex with IpgA). The results of a Phyre2 
prediction of the tertiary structure of IcsB have been used to propose an interaction of IcsB and the N-
WASP-GBD, with an activatory effect on N-WASP. Indications for this interaction have been observed 
in a thermofluor-assay, using N-WASP–IcsB fusion proteins. However, because of the problems in this 
experiment and due to the fact that the results could not be confirmed in pulldown experiments, this 
interaction needs to be validated by an independent method. 
Individual human ATG5 was expressed solubly, purified, crystallized and its structure was solved. It 
showed two ubiquitin-like fold domains and an α-helical bundle region, as observed in the structure of 
ATG5 from the human ATG5-12/16 complex. ATG5 was confirmed to be monomeric in solution by 
SAXS. The molecular basis of the function of T75 phosphorylation was investigated by solving the 
structures of a phosphomimetic mutant T75E as well as a control mutant T75A and comparing them to 
the structure of the wild type protein. Between the ATG5 variants, no differences in their structures, 
their stabilities or their binding to ATG16L1 were observed, indicating a less direct effect of the T75 
phosphorylation on autophagy, e.g. via an unidentified interaction partner. 
Interaction studies were performed to test the interactions between VirG, IcsB and ATG5, which formed 
the basis of the Shigella camouflage mechanism. Between IcsB and VirGE76 and interaction with a KD 
of 600±205 nM has been observed by MST. This interaction could not be confirmed in pulldown studies, 
for this reason it still needs to be verified by an independent method. No interaction was observed 
between IcsB and VirGE94 as well as ATG5 and any VirG-construct. The reason for the missing 
interaction of ATG5 and VirG might have been the missing first 20 aa of the IcsB/ATG5 binding 
domain. It is also possible that other factors are involved in the Shigella camouflage mechanism, e.g. up 
to date unidentified binding partners. 
One possibility might be the involvement of the septin cytoskeleton. In 2010 it was shown that septins 
form rings around the actin tails of Shigella and later also around the bacterial cells themselves, the so 
called septin cages. Those cages consist of alternate rings of actin and septins, with septin caps at the 
bacterial cell poles. In vivo, bacteria are either motile or confined by septin cages, hence these cages 
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might be a way to restrict the ABM and dissemination of Shigella. Enclosed bacteria recruit LC3 and 
p62, indicating that these cells are targeted for autophagic degradation [216]. These results indicate that 
the ABM itself might be a part of the evasion mechanism of Shigella, as it is difficult to enclose a quickly 
moving object in an autophagosome. The human cell first has to stop the bacterium, which is 
accomplished by the septin cages. These results also indicate that the actin tails, produced by 
intracellular Shigella, might represent a PAMP that is recognized by the innate immune response and 
leads to the targeting of Shigella cells to autophagic degradation. The interplay between the components 
of the septin cytoskeleton, the actin cytoskeleton, the ABPs and Shigella promise to be an interesting 
field of research in the future. 
Also the regulation of actin polymerization by the Arp2/3 complex and by formins in ABM, the interplay 
between the two systems and the role of VirG and IcsB in these processes might be an interesting 
research target. Formins have been shown to have a function in the formation of protrusions. IpgB2 has 
been shown to activate the formin Dia1, but is not essential for the formation of protrusions. The human 
protein Toca-1, a known regulator of both the Arp2/3 complex and formins, is recruited to the surface 
of Shigella by IcsB, indicating that IcsB might be involved in the regulation of actin polymerization by 
formins. The putative activating effect of IcsB on N-WASP, which is the activator of the Arp2/3 
complex, indicates that IcsB might have a role in the regulation of ABM by both the Arp2/3 and the 
formin system. 
In the future, the VirG-constructs, generated in this work, espacially VirGE76, might be used for 
interaction studies, using soluble, purified proteins, to identify VirG interaction partners and regions. 
Should the interaction between VirGE76 and IcsB be verified, coexpression and cocrystallization 
experiments, using these two proteins could be performed. The soluble VirG constructs might also be 
cocrystallized with DOC, to identify the binding site and characterize possible conformational changes. 
Also crystallization of VirGK40 might be tested, which was not possible anymore in the time frame of 
this work. For the further characterization of VirG, the SAXS experiments using VirGE76, which failed 
due to aggregation of the protein, could be repeated, to determine the location of the VID and the 
conformation of the β-helical backbone. Also a new screening for soluble constructs, using the C-
terminus of the VID as the C-terminal boundary, by the ESPRIT system or a similar method, might be 
performed. Soluble VirG-constructs are perfect targets for the development of vaccines [217], which is 
being tested at the moment in collaboration with Prof. Dr. Carlos Guzmán from the HZI in 
Braunschweig. For IcsB the putative interaction with the N-WASP-GBD needs to be verified by an 
independent interaction method. 
Finally the results from this work will hopefully help to shed light on the molecular basis of the Shigella 
camouflage mechanism in the future. 
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Appendix 
A1. Oligonucleotides 
 
Table 22: Sequencing primers used in this work. 
Description Identifier Sequence 
T7 forward SA016 taatacgactcactataggg 
T7 reverse SA017 gctagttattgctcagcgg 
Duet mcs1 forward PV001 ggatctcgacgctctccct 
Duet mcs1 reverse PV002 gattatgcggccgtgtacaa 
Duet mcs2 forward PV003 ttgtacacggccgcataatc 
ESPRIT reverse PV023 cctcaagacccgtttagaggcc 
pGEX forward MOSB23 atagcatggcctttgcagg 
pGEX reverse MOSB24 gagctgcatgtgtcagagg 
VirG G159 forward LS001 gtgctgaccataacggtgatgg 
LS047 pESPRIT_seq_for ggaaaaacgccagcaacgcg 
LS048 pESPRIT_seq_rev gccatcctatggaactgcctcgg 
 
Table 23: VirG cloning primers used in this work. 
Description Identifier Sequence 
VirG M1 forward SA009 AAGAATGCGGCCGCatgaatcaaattcacaaatttttttg 
VirG M1 forward LS038 ATGCATGCGGCGCGCCgtatgaatcaaattcacaaatttttttg 
VirG T53 forward SA010 AAGAATGCGGCCGCactcctctttcgggtactcaag 
VirG G77 forward LS092 AAGAATGCGGCCGCggactttctcccttgggagctg 
VirG G117 forward LS133 AAGAATGCGGCCGCggtcatggtggtgctggtg 
VirG G131 forward LS134 AAGAATGCGGCCGCggcggtaatggtggtgactc 
VirG N281 forward LS135 AAGAATGCGGCCGCaacaatggagctattttaggcgg 
VirG Q320 forward SA011 AAGAATGCGGCCGCcaaaatgtagcaggtaatgctatcc 
VirG T303 forward LS094 AAGAATGCGGCCGCaccattgctaatagcggatatataatttc 
VirG E340 forward LS093 AAGAATGCGGCCGCgaaggttctgtcattactggtgatg 
VirG G341 forward LS083 AAGAATGCGGCCGCggttctgtcattactggtgatgtac 
VirG Q349 forward LS150 AAGAATGCGGCCGCcaggttaacaattcatccattctg 
VirG V350 forward LS082 AAGAATGCGGCCGCgttaacaattcatccattctgaaaattatc 
VirG S353 forward LS089 AAGAATGCGGCCGCtcatccattctgaaaattatcaacaatg 
VirG S353 forward LS152 AAGAATGCGGCCGCtcatccattctgaaaattatcaacaatg 
VirG N361 forward LS085 AAGAATGCGGCCGCaatgattacactgggaccacacc 
VirG Y363 forward LS084 AAGAATGCGGCCGCtacactgggaccacaccaactattg 
VirG T364 forward LS087 AAGAATGCGGCCGCactgggaccacaccaactattg 
VirG G377 forward LS080 AAGAATGCGGCCGCggtgattgtacaactgtttcactatc 
VirG G377 forward LS153 AAGAATGCGGCCGCggtgattgtacaactgtttcactatc 
VirG S383 forward LS151 AAGAATGCGGCCGCtcactatcaggtaacaaattcactg 
VirG G398 forward LS154 AAGAATGCGGCCGCggtgagaacagttctttaaatttag 
VirG S409 forward LS086 AAGAATGCGGCCGCagtagtctggaagcttctggaaatatg 
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VirG F419 forward LS096 AAGAATGCGGCCGCtttggcaacaatgtaaaagtggag 
VirG V425 forward LS081 AAGAATGCGGCCGCgtggaggctattataaataactgg 
VirG N430 forward LS088 AAGAATGCGGCCGCaataactgggcgcagaaggac 
VirG A433 forward LS079 AAGAATGCGGCCGCgcgcagaaggactataaactgc 
VirG T469 forward LS090 AAGAATGCGGCCGCacaaaaagctatatcagtgaccag 
VirG S526 forward LS095 AAGAATGCGGCCGCtccctaacaaaatcaggggagg 
VirG N577 forward LS091 AAGAATGCGGCCGCaatttttcaggcatgaaccaaactg 
VirG G420 reverse LS136 GGGGTACCttagccaaatgacatatttccagaagc 
VirG A433 reverse SA013 GGGGTACCtcacgcccagttatttataatagcctc  
VirG S484 reverse LS137 GGGGTACCttagctcaaaccgtagatcaatttattc 
VirG G592 reverse SA048 GGGGTACCttacccactatttaataaagtgttaacag 
VirG G592 reverse LS040 ATGCATGCATGCATtcccactatttaataaagtgttaacag 
VirG D740 reverse LS164 GGGGTACCttaatccatctgactagttagataccac 
VirG R758 reverse SA014 GGGGTACCtcagcgactactcatttgagtagactc 
VirG R758 reverse LS039 ATGCATGCATGCATtgcgactactcatttgagtagactc 
VirG R758 reverse LS097 GGGGTACCttagcgactactcatttgagtagactc 
VirG R779 reverse SA015 GGGGTACCtcagcgccatgtgtgaatactacc  
VirG F1102 reverse SA012 GGGGTACCtcagaaggtatatttcacaccc 
 
Table 24: IcsB and IpgA cloning primers used in this work. 
Description Identifier Sequence 
IcsB M1 forward SA001 AAGAATGCGGCCGCatgatcctcaaaattagcaatttcattg 
IcsB M1 forward LS041 ATGCATGCGGATCCatgatcctcaaaattagcaatttcattg 
IcsB S6 forward LS049 AAGAATGCGGCCGCagcaatttcattgacgcaagcaatac 
IcsB F8 forward LS050 AAGAATGCGGCCGCttcattgacgcaagcaatacaaaag 
IcsB G16 forward LS002 AAGAATGCGGCCGCgggcctatacgcgttgaagatac 
IcsB G26 forward LS003 AAGAATGCGGCCGCggacctatattgatagcacagaaattc 
IcsB G121 forward LS163 AAGAATGCGGCCGCggtacagccaaaaatcttgaaagac 
IcsB G169 forward LS004 AAGAATGCGGCCGCgggaatgttacaaaagatacag 
IcsB I177 forward LS051 AAGAATGCGGCCGCataaactacctttttgaaaaacgctc 
IcsB S185 forward LS005 AAGAATGCGGCCGCtcaggttacagtgtcgatacc 
IcsB S188 forward LS052 AAGAATGCGGCCGCagtgtcgatacctataagcaagac 
IcsB V214 forward LS053 AAGAATGCGGCCGCgttagaaacttattaaattcaaaacaag 
IcsB P233 forward LS054 AAGAATGCGGCCGCcccagagctaatcaaaaaaaagac 
IcsB G265 forward LS006 AAGAATGCGGCCGCggtaaaatcagccataacctttttgg 
IcsB N125 reverse LS012 GGGGTACCttaatttttggctgtaccgatgccatg 
IcsB L130 reverse LS103 GGGGTACCttataaatgtctttcaagatttttggctg 
IcsB G136 reverse LS105 GGGGTACCttatccccagcaacgaaaaactaaatg 
IcsB P167 reverse LS055 GGGGTACCttagggataccagctgagataggtatg 
IcsB E176 reverse LS056 GGGGTACCttattctgtatcttttgtaacattcccg 
IcsB K183 reverse LS057 GGGGTACCttatttttcaaaaaggtagtttatttctgtatc 
IcsB K229 reverse LS013 GGGGTACCttattttttgttgttattttgatcttgttttg 
IcsB P391 reverse LS058 GGGGTACCttatggtgtgtggataaggttaattttattg 
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IcsB S428 reverse LS059 GGGGTACCttatgattttactaagtatgagtggcaag 
IcsB N438 reverse LS060 GGGGTACCttagtttaatacacgagtcatattgctg 
IcsB S464 reverse LS061 GGGGTACCttaagaattgtaataatcaataatttttattg 
IcsB N493 reverse LS062 GGGGTACCttaattagaatgagagttattcaataaaag 
IcsB I494 reverse LS007 GGGGTACCttatatattagaatgagagttattcaataaaag 
IcsB I494 reverse SA003 GGGGTACCctatatattagaatgagagttattcaataaaag 
IcsB I494 reverse LS042 ATGCATGCGCGGCCGCttatatattagaatgagagttattcaataaaag 
IpgA M1 forward SA007 AAGAATGCGGCCGCatgtgtcgcaaactatatgataaac 
IpgA M1 forward LS022 GGGGTTTCATatgtgtcgcaaactatatgataaac 
IpgA N129 reverse SA008 GGGGTACCttagttcacttctgaagtgatgtttg 
IpgA N129 reverse LS023 GGAATTCttagttcacttctgaagtgatgtttg 
 
Table 25: ATG5 cloning primers used in this work. 
Description Identifier Sequence 
ATG5 M1 forward SA033 AAGAATGCGGCCGCatgacagatgacaaagatgtgcttc 
ATG5 D275 reverse SA034 GGGGTACCtcaatctgttggctgtgggatg 
 
Table 26: Other cloning primers used in this work. 
Description Identifier Sequence 
ATG16L1 M1 forward SA018 AAGAATGCGGCCGCatgtcgtcgggcctccgcgc 
ATG16L1 L43 C reverse LS045 GGGGTACCttagcacagcaatttgttatactgcaggatg 
ATG16L1 L43 reverse LS046 GGGGTACCttacagcaatttgttatactgcaggatg 
WASP S242 forward LS071 AAGAATGCGGCCGCagtggattcaagcatgtcagcc 
WASP Q461 forward LS073 AAGAATGCGGCCGCcagagctcagagggactggtg 
WASP Q310 reverse LS072 GGGGTACCttactggcgcctcatctcctgcc 
WASP G492 reverse LS074 GGGGTACCttagccagcctggtcctccccttc 
N-WASP S207 forward LS075 AAGAATGCGGCCGCagcaatttccagcacattggacatg 
N-WASP V399 forward LS106 AAGAATGCGGCCGCgttccaactactgcaggaaac 
N-WASP A462 forward LS077 AAGAATGCGGCCGCgcacccacttcaggaattgtgg 
N-WASP Q275 reverse LS076 GGGGTACCttattgcctccgcagttcatttttaac 
N-WASP T460 reverse LS108 GGGGTACCttatgttggtggtgtagactcttgg 
N-WASP D493 reverse LS078 GGGGTACCttaatcatcttcatcttcatcttcatctg 
N-WASP D505 reverse LS107 GGGGTACCttagtcttcccactcatcatcatcc 
Toca-1 M1 forward LS143 AAGAATGCGGCCGCatgagttggggcacggaactg 
Toca-1 S245 forward LS144 AAGAATGCGGCCGCtcgaagtgtctggagggtatg 
Toca-1 G383 forward LS110 AAGAATGCGGCCGCggtgtctctctgattatgggcc 
Toca-1 G389 forward LS109 AAGAATGCGGCCGCggccctgcgctggaagatttc 
Toca-1 T293 reverse LS145 GGGGTACCttaggtgcggtagatatgctggctg 
Toca-1 M431 reverse LS146 GGGGTACCttacattttgttaagagcatctttctgg 
Toca-1 G480 reverse LS111 GGGGTACCttaacccgttttgccttccacttc 
Toca-1 S488 reverse LS112 GGGGTACCttaggaatgacgccgatctccgcg 
Toca-1 D535 reverse LS147 GGGGTACCttagtcatcgtcctcaaactcatcatc 
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Cip4 S392 forward LS113 AAGAATGCGGCCGCagccacttgcccccagagc 
Cip4 G480 reverse LS114 GGGGTACCttatccccggttgctaaggactcg 
Cdc42 M1 forward LS115 AAGAATGCGGCCGCatgcagacaattaagtgtgttgttg 
Cdc42 E178 reverse LS142 GGGGTACCttactccagggcagccaatattgc 
Diaph1 D78 forward LS117 AAGAATGCGGCCGCgatcccacagcacagtcattgc 
Diaph1 E460 reverse LS118 GGGGTACCttactcaatctggaggtgccggc 
Diaph2 P88 forward LS119 AAGAATGCGGCCGCcctgcagctcagccattatatg 
Diaph2 D476 reverse LS120 GGGGTACCttaatcgatgtctaatctttgcctg 
Diaph3 M264 forward LS121 AAGAATGCGGCCGCatgagtgaggagaggagcctttc 
Diaph3 D488 reverse LS122 GGGGTACCttaatctaaatctagtctttttcgatatg 
Daam2 S39 forward LS123 AAGAATGCGGCCGCtccagccccatcccgaacgc 
Daam2 N427 reverse LS124 GGGGTACCttaattgaagttctccaagggagcc 
Fhod1 S44 forward LS125 AAGAATGCGGCCGCagcctggacggggcgctgc 
Fhod1 G468 reverse LS126 GGGGTACCttacccggcaagtgtctctgccc 
Fmnl1 A23 forward LS127 AAGAATGCGGCCGCgcgcctcccaagcagccg 
Fmnl1 A468 reverse LS128 GGGGTACCttaagcgggaggcgctttctcag 
Fmnl2 A16 forward LS129 AAGAATGCGGCCGCgcgcacaacgtgcctttgaag 
Fmnl2 G487 reverse LS130 GGGGTACCttaccctttcttctgaattttaatggtc 
Fmnl3 S16 forward LS131 AAGAATGCGGCCGCtctgtcccgttgttgctgccg 
Fmnl3 G477 reverse LS132 GGGGTACCttagccccggacatttggctcc 
 
Table 27: Mutagenesis primers used in this work. 
Description Identifier Sequence 
VirG NsiI out forward LS043 tctcatgcgtctagaactaagctacggattaac 
VirG NsiI out reverse LS044 tctagacgcatgagaggggttggaagaag 
VirG del forward LS155 gtcagatacagatggcgacagtcatg 
VirG del GGS forward LS157 tcaggtggcagcgatacagatggcgacagtcatg 
VirG del 2GGS forward LS159 gtggcagcggtggcagcgatacagatggcgacagtcatg 
VirG del 4GGS forward 
LS161 
ggtggcagcggtggcagcggtggcagcggtggcagcgatacagatgg 
cgacagtcatg 
VirG del reverse LS156 ccatctgtatctgacatatttccagaagcttccag 
VirG del GGS reverse LS158 atcgctgccacctgacatatttccagaagcttccag 
VirG del 2GGS reverse LS160 ctgccaccgctgccacctgacatatttccagaagcttccag 
VirG del 4GGS reverse 
LS162 
gctgccaccgctgccaccgctgccaccgctgccacctgacatatttccag 
aagcttccag 
IcsB TAA forward LS010 cattctaatatataaaaggccatagaaatg 
IcsB TAA reverse LS011 catttctatggccttttatatattagaatg 
IcsB SER1 forward LS024 aatgcggcagccgacccctatggttattgggggg 
IcsB SER1 reverse LS025 gtcggctgccgcattagctctgggaaaaaatatttttttg 
IcsB SER2 forward LS026 gatgcggcagccgaaatcatcgaaaaatcaataaaaattattg 
IcsB SER2 reverse LS027 ttcggctgccgcatctgttgcttcggtttttaattcg 
IcsB SER3 forward LS028 tgcgcggcagccgcagatgctttcagacaattggc 
IcsB SER3 reverse LS029 tgcggctgccgcgcatataaattttgacatgtttgtttc 
IcsB SER4 forward LS030 gcggcatctgcagccagtgcgtttgccgcctatgaag 
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IcsB SER4 reverse LS031 ggctgcagatgccgcgctagctaatgtattgaggaaaagc 
IcsB SER5 forward LS032 tttgcggcacgctcaggttacagtgtcgatac 
IcsB SER5 reverse LS033 tgagcgtgccgcaaaaaggtagtttatttctgtatcttttg 
IcsB SER6 forward LS034 aacaacgcggcaatattttttcccagagctaatcaaaaaa 
IcsB SER6 reverse LS035 tattgccgcgttgttattttgatcttgttttgaattta 
IcsB GGS Q99 forward LS104 gtggcagcggtggcagccaacactctttcacaggtagagac 
IcsB GGS G104 forward LS102 gtggcagcggtggcagcggtagagacatcaaattaatgttg 
ATG5 T75E forward LS036 gaaggcgaaccactgaaatggcattatccaattg 
ATG5 T75E reverse LS037 cagtggttcgccttcatattcaaaccatatctc 
N-WASP Q275 GGS reverse LS100 ctgccaccgctgccaccttgcctccgcagttcatttttaac 
N-WASP GGS A462 forward LS101 gtggcagcggtggcagcgcacccacttcaggaattgtgg 
Toca-1 del forward LS148 gaaaccgaaaggccctgcgctggaagatttc 
Toca-1 del reverse LS149 gggcctttcggtttcttcccgaaaagcc 
Daam2 KpnI out forward LS138 ctgggccgttaccgggatgaagtgaatctgaaaacagcc 
Daam2 KpnI out reverse LS139 tcccggtaacggcccagacttcggtctagctcgttc 
Daam2 W414R forward LS140 gatgagcgtggtgtggaccctgacctggctccc 
Daam2 W414R reverse LS141 cacaccacgctcatcctggaggacaatctgctggag 
 
Table 28: Primers used in this work for annealing of oligonucleotides. 
Description Identifier Sequence 
IcsB Q99 forward 
LS067 
ggccgccaacactctttcacaggtagagacatcaaattaatgttgaataccgcagagcgttttc 
atgg 
IcsB G136 forward LS068 catcggtacagccaaaaatcttgaaagacatttagtttttcgttgctggggataaggtac 
IcsB Q99 reverse LS070 cggtattcaacattaatttgatgtctctacctgtgaaagagtgttggc 
IcsB G136 reverse 
LS069 
cttatccccagcaacgaaaaactaaatgtctttcaagatttttggctgtaccgatgccatgaaaa 
cgctctg 
IcsB G104 forward LS063 ggccgcggtagagacatcaaattaatgttgaataccgcagagcgttttcatgg 
IcsB L130 forward LS064 catcggtacagccaaaaatcttgaaagacatttataaggtac 
IcsB G104 reverse LS066 cggtattcaacattaatttgatgtctctaccgc 
IcsB L130 reverse LS065 cttataaatgtctttcaagatttttggctgtaccgatgccatgaaaacgctctg 
OmpA 1 forward LS014 catgaaaaagacagctatcgcgatt 
OmpA 2 forward LS015 gcagtggcactggctggtttcgctaccgtagcgcaggc 
OmpA 3 reverse LS016 catggcctgcgctacggtagcgaaac 
OmpA 4 reverse LS017 cagccagtgccactgcaatcgcgatagctgtcttttt 
PelB 1 forward LS018 catgaaatacctgctgccgaccgctgct 
PelB 2 forward LS019 gctggtctgctgctcctcgctgcccagccggcgatggc 
PelB 3 reverse LS020 catggccatcgccggctgggcagcgag 
PelB 4 reverse LS021 gagcagcagaccagcagcagcggtcggcagcaggtattt 
mcs2 forward LS098 tatggaattcg 
mcs2 reverse LS099 gatccgaattcca 
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A2. Protein constructs 
 
Table 29: VirG protein constructs generated in this work. 
Description Identifier Construct Mutations 
VirGK1 pLS004 Strep-TEV-VirG(53-433)  
VirGK1 pLS022 GST-Thr-TEV-VirG(53-433)  
VirGK1 pLS045 OmpA-Strep-TEV-VirG(53-433)  
VirGK2 pLS005 Strep-TEV-VirG(53-592)  
VirGK2 pLS023 GST-Thr-TEV-VirG(53-592)  
VirGK2 pLS046 OmpA-Strep-TEV-VirG(53-592)  
VirGK3 pLS006 Strep-TEV-VirG(53-758)  
VirGK3 pLS024 GST-Thr-TEV-VirG(53-758)  
VirGK3 pLS047 OmpA-Strep-TEV-VirG(53-758)  
VirGK4 pLS002 His-TEV-VirG(53-779)  
VirGK4 pLS007 Strep-TEV-VirG(53-779)  
VirGK4 pLS025 GST-Thr-TEV-VirG(53-779)  
VirGK4 pLS048 OmpA-Strep-TEV-VirG(53-779)  
VirGK5 pLS008 Strep-TEV-VirG(320-433)  
VirGK5 pLS026 GST-Thr-TEV-VirG(320-433)  
VirGK6 pLS009 Strep-TEV-VirG(320-592)  
VirGK6 pLS027 GST-Thr-TEV-VirG(320-592)  
VirGK7 pLS010 Strep-TEV-VirG(320-758)  
VirGK7 pLS028 GST-Thr-TEV-VirG(320-758)  
VirGK8 pLS011 Strep-TEV-VirG(320-779)  
VirGK8 pLS029 GST-Thr-TEV-VirG(320-779)  
VirGK9 pLS165 His-TEV-VirG(53-420)  
VirGK10 pLS166 His-TEV-VirG(77-420)  
VirGK11 pLS167 His-TEV-VirG(117-420)  
VirGK12 pLS168 His-TEV-VirG(131-420)  
VirGK13 pLS169 His-TEV-VirG(281-420)  
VirGK14 pLS170 His-TEV-VirG(53-484)  
VirGK15 pLS171 His-TEV-VirG(77-484)  
VirGK16 pLS172 His-TEV-VirG(117-484)  
VirGK17 pLS173 His-TEV-VirG(131-484)  
VirGK18 pLS174 His-TEV-VirG(281-484)  
VirGK19 pLS175 His-TEV-VirG(53-758)  
VirGK20 pLS176 His-TEV-VirG(77-758)  
VirGK21 pLS177 His-TEV-VirG(117-758)  
VirGK22 pLS178 His-TEV-VirG(131-758)  
VirGK23 pLS179 His-TEV-VirG(281-758)  
VirGK24 pLS184 His-TEV-VirG(340-758) Δ419-486 
VirGK25 pLS185 His-TEV-VirG(340-758) Δ419-486 GGS 
VirGK26 pLS186 His-TEV-VirG(340-758) Δ419-486 2xGGS 
VirGK27 pLS187 His-TEV-VirG(340-758) Δ419-486 4xGGS 
VirGK28 pLS188 His-TEV-VirG(349-758)  
VirGK29 pLS189 His-TEV-VirG(383-758)  
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VirGK30 pLS190 His-TEV-VirG(353-758)  
VirGK31 pLS191 His-TEV-VirG(377-758)  
VirGK32 pLS192 His-TEV-VirG(398-758)  
VirGK33 pLS193 His-TEV-VirG(349-758) Δ419-486 2xGGS 
VirGK34 pLS194 His-TEV-VirG(383-758) Δ419-486 2xGGS 
VirGK35 pLS195 His-TEV-VirG(353-758) Δ419-486 2xGGS 
VirGK36 pLS196 His-TEV-VirG(377-758) Δ419-486 2xGGS 
VirGK37 pLS197 His-TEV-VirG(398-758) Δ419-486 2xGGS 
VirGK38 pLS198 His-TEV-VirG(340-740) Δ419-486 2xGGS 
VirGK39 pLS199 His-TEV-VirG(349-740) Δ419-486 2xGGS 
VirGK40 pLS200 His-TEV-VirG(383-740) Δ419-486 2xGGS 
VirGK41 pLS201 His-TEV-VirG(340-740)  
VirGK42 pLS202 His-TEV-VirG(349-740)  
VirGK43 pLS203 His-TEV-VirG(383-740)  
VirGK1/ 
ATG5 
coexpression 
pLS004/ 
pLS001 
 
Strep-TEV-VirG(53-433)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK1/ 
IcsB 
coexpression 
pLS004/ 
pLS012 
 
Strep-TEV-VirG(53-433)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK1/ 
ATG5 
coexpression 
pLS022/ 
pLS003 
 
GST-Thr-TEV-VirG(53-433)/ 
Strep-TEV-ATG5(1-275) 
 
 
VirGK1/ 
IcsB 
coexpression 
pLS022/ 
pLS013 
 
GST-Thr-TEV-VirG(53-433)/ 
Strep-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK2/ 
ATG5 
coexpression 
pLS005/ 
pLS001 
 
Strep-TEV-VirG(53-592)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK2/ 
IcsB 
coexpression 
pLS005/ 
pLS012 
 
Strep-TEV-VirG(53-592)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK2/ 
IcsB 
coexpression 
pLS023/ 
pLS013 
 
GST-Thr-TEV-VirG(53-592)/ 
Strep-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK3/ 
ATG5 
coexpression 
pLS006/ 
pLS001 
 
Strep-TEV-VirG(53-758)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK3/ 
IcsB 
coexpression 
pLS006/ 
pLS012 
 
Strep-TEV-VirG(53-758)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK3/ 
ATG5 
coexpression 
pLS024/ 
pLS003 
 
GST-Thr-TEV-VirG(53-758)/ 
Strep-TEV-ATG5(1-275) 
 
 
VirGK3/ 
IcsB 
coexpression 
pLS024/ 
pLS013 
 
GST-Thr-TEV-VirG(53-758)/ 
Strep-TEV-IcsB(1-494) IpgA(1-129) 
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VirGK4/ 
ATG5 
coexpression 
pLS007/ 
pLS001 
 
Strep-TEV-VirG(53-779)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK4/ 
IcsB 
coexpression 
pLS007/ 
pLS012 
 
Strep-TEV-VirG(53-779)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK4/ 
ATG5 
coexpression 
pLS025/ 
pLS003 
 
GST-Thr-TEV-VirG(53-779)/ 
Strep-TEV-ATG5(1-275) 
 
 
VirGK4/ 
IcsB 
coexpression 
pLS025/ 
pLS013 
 
GST-Thr-TEV-VirG(53-779)/ 
Strep-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK5/ 
ATG5 
coexpression 
pLS008/ 
pLS001 
 
Strep-TEV-VirG(320-433)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK5/ 
IcsB 
coexpression 
pLS008/ 
pLS012 
 
Strep-TEV-VirG(320-433)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK5/ 
ATG5 
coexpression 
pLS026/ 
pLS003 
 
GST-Thr-TEV-VirG(320-433)/ 
Strep-TEV-ATG5(1-275) 
 
 
VirGK6/ 
ATG5 
coexpression 
pLS009/ 
pLS001 
 
Strep-TEV-VirG(320-592)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK6/ 
IcsB 
coexpression 
pLS009/ 
pLS012 
 
Strep-TEV-VirG(320-592)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK6/ 
IcsB 
coexpression 
pLS027/ 
pLS013 
 
GST-Thr-TEV-VirG(320-592)/ 
Strep-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK7/ 
ATG5 
coexpression 
pLS010/ 
pLS001 
 
Strep-TEV-VirG(320-758)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK7/ 
IcsB 
coexpression 
pLS010/ 
pLS012 
 
Strep-TEV-VirG(320-758)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK8/ 
ATG5 
coexpression 
pLS011/ 
pLS001 
 
Strep-TEV-VirG(320-779)/ 
His-TEV-ATG5(1-275) 
 
 
VirGK8/ 
IcsB 
coexpression 
pLS011/ 
pLS012 
 
Strep-TEV-VirG(320-779)/ 
His-TEV-IcsB(1-494) IpgA(1-129) 
 
 
VirGK8/ 
ATG5 
coexpression 
pLS029/ 
pLS003 
 
GST-Thr-TEV-VirG(320-779)/ 
Strep-TEV-ATG5(1-275) 
 
 
ESPRIT pLS065 His-TEV-VirG(1-758)-BAP NsiI out 
ESPRIT pLS066 His-TEV-VirG(1-592)-BAP NsiI out 
VirGE4 VirGE4 His-TEV-VirG(433-592)-BAP  
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VirGE5 VirGE5 His-TEV-VirG(377-592)-BAP  
VirGE8 VirGE8 His-TEV-VirG(425-592)-BAP  
VirGE14 VirGE14 His-TEV-VirG(350-592)-BAP  
VirGE14 pLS099 His-TEV-VirG(350-592)  
VirGE15 VirGE15 His-TEV-VirG(341-592)-BAP  
VirGE16 VirGE16 His-TEV-VirG(363-592)-BAP  
VirGE19 VirGE19 His-TEV-VirG(361-592)-BAP  
VirGE19 pLS100 His-TEV-VirG(361-592)  
VirGE20 VirGE20 His-TEV-VirG(409-592)-BAP  
VirGE21 VirGE21 His-TEV-VirG(364-592)-BAP  
VirGE21 pLS101 His-TEV-VirG(364-592)  
VirGE24 VirGE24 His-TEV-VirG(430-592)-BAP  
VirGE33 VirGE33 His-TEV-VirG(353-592)-BAP  
VirGE57 VirGE57 His-TEV-VirG(469-758)-BAP  
VirGE57 pLS102 His-TEV-VirG(469-758)  
VirGE71 VirGE71 His-TEV-VirG(577-758)-BAP  
VirGE73 VirGE73 His-TEV-VirG(77-758)/VirG(638-758)-BAP  
VirGE76 VirGE76 His-TEV-VirG(340-758)-BAP  
VirGE76 pLS123 His-TEV-VirG(340-758)  
VirGE81 VirGE81 His-TEV-VirG(303-758)-BAP  
VirGE82 VirGE82 His-TEV-VirG(526-758)-BAP  
VirGE82 pLS103 His-TEV-VirG(526-758)  
VirGE94 VirGE94 His-TEV-VirG(419-758)-BAP  
VirGE94 pLS104 His-TEV-VirG(419-758)  
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Figure 129: VirG protein constructs generated in this work. 
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Figure 130: VirG protein constructs generated in this work, using the ESPRIT system. 
 
Table 30: IcsB protein constructs generated in this work. 
Description Identifier Construct Mutations 
IcsB pLS012/030/031 His-TEV-IcsB(1-494) IpgA(1-129)  
IcsB pLS013 Strep-TEV-IcsB(1-494) IpgA(1-129)  
IcsB pLS105 His-TEV-IcsB(1-494)  
IcsB pLS106 Flag-TEV-IcsB(1-494)  
IcsB pLS107 Flag-TEV-IcsB(1-494) IpgA(1-129)  
IcsBK1 pLS032 His-TEV-IcsB(1-125) IpgA(1-129)  
IcsBK2 pLS033 His-TEV-IcsB(16-125) IpgA(1-129)  
IcsBK3 pLS034 His-TEV-IcsB(26-125) IpgA(1-129)  
IcsBK3 pLS209 GST-Thr-TEV-IcsB(26-125)  
IcsBK4 pLS035 His-TEV-IcsB(1-229) IpgA(1-129)  
IcsBK5 pLS036 His-TEV-IcsB(16-229) IpgA(1-129)  
IcsBK6 pLS037 His-TEV-IcsB(26-229) IpgA(1-129)  
IcsBK7 pLS038 His-TEV-IcsB(16-494) IpgA(1-129)  
IcsBK8 pLS039 His-TEV-IcsB(26-494) IpgA(1-129)  
IcsBK9 pLS040 His-TEV-IcsB(169-494) IpgA(1-129)  
IcsBK10 pLS041 His-TEV-IcsB(185-494) IpgA(1-129)  
IcsBK11 pLS042 His-TEV-IcsB(265-494) IpgA(1-129)  
IcsBK12 pLS076 His-TEV-IcsB(8-438) IpgA(1-129)  
IcsBK13 pLS077 His-TEV-IcsB(6-391) IpgA(1-129)  
IcsBK14 pLS078 His-TEV-IcsB(6-428) IpgA(1-129)  
IcsBK15 pLS079 His-TEV-IcsB(6-464) IpgA(1-129)  
IcsBK16 pLS080 His-TEV-IcsB(6-493) IpgA(1-129)  
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IcsBK17 pLS081 His-TEV-IcsB(188-391) IpgA(1-129)  
IcsBK18 pLS082 His-TEV-IcsB(188-428) IpgA(1-129)  
IcsBK19 pLS083 His-TEV-IcsB(188-464) IpgA(1-129)  
IcsBK20 pLS084 His-TEV-IcsB(188-493) IpgA(1-129)  
IcsBK21 pLS085 His-TEV-IcsB(233-391) IpgA(1-129)  
IcsBK22 pLS086 His-TEV-IcsB(233-428) IpgA(1-129)  
IcsBK23 pLS087 His-TEV-IcsB(233-464) IpgA(1-129)  
IcsBK24 pLS088 His-TEV-IcsB(233-493) IpgA(1-129)  
IcsBK25 pLS089 His-TEV-IcsB(6-167) IpgA(1-129)  
IcsBK25 pLS096 Strep-TEV-IcsB(6-167)  
IcsBK26 pLS090 His-TEV-IcsB(6-176) IpgA(1-129)  
IcsBK26 pLS097 Strep-TEV-IcsB(6-176)  
IcsBK27 pLS091 His-TEV-IcsB(6-183) IpgA(1-129)  
IcsBK27 pLS098 Strep-TEV-IcsB(6-183)  
IcsBK28 pLS092 His-TEV-IcsB(177-493) IpgA(1-129)  
IcsBK29 pLS093 His-TEV-IcsB(214-493) IpgA(1-129)  
IcsBK30 pLS116 GST-Thr-TEV-IcsB(104-130)  
IcsBK30 pLS117 ZZ-His-TEV-IcsB(104-130)  
IcsBK31 pLS118 GST-Thr-TEV-IcsB(99-136)  
IcsBK31 pLS119 ZZ-His-TEV-IcsB(99-136)  
IcsBK32 pLS208 His-TEV-IcsB(121-494)  
IcsBSER1 pLS053 His-TEV-IcsB(1-494) IpgA(1-129) Q237A, K238A, K239A 
IcsBSER2 pLS054 His-TEV-IcsB(1-494) IpgA(1-129) K447A, K448A, E449A 
IcsBSER3 pLS055 His-TEV-IcsB(1-494) IpgA(1-129) K285A, K286A, K287A 
IcsBSER4 pLS056 His-TEV-IcsB(1-494) IpgA(1-129) E81A, K82A, E85A 
IcsBSER5 pLS057 His-TEV-IcsB(1-494) IpgA(1-129) E182A, K183A 
IcsBSER6 pLS058 His-TEV-IcsB(1-494) IpgA(1-129) K228A, K229A 
ESPRIT pLS067 Flag-TEV-IcsB(1-494)  
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Figure 131: IcsB protein constructs generated in this work. 
 
Table 31: ATG5 protein constructs generated in this work. 
Description Identifier Construct Mutations 
ATG5 pLS001 His-TEV-ATG5(1-275)  
ATG5 pLS003 Strep-TEV-ATG5(1-275)  
ATG5 T75E pLS059 His-TEV-ATG5(1-275) T75E 
ATG5 T75A pLS060 His-TEV-ATG5(1-275) T75A, T101T (silent) 
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Figure 132: ATG5 protein constructs generated in this work. 
 
Table 32: Other protein constructs generated in this work. 
Description Identifier Construct Mutations 
ATG16L1 pLS070 His-MBP-TEV-Atg16L1(1-43)  
ATG16L1 pLS072 His-TEV-Atg16L1(1-43)  
ATG16L1 pLS074 GST-Thr-TEV-Atg16L1(1-43)  
ATG16L1 pLS069 His-MBP-TEV-Atg16L1(1-43) 44C 
ATG16L1 pLS071 His-TEV-Atg16L1(1-43) 44C 
ATG16L1 pLS073 GST-Thr-TEV-Atg16L1(1-43) 44C 
WASP-GBD pLS110 His-TEV-WASP(242-310)  
WASP-GBD pLS111 GST-Thr-TEV-WASP(242-310)  
WASP-C pLS114 GST-Thr-TEV-WASP(461-492)  
WASP-C pLS115 ZZ-His-TEV-WASP(461-492)  
N-WASP-GBD pLS108 His-TEV-N-WASP(207-275)  
N-WASP-GBD pLS109 GST-Thr-TEV-N-WASP(207-275)  
N-WASP-GBD pLS142 Strep-TEV-N-WASP(207-275)  
N-WASP-C pLS112 GST-Thr-TEV-N-WASP(462-493)  
N-WASP-C pLS113 ZZ-His-TEV-N-WASP(462-493)  
N-WASP-C pLS143 Strep-TEV-N-WASP(462-493)  
N-WASP-VVCA pLS147 GST-Thr-TEV-N-WASP(399-505)  
N-WASP-VVCA pLS148 ZZ-His-TEV-N-WASP(399-505)  
N-WASP-VV pLS149 GST-Thr-TEV-N-WASP(399-460)  
N-WASP-VV pLS150 ZZ-His-TEV-N-WASP(399-460)  
Toca-1K1 pLS151 GST-Thr-TEV-Toca-1(389-480)  
Toca-1K2 pLS152 GST-Thr-TEV-Toca-1(389-488)  
Toca-1K3 pLS153 GST-Thr-TEV-Toca-1(383-480)  
Toca-1K4 pLS154 GST-Thr-TEV-Toca-1(383-488)  
Toca-1K5 pLS181 GST-Thr-TEV-Toca-1(1-293)  
Toca-1K6 pLS182 GST-Thr-TEV-Toca-1(245-373)  
Toca-1K7 pLS183 GST-Thr-TEV-Toca-1(245-477)  
Cip4K1 pLS155 GST-Thr-TEV-Cip4(392-480)  
Cdc42 pLS156 GST-Thr-TEV-Cdc42(1-178)  
Diaph2-GBD 
 
pLS158 
 
GST-Thr-TEV-Diaph2(88-476) 
 
S149 → SIVGSKVT 
(isoform 2/3) 
Diaph3-GBD pLS159 GST-Thr-TEV-Diaph3(264-488) Δ1-263 (isoform 1) 
Daam2-GBD pLS160 GST-Thr-TEV-Daam2(39-427)  
Fhod1-GBD pLS161 GST-Thr-TEV-Fhod1(44-468)  
Fmnl2-GBD pLS163 GST-Thr-TEV-Fmnl2(16-487)  
Fmnl3-GBD pLS164 GST-Thr-TEV-Fmnl3(16-477)  
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N-WASP-GBD– 
N-WASP-C 
pLS144 His-TEV-N-WASP(207-275)-GGS- 
N-WASP(462-493)  
N-WASP-GBD– 
IcsBK30 
pLS145 His-TEV-N-WASP(207-275)-GGS- 
IcsB(104-130)  
N-WASP-GBD– 
IcsBK31 
pLS146 His-TEV-N-WASP(207-275)-GGS- 
IcsB(99-136)  
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